Clinical Trials

Abraxane in Treatment of Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: nab-paclitaxel
Sponsor:   Celgene
Completed

Mon, 21 Sep 2015 12:00:00 EDT

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

Conditions:   Breast Cancer;   Triple Negative Breast Cancer;   Stage IV Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: Abraxane alone;   Drug: Abraxane + Tigatuzumab
Sponsors:   University of Alabama at Birmingham;   Susan G. Komen Breast Cancer Foundation;   Daiichi Sankyo UK Ltd.;   Triple Negative Breast Cancer Foundation
Completed

Thu, 03 Mar 2011 12:00:00 EST

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Conditions:   Colorectal Cancer;   Cancer of Gastrointestinal Tract
Intervention:   Drug: Abraxane
Sponsors:   M.D. Anderson Cancer Center;   Celgene
Completed

Wed, 21 Nov 2012 12:00:00 EST

Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer

Condition:   Breast Cancer Stage
Intervention:   Drug: nab-paclitaxel
Sponsor:   Jilin University
Not yet recruiting

Wed, 22 May 2019 12:00:00 EDT

Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy

Condition:   Pancreatic Cancer
Intervention:   Drug: Abraxane
Sponsor:   University of Miami
Completed

Thu, 05 Jun 2008 12:00:00 EDT

Study of Gemcitabine and Abraxane for Pancreas Cancer

Condition:   Pancreatic Cancer
Intervention:   Drug: Gemcitabine and Abraxane
Sponsor:   Georgetown University
Terminated

Wed, 17 Sep 2014 12:00:00 EDT

A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Abraxane and Cisplatin combination
Sponsor:   Fudan University
Completed

Thu, 24 Jun 2010 12:00:00 EDT

PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: PU-H71;   Drug: Nab-paclitaxel
Sponsors:   Memorial Sloan Kettering Cancer Center;   Samus Therapeutics, Inc.
Active, not recruiting

Wed, 24 May 2017 12:00:00 EDT

The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)

Conditions:   Esophageal Cancer;   Toxicity
Intervention:   Drug: Nab-paclitaxel
Sponsors:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Celgene Corporation
Completed

Fri, 24 Oct 2014 12:00:00 EDT

Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer

Condition:   Stomach and Gastro-Esophageal Junction (GEJ) Cancer
Intervention:   Drug: nab-Paclitaxel
Sponsor:   Hellenic Oncology Research Group
Completed

Mon, 29 Sep 2014 12:00:00 EDT

S-1 in Combination With Abraxane in Treating Cholangiocarcinoma

Condition:   Cholangiocarcinoma
Intervention:   Drug: S-1 plus Abraxane
Sponsor:   Yuhong Li
Completed

Wed, 16 Oct 2013 12:00:00 EDT

Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Abraxane;   Drug: Xeloda
Sponsor:   Zhejiang Cancer Hospital
Unknown status

Mon, 27 Aug 2018 12:00:00 EDT

Treatment of Pancreatic Cancer With Abraxane

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: Abraxane;   Drug: Gemcitabine
Sponsor:   Celgene
Completed

Tue, 22 Sep 2015 12:00:00 EDT

Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Abraxane;   Drug: Paclitaxel
Sponsor:   Fondazione Michelangelo
Active, not recruiting

Tue, 02 Apr 2013 12:00:00 EDT

Treatment With Nab-paclitaxel in Cutaneous SCC

Condition:   Cutaneous Squamous Cell Carcinoma
Intervention:   Drug: nab-paclitaxel
Sponsors:   Icahn School of Medicine at Mount Sinai;   Celgene Corporation
Terminated

Mon, 03 Mar 2014 12:00:00 EST

IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Nab-Paclitaxel
Sponsor:   Barwon Health
Unknown status

Fri, 12 Apr 2013 12:00:00 EDT

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly

Conditions:   Non-Small Cell Lung Cancer;   Carcinoma;   Squamous Cell Carcinoma;   Adenocarcinoma;   Carcinoma, Large Cell;   Lung Neoplasm
Interventions:   Drug: nab-paclitaxel;   Drug: Carboplatin
Sponsor:   Celgene
Completed

Fri, 30 May 2014 12:00:00 EDT

The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Abraxane;   Drug: Epirubicin
Sponsor:   Zhejiang Cancer Hospital
Unknown status

Mon, 27 Aug 2018 12:00:00 EDT

Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Abraxane
Sponsor:   Tianjin Medical University
Unknown status

Mon, 23 Jul 2012 12:00:00 EDT

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

Conditions:   Urothelial Cancer;   Bladder Cancer
Intervention:   Drug: ABI-007 (Abraxane®)
Sponsors:   University of Michigan Rogel Cancer Center;   Celgene Corporation
Terminated

Thu, 15 Oct 2009 12:00:00 EDT

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: RX-3117
Sponsor:   Rexahn Pharmaceuticals, Inc.
Completed

Fri, 16 Jun 2017 12:00:00 EDT

A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer

Condition:   Head and Neck Cancer
Intervention:   Drug: ABI-007
Sponsors:   University Health Network, Toronto;   Celgene Corporation
Completed

Mon, 11 Aug 2008 12:00:00 EDT

Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: Fostamatinib and Paclitaxel
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Rigel Pharmaceuticals;   Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Recruiting

Fri, 11 Aug 2017 12:00:00 EDT

Endoscopic Abraxane Injection Into Pancreatic Cysts

Condition:   Pancreatic Cysts
Intervention:   Drug: Albumin bound paclitaxel
Sponsor:   Massachusetts General Hospital
Terminated

Wed, 03 Oct 2012 12:00:00 EDT

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

Condition:   Metastatic Pancreatic Ductal Adenocarcinoma
Interventions:   Drug: Palbociclib;   Drug: Nab-Paclitaxel
Sponsors:   Pfizer;   Celgene
Completed

Fri, 17 Jul 2015 12:00:00 EDT

Single Arm on the Tolerability of Weekly Nab-paclitaxel

Condition:   Non Small Cell Lung Cancer (NSCLC)
Intervention:   Drug: Nab-Paclitaxel
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Celgene
Completed

Mon, 08 Oct 2012 12:00:00 EDT

Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer

Condition:   Squamous Cell Carcinoma of Lung
Intervention:   Drug: nanoparticle albumin-bound paclitaxel
Sponsor:   Chinese Academy of Medical Sciences
Unknown status

Fri, 25 Oct 2013 12:00:00 EDT

The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer

Condition:   Small Cell Lung Cancer
Intervention:   Drug: Nab-paclitaxel
Sponsor:   Tongji University
Unknown status

Mon, 13 Oct 2014 12:00:00 EDT

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

Condition:   Colorectal Neoplasms
Intervention:   Drug: ABI-007
Sponsor:   Celgene
Completed

Thu, 03 Apr 2014 12:00:00 EDT

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Condition:   Breast Cancer
Interventions:   Drug: nab-Paclitaxel+carboplatin;   Drug: Paclitaxel+carboplatin
Sponsor:   Shengjing Hospital
Recruiting

Thu, 24 Oct 2019 12:00:00 EDT

Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Nab-paclitaxel
Sponsors:   Spanish Breast Cancer Research Group;   Celgene
Completed

Wed, 28 Mar 2012 12:00:00 EDT

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

Condition:   Resectable Pancreatic Cancer
Intervention:   Drug: Gemcitabine and Abraxane
Sponsors:   Pancreatic Cancer Research Team;   Celgene Corporation
Completed

Thu, 17 Feb 2011 12:00:00 EST

Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer

Condition:   Advanced Pancreatic Cancer
Intervention:   Drug: Nab-paclitaxel and S-1
Sponsor:   Aiping Zhou
Completed

Tue, 30 Jan 2018 12:00:00 EST

Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer

Condition:   Small Cell Lung Cancer
Intervention:   Drug: pembrolizumab, paclitaxel
Sponsor:   Seoul National University Hospital
Completed

Wed, 16 Sep 2015 12:00:00 EDT

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Condition:   Metastatic Melanoma
Intervention:   Drug: Abraxane
Sponsor:   Celgene Corporation
Withdrawn

Fri, 30 Aug 2013 12:00:00 EDT

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Abraxane;   Drug: Carboplatin
Sponsors:   Duke University;   Celgene Corporation
Terminated

Wed, 22 Sep 2010 12:00:00 EDT

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)

Conditions:   Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions:   Drug: nab-Paclitaxel;   Drug: Paclitaxel
Sponsors:   German Breast Group;   Celgene Corporation;   Roche Pharma AG
Completed

Tue, 24 Apr 2012 12:00:00 EDT

Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer

Condition:   Bladder Cancer
Intervention:   Drug: Paclitaxel, nanoparticle albumin-bound
Sponsors:   Columbia University;   Celgene Corporation
Unknown status

Mon, 31 Dec 2007 12:00:00 EST

Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease

Condition:   Peripheral Arterial Disease
Intervention:   Drug: Paclitaxel
Sponsors:   Lahey Clinic;   National Evaluation System for health Technology Coordinating Center (NESTcc);   Society for Vascular Surgery Patient Safety Organization
Active, not recruiting

Tue, 01 Dec 2020 12:00:00 EST

Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Abraxane
Sponsor:   Fudan University
Completed

Mon, 22 Feb 2016 12:00:00 EST

A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Abraxane and Gemcitabine
Sponsor:   Fudan University
Completed

Mon, 12 Mar 2012 12:00:00 EDT

Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

Conditions:   Breast Cancer;   HER-2 Positive Breast Cancer;   Effects of Chemotherapy
Intervention:   Drug: Nab-paclitaxel
Sponsor:   Osaka Medical College
Completed

Mon, 12 Sep 2011 12:00:00 EDT

Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer

Conditions:   Pancreatic Adenocarcinoma Resectable;   Pancreatic Adenocarcinoma Locally Advanced;   Pancreatic Adenocarcinoma Metastatic
Interventions:   Drug: Gemcitabine;   Drug: Abraxane
Sponsors:   Jean-Luc Van Laethem;   Celgene Corporation
Completed

Fri, 26 Oct 2012 12:00:00 EDT

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Condition:   Breast Neoplasm Female
Intervention:   Drug: Paclitaxel
Sponsor:   University of Wisconsin, Madison
Recruiting

Thu, 30 Mar 2017 12:00:00 EDT

Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer

Condition:   Advanced Gastric Cancer
Intervention:   Drug: Albumin-paclitaxel, Apatinib, Camrelizumab
Sponsor:   China Medical University, China
Not yet recruiting

Thu, 27 Feb 2020 12:00:00 EST

Hepatic Arterial Infusion (HAI) of Abraxane

Conditions:   Liver Cancer;   Advanced Cancers;   Solid Tumors
Interventions:   Drug: HAI Abraxane;   Procedure: Hepatic Artery Catheter;   Drug: IV Abraxane
Sponsors:   M.D. Anderson Cancer Center;   National Comprehensive Cancer Network
Completed

Tue, 12 Aug 2008 12:00:00 EDT

Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression

Condition:   Cord Compression
Interventions:   Radiation: Radiation therapy;   Drug: nab-Paclitaxel
Sponsors:   Washington University School of Medicine;   Celgene
Recruiting

Fri, 31 Aug 2018 12:00:00 EDT

Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma

Conditions:   Tumor, Desmoplastic Small Round Cell, Adult;   Tumor, Desmoplastic Small Round Cell, Childhood;   Sarcoma, Ewing;   Sarcoma;   Desmoid
Intervention:   Drug: nab paclitaxel
Sponsor:   Grupo Espanol de Investigacion en Sarcomas
Active, not recruiting

Fri, 08 Sep 2017 12:00:00 EDT

Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer

Condition:   Gastric Caner
Interventions:   Drug: Albumin Bound Paclitaxel;   Drug: 5-FU
Sponsor:   Sun Yat-sen University
Unknown status

Fri, 29 Aug 2014 12:00:00 EDT

Schedules of Nab-Paclitaxel in Metastatic Breast Cancer

Condition:   Metastatic Breastcancer
Intervention:   Drug: nab-Paclitaxel
Sponsors:   International Breast Cancer Study Group;   Breast International Group
Active, not recruiting

Mon, 10 Dec 2012 12:00:00 EST

Abraxane/Bevacizumab

Conditions:   Ovarian Cancer;   Peritoneal Cancer
Interventions:   Drug: Abraxane;   Drug: Bevacizumab
Sponsor:   OHSU Knight Cancer Institute
Terminated

Mon, 01 Apr 2013 12:00:00 EDT

First Line Therapy for Patients With Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: ABI-007
Sponsor:   Celgene
Terminated

Thu, 05 Apr 2007 12:00:00 EDT

Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

Conditions:   Pancreatic Cancer;   Metastatic Pancreatic Cancer
Intervention:   Drug: nab paclitaxel plus gemcitabine
Sponsors:   Asan Medical Center;   Bundang CHA Hospital;   Ulsan University Hospital
Completed

Mon, 21 Oct 2019 12:00:00 EDT

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Conditions:   Urothelial Carcinoma;   Bladder Cancer;   Transitional Cell Carcinoma
Interventions:   Drug: nab-paclitaxel;   Drug: Gemcitabine
Sponsors:   SCRI Development Innovations, LLC;   Celgene
Terminated

Fri, 02 Sep 2016 12:00:00 EDT

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus

Condition:   Squamous Cell Carcinoma of Esophagus
Intervention:   Drug: nanoparticle albumin-bound paclitaxel
Sponsor:   Zhejiang University
Withdrawn

Fri, 10 Jan 2014 12:00:00 EST

Abraxane and Alimta in Advanced Solid Tumors

Conditions:   Breast Cancer;   Lung Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: Abraxane;   Drug: Alimta
Sponsors:   University of California, Davis;   Celgene;   Eli Lilly and Company
Terminated

Mon, 07 May 2007 12:00:00 EDT

A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer

Condition:   Castration-resistant Prostate Cancer
Interventions:   Drug: nab-paclitaxel;   Drug: carboplatin
Sponsor:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Unknown status

Mon, 04 Nov 2019 12:00:00 EST

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel;   Radiation: Radiation therapy
Sponsor:   NYU Langone Health
Completed

Fri, 31 Oct 2014 12:00:00 EDT

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Conditions:   HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions:   Drug: Romidepsin;   Drug: Abraxane
Sponsors:   Sidney Kimmel Cancer Center at Thomas Jefferson University;   Celgene Corporation
Terminated

Tue, 10 Sep 2013 12:00:00 EDT

Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Conditions:   Stage IA Pancreatic Adenocarcinoma;   Stage IB Pancreatic Adenocarcinoma;   Stage IIA Pancreatic Adenocarcinoma;   Stage IIB Pancreatic Adenocarcinoma
Interventions:   Drug: nab-paclitaxel;   Drug: gemcitabine
Sponsor:   Xian-Jun Yu
Completed

Mon, 30 Dec 2013 12:00:00 EST

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: ABI-007;   Drug: Bevacizumab
Sponsor:   Celgene
Completed

Tue, 31 Oct 2006 12:00:00 EST

NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma

Condition:   Cancer of Stomach
Interventions:   Drug: nab-paclitaxel;   Drug: FOLFOX
Sponsors:   GERCOR - Multidisciplinary Oncology Cooperative Group;   Celgene Corporation
Recruiting

Wed, 01 Jul 2015 12:00:00 EDT

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Mifepristone;   Other: Placebo;   Drug: Nab-Paclitaxel
Sponsor:   University of Chicago
Recruiting

Thu, 02 Jun 2016 12:00:00 EDT

Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer

Condition:   Gastric Cancer
Interventions:   Drug: Albumin Bound Paclitaxel;   Drug: S-1
Sponsor:   Sun Yat-sen University
Completed

Fri, 29 Aug 2014 12:00:00 EDT

Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients

Condition:   Gastric Adenocarcinoma
Intervention:   Drug: nanoparticle Albumin-Bound paclitaxel
Sponsor:   Yanqiao Zhang
Unknown status

Tue, 17 Jul 2012 12:00:00 EDT

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Condition:   Metastatic Pancreatic Ductal Adenocarcinoma
Interventions:   Drug: Relacorilant, 100 mg and 25 mg;   Drug: Nab paclitaxel
Sponsor:   Corcept Therapeutics
Active, not recruiting

Wed, 01 Apr 2020 12:00:00 EDT

Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma

Conditions:   Lymphoma, Non-Hodgkin;   Hodgkin Disease
Intervention:   Drug: Abraxane
Sponsor:   Washington University School of Medicine
Terminated

Fri, 16 Mar 2012 12:00:00 EDT

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Bevacizumab, Abraxane
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Genentech, Inc.
Completed

Mon, 14 May 2007 12:00:00 EDT

Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab

Condition:   Head and Neck Cancer
Interventions:   Drug: Abraxane;   Drug: Cetuximab
Sponsor:   University of California, Irvine
Terminated

Thu, 27 Apr 2006 12:00:00 EDT

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Condition:   Transitional Cell Carcinoma
Intervention:   Drug: Paclitaxel
Sponsors:   Sunnybrook Health Sciences Centre;   Celgene Corporation
Completed

Fri, 23 May 2008 12:00:00 EDT

A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus

Condition:   Endometrial Cancer
Interventions:   Drug: Carboplatin AUC;   Drug: Abraxane
Sponsor:   NYU Langone Health
Completed

Wed, 20 Apr 2016 12:00:00 EDT

A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Camrelizumab;   Drug: nb-Paclitaxel
Sponsors:   Sun Yat-sen University;   Jiangsu HengRui Medicine Co., Ltd.
Recruiting

Tue, 19 Nov 2019 12:00:00 EST

A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)

Condition:   Advanced Gastric Cancer
Interventions:   Combination Product: fruquintinib +paclitaxel;   Combination Product: fruquintinib placebo + paclitaxel
Sponsors:   Hutchison Medipharma Limited;   Sun Yat-sen University
Recruiting

Fri, 21 Jul 2017 12:00:00 EDT

Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients

Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: Nab paclitaxel / gemcitabine
Sponsor:   Helse Stavanger HF
Unknown status

Mon, 14 Mar 2016 12:00:00 EDT

Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma

Condition:   Angiosarcoma Metastatic
Intervention:   Drug: Abraxane combined with liposomal doxorubicin
Sponsor:   Sun Yat-sen University
Not yet recruiting

Mon, 26 Apr 2021 12:00:00 EDT

Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

Condition:   Cancer
Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel
Sponsors:   Emory University;   Celgene Corporation
Recruiting

Wed, 25 Apr 2018 12:00:00 EDT

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma

Condition:   Relapsed or Refractory Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: nab-paclitaxel
Sponsors:   NYU Langone Health;   Celgene Corporation
Terminated

Mon, 03 Mar 2014 12:00:00 EST

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

Conditions:   Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma
Intervention:   Drug: Pazopanib and Paclitaxel
Sponsors:   University of California, Irvine;   GlaxoSmithKline
Completed

Wed, 21 Apr 2010 12:00:00 EDT

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

Condition:   Small Cell Lung Cancer (SCLC)
Interventions:   Drug: Nab-paclitaxel;   Drug: Gemcitabine
Sponsors:   Muhammad Furqan;   Celgene Corporation
Active, not recruiting

Thu, 12 May 2016 12:00:00 EDT

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

Condition:   Advanced Cancers
Interventions:   Drug: Satraplatin;   Drug: Abraxane
Sponsors:   Yale University;   Agennix
Completed

Tue, 15 May 2007 12:00:00 EDT

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

Condition:   Breast Neoplasms
Intervention:   Drug: Cirmtuzumab + Paclitaxel
Sponsors:   Barbara Parker, MD;   Oncternal Therapeutics, Inc
Active, not recruiting

Wed, 18 May 2016 12:00:00 EDT

Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer

Condition:   Pancreatic Cancer
Intervention:   Drug: SHR-1020+albumin-bound paclitaxel
Sponsor:   Tianjin Medical University Cancer Institute and Hospital
Recruiting

Wed, 24 Mar 2021 12:00:00 EDT

NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma

Condition:   Soft Tissue Sarcoma
Interventions:   Drug: Nab-Paclitaxel;   Drug: gemcitabine
Sponsor:   Swiss Group for Clinical Cancer Research
Active, not recruiting

Tue, 15 May 2018 12:00:00 EDT

A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer

Condition:   Gastric Cancer
Intervention:   Drug: fruquintinib+paclitaxel
Sponsor:   Hutchison Medipharma Limited
Completed

Tue, 14 Apr 2015 12:00:00 EDT

Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer

Condition:   Small Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Abraxane
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Celgene Corporation
Terminated

Fri, 30 Mar 2007 12:00:00 EDT

An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Nanoparticle albumin-bound paclitaxel;   Drug: Phenelzine Sulfate
Sponsors:   EpiAxis Therapeutics;   The Canberra Hospital;   Southern Medical Day Care Centre;   Liverpool Cancer Therapy Centre
Completed

Mon, 23 Apr 2018 12:00:00 EDT

Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: Abraxane;   Radiation: Radiation Therapy
Sponsor:   Olugbenga Olowokure
Terminated

Wed, 26 Sep 2012 12:00:00 EDT

Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer

Condition:   Gastric Cancer
Intervention:   Drug: Paclitaxel + S-1 + Oxaliplatin
Sponsor:   Affiliated Hospital of Qinghai University
Unknown status

Mon, 28 Aug 2017 12:00:00 EDT

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Conditions:   Neuroblastoma;   Rhabdomyosarcoma;   Ewing's Sarcoma;   Ewing's Tumor;   Sarcoma, Ewing's;   Sarcomas, Epitheliod;   Sarcoma, Soft Tissue;   Sarcoma, Spindle Cell;   Melanoma;   Malignant Melanoma;   Clinical Oncology;   Oncology, Medical;   Pediatrics, Osteosarcoma;   Osteogenic Sarcoma;   Osteosarcoma Tumor;   Sarcoma, Osteogenic;   Tumors;   Cancer;   Neoplasia;   Neoplasm;   Histiocytoma;   Fibrosarcoma;   Dermatofibrosarcoma
Intervention:   Drug: nab-paclitaxel
Sponsor:   Celgene
Completed

Mon, 14 Oct 2013 12:00:00 EDT

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Condition:   Gastroesophageal Cancer
Interventions:   Drug: nab-paclitaxel;   Biological: ramucirumab
Sponsors:   SCRI Development Innovations, LLC;   Celgene
Completed

Wed, 17 Dec 2014 12:00:00 EST

LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer

Condition:   Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Abraxane
Sponsors:   Kathryn Mileham;   Celgene
Completed

Wed, 31 Dec 2014 12:00:00 EST

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Conditions:   Melanoma;   Liver Metastasis
Intervention:   Drug: Nab-Paclitaxel (Abraxane)
Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
Completed

Mon, 02 Feb 2009 12:00:00 EST

A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

Condition:   Gastrointestinal Neuroendocrine Carcinomas
Interventions:   Drug: NAB paclitaxel;   Drug: Carboplatin
Sponsors:   Barwon Health;   Specialised Therapeutics Australia;   Deakin University;   Australasian Gastro-Intestinal Trials Group
Unknown status

Wed, 13 Aug 2014 12:00:00 EDT

Paclitaxel-Avelumab for Angiosarcoma

Condition:   Angiosarcoma Metastatic
Interventions:   Drug: Avelumab;   Drug: Paclitaxel
Sponsors:   Sung Yong Oh;   Merck KGaA, Darmstadt, Germany
Recruiting

Tue, 01 May 2018 12:00:00 EDT

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

Condition:   Recurrent or Metastatic Breast Cancer
Interventions:   Drug: DHP107;   Drug: IV Paclitaxel
Sponsor:   Daehwa Pharmaceutical Co., Ltd.
Recruiting

Mon, 30 Oct 2017 12:00:00 EDT

Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer

Condition:   Uterine Cervical Cancer
Intervention:   Drug: albumin-bound paclitaxel plus nedaplatin
Sponsor:   Chinese Academy of Medical Sciences
Unknown status

Fri, 17 Aug 2012 12:00:00 EDT

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer

Condition:   Non Small Cell Lung Cancer
Intervention:   Drug: nanoparticle albumin-bound paclitaxel
Sponsor:   Zhejiang University
Unknown status

Thu, 19 Dec 2013 12:00:00 EST

Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)

Condition:   Ovarian Carcinoma
Interventions:   Device: NovoTTF-100L(O);   Drug: Paclitaxel
Sponsor:   NovoCure Ltd.
Unknown status

Fri, 19 Sep 2014 12:00:00 EDT

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Abraxane
Sponsors:   Harold J. Burstein, MD, PhD;   Celgene Corporation;   Beth Israel Deaconess Medical Center;   Massachusetts General Hospital
Completed

Wed, 29 Mar 2006 12:00:00 EST

Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors

Condition:   Solid Tumors
Intervention:   Drug: CORT125134 with nab-paclitaxel
Sponsor:   Corcept Therapeutics
Completed

Thu, 05 May 2016 12:00:00 EDT

Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)

Condition:   Penile Squamous Cell Carcinoma Stage IV
Interventions:   Drug: Pazopanib;   Drug: Paclitaxel
Sponsor:   Spanish Oncology Genito-Urinary Group
Terminated

Fri, 31 Oct 2014 12:00:00 EDT

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer

Condition:   Advanced Pancreatic Cancer
Interventions:   Drug: nanoparticle albumin-bound paclitaxel;   Drug: S-1
Sponsor:   Chinese PLA General Hospital
Unknown status

Mon, 28 Apr 2014 12:00:00 EDT

A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients

Condition:   Metastatic Pancreatic Ductal Adenocarcinoma
Intervention:   Drug: Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
Sponsors:   Pancreatic Cancer Action Network;   Novartis Pharmaceuticals
Recruiting

Fri, 09 Oct 2020 12:00:00 EDT

Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Biological: Pembrolizumab;   Drug: Nab-Paclitaxel
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Centre de Recherche du Centre Hospitalier de l'Université de Montréal;   Merck Canada Inc.;   Celgene;   Jewish General Hospital
Completed

Mon, 11 Apr 2016 12:00:00 EDT

Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

Condition:   Hemodialysis Graft Dysfunction
Intervention:   Drug: ABI-007
Sponsor:   Celgene
Terminated

Mon, 07 Nov 2005 12:00:00 EST

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

Condition:   Prostate Cancer
Intervention:   Drug: Abraxane
Sponsors:   Kaiser Permanente;   Celgene Corporation
Completed

Wed, 01 Feb 2006 12:00:00 EST

The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma

Condition:   Biliary Tract Cancer
Intervention:   Drug: Nab-paclitaxel,S-1
Sponsor:   Aiping Zhou
Completed

Tue, 05 Feb 2019 12:00:00 EST

A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and Cisplatin

Condition:   Esophageal Cancer
Intervention:   Drug: paclitaxel and cisplatin
Sponsors:   Chinese Academy of Medical Sciences;   Beijing Municipal Science & Technology Commission
Unknown status

Fri, 30 Sep 2011 12:00:00 EDT

Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer

Condition:   Pancreatic Neoplasms
Interventions:   Drug: nab-paclitaxel;   Drug: Gemcitabine
Sponsor:   Celgene
Completed

Fri, 20 Dec 2013 12:00:00 EST

Effects of Paclitaxel on Intimal Hyperplasia

Condition:   Peripheral Vascular Disease
Intervention:   Drug: Paclitaxel
Sponsor:   Patrick Kelly
Completed

Wed, 19 Oct 2011 12:00:00 EDT

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Condition:   Melanoma
Interventions:   Drug: ABI-007;   Drug: Ipilimumab;   Behavioral: Phone Call
Sponsors:   M.D. Anderson Cancer Center;   Celgene
Completed

Tue, 09 Apr 2013 12:00:00 EDT

Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement

Condition:   Advanced Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   M.D. Anderson Cancer Center
Completed

Fri, 27 Jul 2007 12:00:00 EDT

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: ABI-007;   Drug: Docetaxel
Sponsor:   Celgene
Completed

Wed, 11 Jan 2006 12:00:00 EST

Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Paclitaxel
Sponsors:   Queen Mary University of London;   Merck Sharp & Dohme Corp.;   European Institute of Oncology
Not yet recruiting

Fri, 15 Feb 2019 12:00:00 EST

A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

Conditions:   Unspecified Adult Solid Tumor, Protocol Specific;   Gastric Cancer;   Breast Cancer
Intervention:   Drug: KX2-391 and Paclitaxel
Sponsor:   Hanmi Pharmaceutical Company Limited
Unknown status

Wed, 09 Jan 2013 12:00:00 EST

Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.

Condition:   Pancreatic Cancer Stage II
Interventions:   Drug: Nab-paclitaxel and Gemcitabine;   Drug: Gemcitabine
Sponsors:   Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente;   Unità Sperimentazioni cliniche;   Istituto Nazionale Tumori di Napoli
Completed

Thu, 23 Jan 2014 12:00:00 EST

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Condition:   Triple-Negative Breast Cancer
Interventions:   Drug: Atezolizumab;   Drug: Nab-Paclitaxel
Sponsor:   Hoffmann-La Roche
Recruiting

Mon, 04 Nov 2019 12:00:00 EST

The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer

Conditions:   Pancreatic Cancer;   Chemotherapy Effect
Interventions:   Drug: raltitrexed for injection;   Drug: nab-paclitaxel
Sponsor:   Fudan University
Recruiting

Fri, 09 Oct 2020 12:00:00 EDT

Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

Condition:   Urothelial Carcinoma
Interventions:   Drug: Pembrolizumab;   Drug: Abraxane
Sponsor:   University of Michigan Rogel Cancer Center
Recruiting

Fri, 04 Aug 2017 12:00:00 EDT

Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

Condition:   Angiosarcoma
Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   Centre Oscar Lambret;   French Sarcoma Group;   Study Group of Bone Tumors
Completed

Thu, 24 Feb 2011 12:00:00 EST

Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Cancer
Intervention:   Drug: paclitaxel; cisplatin
Sponsor:   Chinese Academy of Medical Sciences
Completed

Thu, 08 May 2014 12:00:00 EDT

LDE225 and Paclitaxel in Solid Tumors

Conditions:   Solid Tumor;   Ovarian Cancer
Interventions:   Drug: LDE225;   Drug: Paclitaxel
Sponsor:   Swiss Group for Clinical Cancer Research
Completed

Tue, 01 Oct 2013 12:00:00 EDT

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Condition:   Malignant Melanoma
Interventions:   Drug: ABI-007;   Drug: Dacarbazine
Sponsors:   Celgene;   University of Arizona
Completed

Wed, 18 Mar 2009 12:00:00 EDT

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Conditions:   Breast Cancer;   HER2-positive Breast Cancer
Interventions:   Drug: Pyrotinib Plus And;   Drug: Trastuzumab;   Drug: Abraxane
Sponsor:   Shandong Cancer Hospital and Institute
Not yet recruiting

Fri, 20 Nov 2020 12:00:00 EST

Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma

Condition:   Bladder Cancer
Interventions:   Drug: paclitaxel;   Drug: RAD001
Sponsor:   Heinrich-Heine University, Duesseldorf
Terminated

Tue, 07 Jul 2009 12:00:00 EDT

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: T-DM1;   Drug: Lapatinib;   Drug: Abraxane
Sponsors:   Jenny C. Chang, MD;   The Methodist Hospital Research Institute
Completed

Thu, 27 Feb 2014 12:00:00 EST

A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy

Condition:   Stage IV Gastric Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   Daehwa Pharmaceutical Co., Ltd.
Completed

Thu, 25 Apr 2013 12:00:00 EDT

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Condition:   Recurrent or Metastatic Breast Cancer
Interventions:   Drug: Oral paclitaxel;   Drug: Paclitaxel injection
Sponsor:   Daehwa Pharmaceutical Co., Ltd.
Recruiting

Fri, 20 Oct 2017 12:00:00 EDT

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Condition:   Breast Cancer
Interventions:   Drug: everolimus;   Drug: abraxane
Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
Terminated

Wed, 08 Jul 2009 12:00:00 EDT

A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer

Conditions:   Pancreatic Cancer;   Metastatic Pancreatic Cancer
Intervention:   Drug: CPI 613 in Combination With Gemcitabine and Nab-paclitaxel
Sponsors:   Atlantic Health System;   Rafael Pharmaceuticals Inc.
Unknown status

Mon, 19 Feb 2018 12:00:00 EST

Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma

Condition:   Cutaneous Angiosarcoma
Interventions:   Drug: Paclitaxel;   Radiation: Radiation therapy;   Procedure: Research blood draw
Sponsor:   Washington University School of Medicine
Recruiting

Fri, 19 Apr 2019 12:00:00 EDT

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Condition:   Gastric Adenocarcinoma
Intervention:   Drug: Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1
Sponsor:   Beijing Cancer Hospital
Recruiting

Wed, 07 Aug 2019 12:00:00 EDT

Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm

Conditions:   Mucinous Cystic Tumor With Moderate Dysplasia;   Mucinous Cystadenoma of Pancreas;   Mucinous Cystadenocarcinoma of Pancreas;   Benign Neoplasm of Pancreas
Intervention:   Drug: Ethanol and Paclitaxel Injection
Sponsors:   Lawson Health Research Institute;   University of Western Ontario, Canada
Terminated

Fri, 03 Feb 2012 12:00:00 EST

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Condition:   Gastric Carcinoma
Interventions:   Drug: Albumin-Bound Paclitaxel;   Drug: Toripalimab
Sponsor:   China Medical University, China
Recruiting

Tue, 23 Jun 2020 12:00:00 EDT

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: nab-Paclitaxel;   Drug: Carboplatin
Sponsor:   Celgene
Completed

Thu, 13 Nov 2014 12:00:00 EST

Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: Paclitaxel for Injection(Albumin Bound);   Drug: Gemcitabine
Sponsors:   Fudan University;   CSPC Ouyi Pharmaceutical Co., Ltd.
Recruiting

Fri, 26 Apr 2019 12:00:00 EDT

Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

Conditions:   Pancreatic Carcinoma Non-resectable;   Stage IV Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: nab-Paclitaxel
Sponsor:   Western Regional Medical Center
Terminated

Fri, 10 May 2013 12:00:00 EDT

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Drug: albumin-bound paclitaxel plus cisplatin
Sponsors:   Zhejiang Cancer Hospital;   Second Affiliated Hospital, School of Medicine, Zhejiang University
Completed

Fri, 10 Dec 2010 12:00:00 EST

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions:   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma;   Recurrent Ovarian Carcinoma
Intervention:   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed

Wed, 11 Jul 2007 12:00:00 EDT

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

Conditions:   Pancreatic Neoplasms;   Digestive System Neoplasms;   Neoplasms by Site;   Neoplasms;   Endocrine Gland Neoplasms;   Pancreatic Diseases;   Digestive System Diseases;   Endocrine System Diseases;   Gemcitabine;   Antimetabolites, Antineoplastic
Interventions:   Drug: nab-Paclitaxel;   Drug: Gemcitabine
Sponsor:   Celgene
Active, not recruiting

Thu, 17 Oct 2013 12:00:00 EDT

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

Condition:   Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Abraxane (Induction);   Drug: Carboplatin (Induction);   Drug: Abraxane (Maintenance);   Other: Best Supportive Care (Maintenance)
Sponsor:   Celgene
Completed

Mon, 06 Jan 2014 12:00:00 EST

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

Conditions:   Stomach Cancer;   Stomach Neoplasm;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Ramucirumab;   Drug: Paclitaxel
Sponsors:   Federation Francophone de Cancerologie Digestive;   Eli Lilly and Company
Recruiting

Fri, 30 Nov 2018 12:00:00 EST

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung

Condition:   Non-small Cell Lung Cancer
Intervention:   Drug: nanoparticle albumin-bound paclitaxel/carboplatin
Sponsor:   The First Affiliated Hospital of Guangzhou Medical University
Unknown status

Fri, 07 Jun 2013 12:00:00 EDT

VQI DELTA Paclitaxel Device Safety Analysis

Condition:   Peripheral Vascular Disease
Interventions:   Drug: Paclitaxel;   Device: Non-drug coated Device Treatment
Sponsors:   Lahey Clinic;   Society for Vascular Surgery Patient Safety Organization
Completed

Tue, 01 Oct 2019 12:00:00 EDT

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Condition:   Advanced Solid Tumors
Interventions:   Drug: Paclitaxel Micelles for Injection;   Drug: Paclitaxel injection
Sponsors:   First Affiliated Hospital of Zhejiang University;   Hangzhou Dihua Biotechnology Co., LTD.
Not yet recruiting

Wed, 03 Mar 2021 12:00:00 EST

Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients

Condition:   Breast Cancer
Intervention:   Drug: Paclitaxel 80mg/m2 weekly x 12 weeks
Sponsor:   University of Michigan Rogel Cancer Center
Completed

Wed, 14 Jan 2015 12:00:00 EST

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Pazopanib;   Drug: Paclitaxel
Sponsors:   ARCAGY/ GINECO GROUP;   Novartis
Completed

Mon, 09 Mar 2015 12:00:00 EDT

Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Condition:   Pancreatic Cancer
Intervention:   Drug: gemcitabine and nab paclitaxel
Sponsors:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Novartis;   Celgene Corporation
Completed

Fri, 06 Feb 2015 12:00:00 EST

Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer

Condition:   Advanced Pancreatic Cancer
Interventions:   Drug: nanoparticle albumin-bound paclitaxel;   Drug: gemcitabine
Sponsor:   Chinese PLA General Hospital
Unknown status

Mon, 12 May 2014 12:00:00 EDT

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Condition:   Metastatic Head-and-neck Squamous-cell Carcinoma
Interventions:   Drug: nab-paclitaxel;   Drug: Nivolumab
Sponsors:   Washington University School of Medicine;   Bristol-Myers Squibb
Recruiting

Mon, 05 Apr 2021 12:00:00 EDT

Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma

Condition:   Pancreatic Carcinoma Metastatic
Interventions:   Drug: Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4;   Drug: Gemcitabine 1000 weeks 1,2,3/4
Sponsors:   Asociación de Oncología Médica del Hospital de Cruces;   Apices Soluciones S.L.;   Celgene
Completed

Wed, 18 Mar 2015 12:00:00 EDT

Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC

Condition:   Efficacy and Safety
Intervention:   Drug: Albumin paclitaxel combined with cisplatin
Sponsor:   Guizhou Medical University
Active, not recruiting

Tue, 25 Feb 2020 12:00:00 EST

EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT Cancer

Condition:   Breast Cancer
Intervention:   Drug: Nab-paclitaxel
Sponsor:   Fondazione Sandro Pitigliani
Completed

Thu, 26 May 2016 12:00:00 EDT

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Condition:   Melanoma
Interventions:   Drug: trametinib;   Drug: nab-paclitaxel
Sponsors:   SCRI Development Innovations, LLC;   Celgene;   GlaxoSmithKline
Withdrawn

Tue, 25 Nov 2014 12:00:00 EST

A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: Nab-Paclitaxel
Sponsor:   Osaka Medical Center for Cancer and Cardiovascular Diseases
Completed

Thu, 23 Oct 2014 12:00:00 EDT

Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab

Condition:   Nonsquamous Nonsmall Cell Neoplasm of Lung
Intervention:   Drug: paclitaxel, carboplatin and bevacizumab
Sponsor:   Spanish Lung Cancer Group
Completed

Tue, 19 Mar 2013 12:00:00 EDT

Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma

Condition:   Cholangiocarcinoma
Intervention:   Drug: Nab-Paclitaxel and Gemcitabine
Sponsors:   PrECOG, LLC.;   Celgene Corporation
Completed

Fri, 04 Jul 2014 12:00:00 EDT

A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Paclitaxel;   Drug: Lovastatin
Sponsor:   University of Iowa
Terminated

Wed, 02 Jan 2008 12:00:00 EST

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Conditions:   Breast Cancer;   Breast Carcinoma;   Breast Tumors;   Malignant Neoplasm of Breast
Interventions:   Drug: Paclitaxel;   Drug: Alisertib
Sponsors:   US Oncology Research;   Millennium Pharmaceuticals, Inc.
Active, not recruiting

Fri, 11 Jul 2014 12:00:00 EDT

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy

Condition:   Head and Neck Cancer
Interventions:   Drug: Paclitaxel;   Drug: Cetuximab + Paclitaxel
Sponsors:   Grupo Español de Tratamiento de Tumores de Cabeza y Cuello;   Merck Sharp & Dohme Corp.;   Pivotal S.L.
Terminated

Mon, 25 Mar 2019 12:00:00 EDT

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.

Condition:   Advanced Cancer
Interventions:   Drug: AZD2014 3 on/4 off & weekly paclitaxel;   Drug: AZD2014 2 on/5 off & weekly paclitaxel
Sponsors:   Royal Marsden NHS Foundation Trust;   Institute of Cancer Research, United Kingdom;   AstraZeneca
Completed

Thu, 17 Jul 2014 12:00:00 EDT

Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Device: Elasto-Gel™;   Drug: Paclitaxel
Sponsors:   National Cancer Centre, Singapore;   Terry Fox Foundation;   Duke-NUS Academic Medicine Research Institute;   Singapore General Hospital
Unknown status

Mon, 12 Feb 2018 12:00:00 EST

Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: nanoparticle albumin-bound paclitaxel;   Drug: S1;   Drug: Gemcitabine
Sponsor:   Peking University
Unknown status

Fri, 17 Aug 2018 12:00:00 EDT

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Conditions:   Breast Neoplasms;   Neoplasm Metastasis
Interventions:   Drug: ABI-007 (Abraxane);   Drug: bevacizumab
Sponsor:   Celgene
Terminated

Wed, 25 Jan 2006 12:00:00 EST

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Abraxane;   Drug: Bevacizumab;   Drug: Carboplatin
Sponsors:   Duke University;   Genentech, Inc.;   Celgene Corporation
Completed

Mon, 28 May 2007 12:00:00 EDT

Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma

Conditions:   Pancreatic Neoplasms;   Pancreatic Cancer;   Adenocarcinoma
Intervention:   Drug: nab-paclitaxel, gemcitabine, capecitabine
Sponsors:   University of California, San Francisco;   Celgene Corporation
Completed

Tue, 13 Jul 2010 12:00:00 EDT

Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Paclitaxel/Gemcitabine
Sponsor:   National Cancer Center, Korea
Terminated

Thu, 20 Sep 2007 12:00:00 EDT

FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

Condition:   Squamous Cell Carcinoma of the Head and Neck
Intervention:   Drug: Durvalumab with Carboplatin/Paclitaxel
Sponsor:   Centre Leon Berard
Recruiting

Tue, 30 Oct 2018 12:00:00 EDT

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC

Condition:   Nasopharyngeal Carcinoma
Intervention:   Drug: Nab-paclitaxel
Sponsor:   Fuzhou General Hospital
Recruiting

Thu, 11 Jul 2019 12:00:00 EDT

Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Nab-Paclitaxel
Sponsor:   German Breast Group
Terminated

Mon, 15 Aug 2011 12:00:00 EDT

Safety, Tolerability and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced GC or GEJ Cancer.

Conditions:   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Rivoceranib;   Drug: Paclitaxel
Sponsor:   Elevar Therapeutics
Recruiting

Tue, 16 Oct 2018 12:00:00 EDT

Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: Hormone Suppressors;   Drug: Paclitaxel;   Radiation: Radiation Therapy
Sponsor:   NYU Langone Health
Completed

Thu, 22 Sep 2016 12:00:00 EDT

Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: ABI-007;   Drug: Gemcitabine;   Drug: simplified LV5FU2
Sponsors:   GERCOR - Multidisciplinary Oncology Cooperative Group;   Celgene Corporation
Unknown status

Thu, 17 Oct 2013 12:00:00 EDT

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Condition:   Intraocular Melanoma
Intervention:   Drug: nab-paclitaxel
Sponsors:   Ohio State University Comprehensive Cancer Center;   National Comprehensive Cancer Network;   Celgene Corporation
Completed

Wed, 20 Aug 2008 12:00:00 EDT

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

Conditions:   NSCLC;   HER2-expression;   EGFR-mutation
Intervention:   Drug: Paclitaxel-trastzumab
Sponsor:   VU University Medical Center
Unknown status

Wed, 27 Aug 2014 12:00:00 EDT

Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer

Conditions:   Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer;   Mixed Tumor, Mesodermal
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital
Terminated

Mon, 08 May 2006 12:00:00 EDT

Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology

Condition:   Pancreatic Adenocarcinoma
Interventions:   Drug: Gemcitabine;   Drug: nab-paclitaxel
Sponsor:   Benaroya Research Institute
Recruiting

Thu, 11 Oct 2018 12:00:00 EDT

Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Nab-Paclitaxel;   Drug: Carboplatin
Sponsors:   iOMEDICO AG;   Bristol-Myers Squibb
Completed

Wed, 15 Jun 2016 12:00:00 EDT

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Conditions:   HER-2 Positive Gastric Cancer;   Gastrooesophageal Cancer;   Esophageal Cancer
Interventions:   Drug: Afatinib;   Drug: Paclitaxel
Sponsors:   Columbia University;   Boehringer Ingelheim
Withdrawn

Fri, 24 Oct 2014 12:00:00 EDT

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Conditions:   High-Risk;   Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions:   Drug: Tislelizumab;   Drug: Nab-paclitaxel
Sponsor:   Tianjin Medical University Second Hospital
Recruiting

Fri, 29 Jan 2021 12:00:00 EST

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: paclitaxel;   Drug: sorafenib tosylate
Sponsor:   University of Texas Southwestern Medical Center
Terminated

Mon, 25 Feb 2008 12:00:00 EST

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Condition:   Metastatic Triple Negative Breast Cancer
Interventions:   Drug: Carboplatin;   Drug: Nab-paclitaxel;   Drug: Pembrolizumab
Sponsor:   Case Comprehensive Cancer Center
Active, not recruiting

Thu, 20 Apr 2017 12:00:00 EDT

Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: DOXIL;   Drug: Abraxane
Sponsors:   West Virginia University;   Ortho Biotech, Inc.
Completed

Thu, 01 Mar 2007 12:00:00 EST

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Conditions:   Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,;   Primary Peritoneal Cancer or Endometrial Cancer;   Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Interventions:   Drug: MM-121;   Drug: Paclitaxel
Sponsors:   Merrimack Pharmaceuticals;   Sanofi
Completed

Mon, 27 Sep 2010 12:00:00 EDT

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

Condition:   Solid Tumors
Interventions:   Drug: ABT-263;   Drug: paclitaxel
Sponsors:   AbbVie;   Genentech, Inc.
Completed

Fri, 01 May 2009 12:00:00 EDT

Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.

Condition:   Gastrointestinal Stromal Tumors
Intervention:   Drug: Paclitaxel
Sponsor:   Asan Medical Center
Recruiting

Thu, 09 May 2019 12:00:00 EDT

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

Condition:   Pancreatic Neoplasms
Interventions:   Drug: nab-Paclitaxel;   Drug: Gemcitabine;   Drug: Chemoradiation;   Drug: Capecitabine;   Procedure: Surgery
Sponsor:   Celgene
Completed

Tue, 25 Nov 2014 12:00:00 EST

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

Condition:   HEAD & NECK Cancer
Intervention:   Other: Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)
Sponsors:   Memorial Sloan Kettering Cancer Center;   Celgene Corporation;   National Comprehensive Cancer Network
Completed

Mon, 18 Aug 2008 12:00:00 EDT

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

Condition:   Coronary Restenosis
Intervention:   Drug: Nanoparticle Paclitaxel
Sponsor:   Celgene Corporation
Completed

Fri, 29 Jul 2005 12:00:00 EDT

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Conditions:   Bladder Cancer;   Bladder (Urothelial, Transitional Cell) Cancer;   Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive);   Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy);   Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Interventions:   Drug: Pazopanib (GW786034);   Drug: Paclitaxel
Sponsors:   Sandy Srinivas;   GlaxoSmithKline
Completed

Wed, 21 Apr 2010 12:00:00 EDT

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: Demcizumab;   Drug: Abraxane®;   Drug: Gemcitabine
Sponsors:   OncoMed Pharmaceuticals, Inc.;   Novotech (Australia) Pty Limited
Completed

Fri, 27 Aug 2010 12:00:00 EDT

Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 02 Dec 2009 12:00:00 EST

AMG 386 Drug-Drug Interaction Study With Paclitaxel

Condition:   Advanced Solid Tumors
Interventions:   Drug: AMG 386;   Drug: Paclitaxel
Sponsor:   Amgen
Completed

Mon, 25 Nov 2013 12:00:00 EST

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: lapatinib ditosylate;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   Northwestern University;   GlaxoSmithKline;   Celgene Corporation
Completed

Wed, 31 May 2006 12:00:00 EDT

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

Condition:   Non-Small Cell Lung Cancer (NSCLC)
Intervention:   Drug: ABI-007 (Abraxane) and Carboplatin
Sponsor:   Celgene
Completed

Wed, 11 Jan 2006 12:00:00 EST

Reirradiation With Concurrent Paclitaxel for Breast Cancer

Condition:   Breast Cancer
Intervention:   Radiation: Paclitaxel+Initial Radiation+Boost
Sponsor:   University of Kentucky
Withdrawn

Mon, 10 Feb 2014 12:00:00 EST

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer

Condition:   Head and Neck Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 04 Sep 2009 12:00:00 EDT

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 04 Sep 2009 12:00:00 EDT

Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 02 Dec 2009 12:00:00 EST

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Conditions:   Breast Cancer;   Triple-negative Breast Cancer;   Nab-paclitaxel
Interventions:   Drug: Nab-paclitaxel + Carboplatin;   Drug: Nab-paclitaxel + Epirubicin
Sponsors:   Hebei Medical University Fourth Hospital;   Beijing 302 Hospital;   CSPC Ouyi Pharmaceutical Co., Ltd.
Recruiting

Thu, 24 Oct 2019 12:00:00 EDT

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: carboplatin and paclitaxel and or without trastuzumab
Sponsor:   Guangdong Provincial People's Hospital
Unknown status

Tue, 11 Feb 2014 12:00:00 EST

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer

Condition:   Esophageal Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 04 Sep 2009 12:00:00 EDT

Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Nab-paclitaxel;   Drug: Gemcitabine
Sponsors:   West Virginia University;   Celgene Corporation
Withdrawn

Wed, 01 Apr 2015 12:00:00 EDT

Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer

Condition:   Pancreatic Cancer
Intervention:   Drug: Gemcitabine plus nab-paclitaxel
Sponsor:   Grupo Hospital de Madrid
Completed

Thu, 29 Sep 2011 12:00:00 EDT

Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma

Condition:   Cholangiocarcinoma, Intrahepatic
Intervention:   Drug: combined therapy using nab-paclitaxel and gemcitabine chemotherapy
Sponsor:   Shanghai Zhongshan Hospital
Not yet recruiting

Wed, 04 Sep 2019 12:00:00 EDT

Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer

Condition:   Head and Neck Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 02 Dec 2009 12:00:00 EST

Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma

Condition:   Recurrent, Persistent or Metastasized Cervical Cancer
Interventions:   Drug: Paclitaxel;   Drug: Cisplatin/Paclitaxel
Sponsors:   Institut fuer Frauengesundheit;   GlaxoSmithKline;   Schantl Pharma Service, Germany
Unknown status

Fri, 29 Jul 2011 12:00:00 EDT

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

Conditions:   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Metastatic Gastric Adenocarcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Peritoneal Carcinomatosis;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Intervention:   Drug: Paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Tue, 07 Jan 2020 12:00:00 EST

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: Albumin-bound paclitaxel
Sponsor:   Celgene
Completed

Fri, 10 Nov 2006 12:00:00 EST

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Condition:   Cancer
Interventions:   Drug: BBI608;   Drug: Paclitaxel
Sponsor:   Sumitomo Dainippon Pharma Oncology, Inc
Completed

Tue, 29 Mar 2011 12:00:00 EDT

Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments

Condition:   Solid Tumors
Interventions:   Drug: Paclitaxel liposome injection;   Drug: Paclitaxel injection
Sponsor:   Nanjing Luye Sike Pharmaceutical Co., Ltd.
Unknown status

Mon, 25 Nov 2013 12:00:00 EST

Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer

Condition:   Head and Neck Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   Bristol-Myers Squibb
Completed

Wed, 04 Mar 2009 12:00:00 EST

Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0

Condition:   Gynecologic Malignancies
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Case Comprehensive Cancer Center
Terminated

Fri, 29 Apr 2016 12:00:00 EDT

Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Condition:   Bladder Cancer
Intervention:   Drug: Paclitaxel-binding albumin
Sponsor:   Third Military Medical University
Recruiting

Mon, 19 Aug 2019 12:00:00 EDT

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: ramucirumab;   Drug: nab-paclitaxel
Sponsor:   Liza Villaruz, MD
Completed

Wed, 06 Apr 2016 12:00:00 EDT

Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer

Condition:   Extensive Stage Small Cell Lung Cancer
Interventions:   Drug: nab-paclitaxel;   Drug: Topotecan
Sponsor:   Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting

Mon, 30 Dec 2019 12:00:00 EST

The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer

Conditions:   Pancreatic Adenocarcinoma;   Chemotherapy Effect
Intervention:   Drug: Chemotherapy (Gemcitabine + nab-paclitaxel)
Sponsor:   Seoul National University Hospital
Unknown status

Wed, 17 Jan 2018 12:00:00 EST

Paclitaxel and TAK-228 in Urothelial Carcinoma

Condition:   Metastatic Urothelial Cancer
Intervention:   Combination Product: Paclitaxel and TAK-228
Sponsors:   Associació per a la Recerca Oncologica, Spain;   Takeda;   Pivotal S.L.
Unknown status

Mon, 19 Nov 2018 12:00:00 EST

Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: carboplatin paclitaxel bevacizumab;   Drug: Standard treatment plus nitroglycerin
Sponsor:   Dutch Society of Physicians for Pulmonology and Tuberculosis
Completed

Wed, 28 Jul 2010 12:00:00 EDT

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

Condition:   Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
Interventions:   Drug: BYL719;   Drug: Paclitaxel
Sponsor:   Novartis Pharmaceuticals
Completed

Fri, 31 Jan 2014 12:00:00 EST

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Nab-Paclitaxel;   Procedure: Biopsy
Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
Recruiting

Wed, 21 Dec 2016 12:00:00 EST

Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer

Conditions:   Locally Advanced Pancreatic Cancer;   Borderline Pancreatic Inoperable Cancer;   Pancreatic Cancer
Interventions:   Drug: Folfirinox;   Drug: Gemcitabine nab-Paclitaxel
Sponsor:   University of Alabama at Birmingham
Terminated

Thu, 26 Jul 2018 12:00:00 EDT

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Conditions:   Pancreatic Neoplasms;   Cholestasis
Interventions:   Drug: nab-paclitaxel;   Drug: Gemcitabine
Sponsor:   Celgene
Terminated

Fri, 17 Oct 2014 12:00:00 EDT

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Drug: Ficlatuzumab
Sponsors:   Dana-Farber Cancer Institute;   AVEO Pharmaceuticals, Inc.
Completed

Fri, 20 Oct 2017 12:00:00 EDT

Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer

Conditions:   Esophageal Cancer;   Induction Chemotherapy
Intervention:   Drug: carboplatin paclitaxel
Sponsor:   Instituto Nacional de Cancer, Brazil
Unknown status

Wed, 05 Oct 2016 12:00:00 EDT

Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Avastin;   Drug: Gemcitabine;   Drug: Abraxane
Sponsor:   University of Miami
Completed

Thu, 19 Jul 2007 12:00:00 EDT

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Intervention:   Drug: Abraxane
Sponsors:   Southeastern Gynecologic Oncology;   Celgene Corporation
Completed

Fri, 27 Apr 2007 12:00:00 EDT

Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer

Conditions:   Locally Advanced Cancer;   Cervical Cancer
Intervention:   Drug: Carboplatin-Paclitaxel adjuvant chemotherapy
Sponsor:   Centre Oscar Lambret
Recruiting

Thu, 11 Jul 2019 12:00:00 EDT

Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis

Condition:   Coronary In-stent Restenosis
Interventions:   Device: Paclitaxel eluting PTCA balloon;   Device: SeQuent® Please paclitaxel eluting balloon
Sponsors:   Second Affiliated Hospital, School of Medicine, Zhejiang University;   West China Hospital;   First Affiliated Hospital of Wenzhou Medical University;   Second Affiliated Hospital of Wenzhou Medical University;   The Third Xiangya Hospital of Central South University;   Hebei Medical University Third Hospital;   TEDA International Cardiovascular Hospital;   Tianjin People's Hospital;   The Second Hospital of Shandong University;   Hainan People's Hospital;   The First Affiliated Hospital of Xiamen University;   Shanghai Chest Hospital;   Renmin Hospital of Wuhan University;   Taizhou Hospital
Recruiting

Mon, 30 Dec 2019 12:00:00 EST

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Imatinib mesylate;   Drug: Paclitaxel
Sponsors:   New Mexico Cancer Care Alliance;   Fred Hutchinson Cancer Research Center;   Novartis
Completed

Wed, 11 Nov 2009 12:00:00 EST

Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer

Conditions:   Head and Neck Neoplasms;   Squamous Cell Carcinoma
Interventions:   Drug: metformin up to 2500mg/d;   Drug: paclitaxel 175mg/m² q21d;   Drug: placebo
Sponsors:   Lucas Vieira dos Santos;   Fundação de Amparo à Pesquisa do Estado de São Paulo;   University of Campinas, Brazil
Terminated

Tue, 12 Apr 2011 12:00:00 EDT

TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions:   Epithelial Ovarian;   Fallopian Tube;   Primary Peritoneal Cancer
Interventions:   Drug: Paclitaxel/Bev (control);   Drug: Paclitaxel/Bev + ZA (experimental)
Sponsors:   M.D. Anderson Cancer Center;   Gateway for Cancer Research;   National Cancer Institute (NCI)
Not yet recruiting

Wed, 22 Sep 2021 12:00:00 EDT

Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)

Condition:   Breast Cancer
Intervention:   Drug: paclitaxel, gemcitabine, lapatinib
Sponsors:   Jungsil Ro;   GlaxoSmithKline;   HK inno.N Corporation
Completed

Mon, 31 May 2010 12:00:00 EDT

Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis

Condition:   In-stent Coronary Artery Restenosis
Intervention:   Device: Paclitaxel Releasing Balloon
Sponsor:   Biotronik AG
Completed

Tue, 18 Aug 2009 12:00:00 EDT

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: BKM120 matching placebo;   Drug: BKM120
Sponsor:   Novartis Pharmaceuticals
Completed

Fri, 06 Apr 2012 12:00:00 EDT

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Conditions:   Triple Negative Breast Cancer;   Nab-paclitaxel
Interventions:   Drug: Nab-paclitaxel + Carboplatin;   Drug: Nab-paclitaxel + Capecitabine
Sponsors:   Hebei Medical University Fourth Hospital;   Beijing 302 Hospital;   CSPC Ouyi Pharmaceutical Co., Ltd.
Recruiting

Tue, 12 Nov 2019 12:00:00 EST

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Cisplatin;   Drug: Paclitaxel
Sponsors:   Dana-Farber Cancer Institute;   Myriad Genetics, Inc.;   Translational Breast Cancer Research Consortium
Active, not recruiting

Wed, 13 Nov 2013 12:00:00 EST

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: CRLX101;   Drug: Paclitaxel
Sponsor:   NewLink Genetics Corporation
Terminated

Tue, 17 Mar 2015 12:00:00 EDT

Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis (PaciFIST-2)

Condition:   Arteriovenous Access Fistula Stenosis
Interventions:   Drug: Paclitaxel;   Procedure: Standard Therapy
Sponsor:   Englewood Hospital and Medical Center
Withdrawn

Mon, 20 Jan 2014 12:00:00 EST

Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer

Condition:   Pancreatic Neoplasms
Intervention:   Drug: Nab paclitaxel and S-1
Sponsor:   Tianjin Medical University Cancer Institute and Hospital
Recruiting

Mon, 22 Mar 2021 12:00:00 EDT

HAI Abraxane With Gemcitabine and Bevacizumab

Condition:   Advanced Cancers
Interventions:   Drug: HAI Abraxane;   Drug: Gemcitabine;   Drug: Bevacizumab;   Drug: Filgrastim
Sponsor:   M.D. Anderson Cancer Center
Completed

Wed, 27 Jan 2010 12:00:00 EST

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Genetic: SGT-53;   Drug: nab-paclitaxel;   Drug: Gemcitabine
Sponsor:   SynerGene Therapeutics, Inc.
Recruiting

Fri, 16 Jan 2015 12:00:00 EST

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

Condition:   Merkel Cell Carcinoma
Interventions:   Drug: Arm A: F16IL2 in combination with paclitaxel;   Drug: Arm B: Paclitaxel
Sponsors:   Philogen S.p.A.;   immatics Biotechnologies GmbH
Terminated

Tue, 04 Feb 2014 12:00:00 EST

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: nab-paclitaxel IV;   Drug: CC-486;   Drug: Duravalumab
Sponsor:   Celgene
Active, not recruiting

Fri, 26 Sep 2014 12:00:00 EDT

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Condition:   Carcinoma, Pancreatic Ductal
Interventions:   Drug: Napabucasin;   Drug: Nab-paclitaxel;   Drug: Gemcitabine
Sponsor:   Sumitomo Dainippon Pharma Oncology, Inc
Completed

Thu, 15 Dec 2016 12:00:00 EST

Lenalidomide and Paclitaxel in Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: Lenalidomide;   Drug: Paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
Terminated

Tue, 07 Jul 2009 12:00:00 EDT

Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis

Condition:   Fistula Stenosis
Interventions:   Drug: Paclitaxel;   Procedure: Standard Therapy
Sponsors:   Englewood Hospital and Medical Center;   Spectranetics Corporation
Terminated

Wed, 05 Jun 2013 12:00:00 EDT

Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women

Conditions:   Tubular Breast Cancer;   Mucinous Breast Cancer;   Invasive Duct Carcinoma of Breast
Interventions:   Drug: Paclitaxel, Cisplatin;   Drug: EC to docetaxel or paclitaxel
Sponsor:   RenJi Hospital
Recruiting

Wed, 28 Jun 2017 12:00:00 EDT

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Carcinoma
Interventions:   Drug: Albumin-bound paclitaxel;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Celgene
Completed

Mon, 08 Oct 2007 12:00:00 EDT

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

Conditions:   Malignant Melanoma of Skin Stage III;   Metastatic Melanoma
Intervention:   Drug: Rituxan
Sponsor:   California Cancer Assocaties for Research & Excellence
Unknown status

Tue, 20 May 2014 12:00:00 EDT

Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)

Condition:   Pancreatic Adenocarcinoma
Interventions:   Drug: Abraxane;   Drug: Gemcitabine
Sponsors:   CCTU- Cancer Theme;   Cambridge University Hospitals NHS Foundation Trust;   Cancer Research UK;   Celgene
Terminated

Mon, 28 Apr 2014 12:00:00 EDT

Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: paclitaxel;   Drug: BKM120
Sponsor:   Washington University School of Medicine
Withdrawn

Tue, 01 Oct 2013 12:00:00 EDT

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: PF-3512676 + Paclitaxel + Carboplatin;   Drug: Paclitaxel + Carboplatin
Sponsor:   Pfizer
Terminated

Thu, 17 Nov 2005 12:00:00 EST

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Conditions:   Bladder Cancer;   Brain and Central Nervous System Tumors;   Breast Cancer;   Esophageal Cancer;   Extragonadal Germ Cell Tumor;   Gastric Cancer;   Lung Cancer;   Ovarian Cancer;   Prostate Cancer
Interventions:   Drug: lapatinib;   Drug: paclitaxel
Sponsors:   University of California, San Francisco;   National Cancer Institute (NCI)
Completed

Wed, 12 Apr 2006 12:00:00 EDT

Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: LCL161;   Drug: Gemcitabine;   Drug: nab-Paclitaxel
Sponsors:   US Oncology Research;   Novartis Pharmaceuticals;   Delta Clinical Research, LLC
Unknown status

Wed, 04 Sep 2013 12:00:00 EDT

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Condition:   Urologic Neoplasm
Interventions:   Drug: Cetuximab;   Drug: Paclitaxel
Sponsors:   Fox Chase Cancer Center;   Bristol-Myers Squibb
Completed

Mon, 10 Jul 2006 12:00:00 EDT

Feasibility Study of Intraperitoneal Paclitaxel

Condition:   Gastric Cancer
Intervention:   Drug: IP Paclitaxel
Sponsor:   National University Hospital, Singapore
Unknown status

Tue, 04 Dec 2012 12:00:00 EST

Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Abraxane
Sponsors:   Accelerated Community Oncology Research Network;   Genentech, Inc.;   Celgene Corporation
Completed

Tue, 05 Dec 2006 12:00:00 EST

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Condition:   Borderline Resectable Pancreatic Cancer
Intervention:   Drug: nab-paclitaxel and S-1
Sponsor:   Peking Union Medical College Hospital
Recruiting

Fri, 22 Feb 2019 12:00:00 EST

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Conditions:   Osteosarcoma;   Ewing Sarcoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma
Interventions:   Drug: nab-Paclitaxel;   Drug: Gemcitabine
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   National Pediatric Cancer Foundation
Recruiting

Wed, 26 Oct 2016 12:00:00 EDT

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

Condition:   Breast Cancer
Interventions:   Drug: BIBF + Paclitaxel;   Drug: Paclitaxel
Sponsors:   Centro Nacional de Investigaciones Oncologicas CARLOS III;   Hospital Universitario de Fuenlabrada;   M.D. Anderson Cancer Center;   Hospital Universitari de Bellvitge;   Grupo Espanol de Investigacion del Cancer de Mama
Completed

Fri, 02 Dec 2011 12:00:00 EST

Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer

Condition:   Gastric Cancer
Intervention:   Drug: Nab-paclitaxel combined with S-1
Sponsor:   Shanghai Zhongshan Hospital
Not yet recruiting

Thu, 06 Jun 2019 12:00:00 EDT

Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer

Conditions:   Cervical Cancer;   Chemotherapy Effect;   Programmed Cell Death 1 Receptor / Antagonists & Inhibitors;   Neoadjuvant Therapy
Intervention:   Drug: Sindilimab +paclitaxel+ cisplantin
Sponsor:   Sun Yat-sen University
Not yet recruiting

Tue, 16 Mar 2021 12:00:00 EDT

Study of Weekly LOC-paclitaxel Injection for Melanoma

Condition:   Melanoma
Intervention:   Drug: LOC-paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   American Regent, Inc.
Terminated

Fri, 25 Dec 2009 12:00:00 EST

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: Albumin-bound paclitaxel (ABI-007);   Drug: Gemcitabine
Sponsor:   Celgene
Completed

Mon, 16 Feb 2009 12:00:00 EST

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane);   Drug: Sorafenib (Nexavar)
Sponsors:   Veeda Oncology;   Bayer;   Celgene Corporation
Terminated

Tue, 05 Feb 2008 12:00:00 EST

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Condition:   Ovarian Cancer
Interventions:   Device: NovoTTF-100L(O);   Drug: Paclitaxel
Sponsor:   NovoCure Ltd.
Recruiting

Tue, 07 May 2019 12:00:00 EDT

Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Oraxol;   Drug: IV paclitaxel
Sponsor:   Athenex, Inc.
Active, not recruiting

Tue, 03 Nov 2015 12:00:00 EST

Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer

Condition:   Locally Advanced Pancreatic Cancer
Intervention:   Drug: Nab-paclitaxel and S-1
Sponsor:   Peking Union Medical College Hospital
Recruiting

Thu, 21 Mar 2019 12:00:00 EDT

Local Paclitaxel Delivery for SFA Disease

Conditions:   Atherosclerosis;   Angioplasty;   Peripheral Arterial Disease
Intervention:   Drug: Paclitaxel
Sponsor:   University of Oklahoma
Completed

Mon, 12 Jan 2009 12:00:00 EST

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

Condition:   Early Breast Cancer
Intervention:   Drug: Nab-paclitaxel in combination with pyrotinib
Sponsors:   Peking Union Medical College Hospital;   Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting

Wed, 09 Dec 2020 12:00:00 EST

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Condition:   Carcinoma, Transitional Cell
Interventions:   Drug: nanoparticle albumin-bound paclitaxel, S-1;   Drug: Gemcitabine, cisplatin
Sponsor:   Chinese PLA General Hospital
Completed

Mon, 13 Feb 2017 12:00:00 EST

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Condition:   Ovarian Cancer
Intervention:   Drug: Gleevec/Paclitaxel
Sponsors:   NYU Langone Health;   Novartis
Terminated

Tue, 10 Feb 2009 12:00:00 EST

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Condition:   Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Interventions:   Drug: Necitumumab;   Drug: Nab-Paclitaxel;   Drug: Carboplatin
Sponsors:   Eli Lilly and Company;   Celgene
Completed

Thu, 19 Mar 2015 12:00:00 EDT

Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study

Condition:   Metastatic Malignant Melanoma
Interventions:   Drug: Avastin;   Drug: Abraxane
Sponsors:   Lynn E. Spitler, MD;   Celgene Corporation;   Genentech, Inc.
Completed

Thu, 19 Apr 2007 12:00:00 EDT

Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast Cancer

Condition:   Triple-Negative Breast Cancer
Interventions:   Biological: Magrolimab;   Drug: Nab-Paclitaxel;   Drug: Paclitaxel
Sponsor:   Gilead Sciences
Not yet recruiting

Mon, 12 Jul 2021 12:00:00 EDT

QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

Condition:   Pancreatic Cancer, Adult
Interventions:   Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: NPC-1C
Sponsor:   Precision Biologics, Inc
Terminated

Wed, 17 Apr 2013 12:00:00 EDT

Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: nab-paclitaxel
Sponsor:   Shanghai Cancer Hospital, China
Unknown status

Thu, 21 Jun 2012 12:00:00 EDT

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Condition:   Anaplastic Thyroid Cancer
Interventions:   Drug: Trametinib;   Drug: Paclitaxel
Sponsors:   Memorial Sloan Kettering Cancer Center;   Novartis
Recruiting

Tue, 21 Mar 2017 12:00:00 EDT

A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

Condition:   Stage IV Pancreatic Cancer
Interventions:   Drug: OMP-59R5;   Drug: Gemcitabine;   Drug: Placebo;   Drug: Nab-Paclitaxel
Sponsor:   OncoMed Pharmaceuticals, Inc.
Completed

Tue, 24 Jul 2012 12:00:00 EDT

Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)

Condition:   Locally Advanced, Squamous Cell Carcinoma of the Vulva
Intervention:   Drug: Paclitaxel and Carboplatin
Sponsor:   The Netherlands Cancer Institute
Recruiting

Tue, 10 Dec 2019 12:00:00 EST

A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

Condition:   Advanced Urothelial Carcinoma
Interventions:   Drug: anti-PD-L1 antibody;   Drug: albumin bound paclitaxel
Sponsor:   Lee's Pharmaceutical Limited
Recruiting

Tue, 27 Oct 2020 12:00:00 EDT

Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis

Conditions:   Stomach Neoplasms;   Paclitaxel;   Peritoneal Metastases
Intervention:   Drug: Paclitaxel
Sponsor:   Seoul St. Mary's Hospital
Recruiting

Tue, 29 Jun 2021 12:00:00 EDT

Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer

Condition:   Anaplastic Thyroid Cancer
Interventions:   Drug: Fosbretabulin + paclitaxel + carboplatin;   Drug: Placebo + paclitaxel + carboplatin
Sponsor:   Mateon Therapeutics
Withdrawn

Fri, 05 Oct 2012 12:00:00 EDT

Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

Condition:   Mixed Tumor, Mullerian
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   M.D. Anderson Cancer Center
Completed

Tue, 17 Jul 2007 12:00:00 EDT

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Condition:   Uterine Cancer
Interventions:   Drug: Imatinib Mesylate;   Drug: Paclitaxel
Sponsor:   M.D. Anderson Cancer Center
Terminated

Wed, 25 Jul 2007 12:00:00 EDT

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Condition:   Advanced Solid Cancers
Interventions:   Drug: Rapamune;   Drug: Abraxane
Sponsors:   Yale University;   Celgene Corporation
Terminated

Thu, 15 Jun 2006 12:00:00 EDT

Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma

Condition:   Neuroendocrine Carcinoma
Intervention:   Drug: Nab-paclitaxel Combined With Bevacizumab
Sponsors:   Peking University;   Qilu Pharmaceutical Co., Ltd.
Recruiting

Tue, 12 Jan 2021 12:00:00 EST

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: defactinib;   Drug: Paclitaxel
Sponsor:   Verastem, Inc.
Completed

Tue, 29 Jan 2013 12:00:00 EST

Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy

Condition:   Metastatic Squamous Cell Carcinoma of the Vulva
Intervention:   Drug: Paclitaxel and Carboplatin
Sponsor:   The Netherlands Cancer Institute
Recruiting

Wed, 13 Nov 2019 12:00:00 EST

Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix

Conditions:   Cervical Cancer;   Uterine Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Terminated

Fri, 29 Feb 2008 12:00:00 EST

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Biological: Intraperitoneal tgDCC-E1A;   Drug: Paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Terminated

Tue, 01 Feb 2005 12:00:00 EST

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Nab-Paclitaxel;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Active, not recruiting

Fri, 24 Apr 2015 12:00:00 EDT

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: nab-paclitaxel;   Drug: gemcitabine;   Drug: placebo;   Drug: Necuparanib
Sponsor:   Momenta Pharmaceuticals, Inc.
Terminated

Mon, 18 Jun 2012 12:00:00 EDT

Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Albumin paclitaxel plus carboplatin;   Drug: Gemcitabine plus carboplatin
Sponsor:   Chinese Society of Lung Cancer
Completed

Tue, 09 Nov 2010 12:00:00 EST

Prospective, Multicenter, Non-randomized, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease.

Condition:   Hemodialysis Access Failure
Intervention:   Device: Paclitaxel-eluting graft
Sponsor:   Samsung Medical Center
Recruiting

Wed, 26 Feb 2020 12:00:00 EST

Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy

Condition:   Cervical Cancer
Interventions:   Drug: paclitaxel;   Drug: cisplatin;   Procedure: Radical hysterectomy and bilateral pelvic lymphadenectomy
Sponsors:   Chang Gung Memorial Hospital;   Asian Gynecologic Oncology Group;   Taiwanese Gynecologic Oncology Group
Recruiting

Mon, 04 May 2015 12:00:00 EDT

Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer

Condition:   Advanced Gastric Cancer
Intervention:   Drug: CM082 plus paclitaxel
Sponsor:   AnewPharma
Unknown status

Mon, 18 Sep 2017 12:00:00 EDT

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Nab-Paclitaxel
Sponsor:   NYU Langone Health
Recruiting

Wed, 27 Apr 2016 12:00:00 EDT

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

Condition:   Pancreatic Cancer
Intervention:   Drug: albumin-bound paclitaxel
Sponsor:   Tianjin Medical University Cancer Institute and Hospital
Recruiting

Sun, 05 Sep 2021 12:00:00 EDT

Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer

Conditions:   Pancreatic Cancer;   Neoadjuvant Chemotherapy
Interventions:   Drug: S1,;   Drug: Paclitaxel-albumin
Sponsor:   Zhejiang Provincial People's Hospital
Terminated

Thu, 12 Jul 2018 12:00:00 EDT

Treatment of Moderate Vein Graft Lesions With Paclitaxel Drug Eluting Stents: The VELETI Trial

Condition:   Coronary Artery Bypass Grafting
Intervention:   Device: Paclitaxel eluting stent
Sponsors:   Laval University;   Boston Scientific Corporation
Completed

Fri, 10 Feb 2006 12:00:00 EST

ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Small Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Carcinoma
Interventions:   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Laboratory Biomarker Analysis
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed

Mon, 03 Apr 2006 12:00:00 EDT

Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Paclitaxel, Carboplatin
Sponsors:   Shanghai Jiao Tong University School of Medicine;   Fudan University;   Ruijin Hospital
Completed

Thu, 16 Sep 2010 12:00:00 EDT

A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

Condition:   Solid Tumor
Intervention:   Drug: HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules
Sponsors:   Athenex, Inc.;   PharmaEssentia;   Zenith Technology Corporation Limited
Completed

Mon, 29 Jul 2019 12:00:00 EDT

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

Condition:   Advanced Gastric Adenocarcinoma
Intervention:   Other: Camrelizumab, Albumin-bound paclitaxel, S-1
Sponsor:   Henan Cancer Hospital
Not yet recruiting

Sat, 19 Dec 2020 12:00:00 EST

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: BYL-719 (alpelisib);   Drug: Nab-paclitaxel
Sponsors:   Priyanka Sharma;   Novartis Pharmaceuticals
Active, not recruiting

Wed, 04 Mar 2015 12:00:00 EST

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Condition:   Breast Cancer
Intervention:   Drug: Dasatinib and Paclitaxel
Sponsors:   Memorial Sloan Kettering Cancer Center;   Bristol-Myers Squibb
Completed

Mon, 12 Jan 2009 12:00:00 EST

Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy

Condition:   Squamous Cell Carcinoma of the Esophagus
Interventions:   Drug: Ramucirumab;   Drug: Paclitaxel
Sponsors:   Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest;   Eli Lilly and Company;   Trium Analysis Online GmbH
Active, not recruiting

Mon, 03 Dec 2018 12:00:00 EST

Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer
Intervention:   Drug: Pazopanib plus Paclitaxel
Sponsors:   Loyola University;   GlaxoSmithKline
Withdrawn

Wed, 11 Aug 2010 12:00:00 EDT

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Conditions:   Pancreatic Cancer;   Pancreatic Adenocarcinoma;   Pancreas Ductal Adenocarcinoma
Interventions:   Drug: Nab-paclitaxel and gemcitabine for R-PDAC Patients;   Drug: Nab-paclitaxel and gemcitabine for BR-PDAC Patients
Sponsors:   Academic Thoracic Oncology Medical Investigators Consortium;   Celgene Corporation;   Criterium, Inc.;   University of Colorado, Denver
Recruiting

Wed, 30 Mar 2016 12:00:00 EDT

Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention

Conditions:   Restenosis;   Peripheral Arterial Disease
Interventions:   Drug: Paclitaxel;   Drug: Placebo
Sponsors:   Midwest Cardiovascular Research Foundation;   Spectranetics Corporation
Unknown status

Tue, 15 May 2012 12:00:00 EDT

PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: AZD5363;   Drug: Placebo
Sponsors:   Queen Mary University of London;   AstraZeneca;   Cancer Research UK
Active, not recruiting

Wed, 22 Apr 2015 12:00:00 EDT

Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib

Condition:   Solid Tumors
Interventions:   Drug: Weekly Abraxane and Daily Vandetanib;   Drug: Abraxane every three weeks and daily vandetanib
Sponsors:   University of Southern California;   AstraZeneca;   Celgene Corporation
Completed

Fri, 25 Apr 2008 12:00:00 EDT

Recurrent Stenoses in Arteriovenous Fistula (AVF) for Dialysis Access: CuttIng ballooN angioplaSTy Combined wITh Paclitaxel drUg coaTed Balloon Angioplasty, an observatIONal Clinical Study

Condition:   Dialysis Access Malfunction
Intervention:   Device: Cutting balloon followed by paclitaxel coated balloon
Sponsors:   Singapore General Hospital;   Boston Scientific Corporation
Completed

Tue, 24 Aug 2021 12:00:00 EDT

Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients

Condition:   Cancer of Pancreas
Interventions:   Drug: Nab-paclitaxel plus Gemcitabine;   Drug: Gemcitabine monotherapy;   Drug: S-1 monotherapy
Sponsor:   Chinese PLA General Hospital
Unknown status

Mon, 11 Sep 2017 12:00:00 EDT

Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line

Condition:   Squamous Cell Carcinoma
Interventions:   Dietary Supplement: Licochalcone A;   Drug: Paclitaxel
Sponsor:   Cairo University
Unknown status

Tue, 26 Sep 2017 12:00:00 EDT

Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Paclitaxel dosing according to SmPC;   Drug: Individualized pharmacokinetically driven paclitaxel dosing
Sponsors:   Central European Society for Anticancer Drug Research;   Saladax Biomedical, Inc.;   Cantonal Hospital of St. Gallen;   University Hospital, Basel, Switzerland;   Assign Data Management and Biostatistics GmbH;   Wake Forest University;   University Hospital, Essen
Completed

Thu, 31 Mar 2011 12:00:00 EDT

Pharmacokinetics Study of Liposomal Paclitaxel in Humans

Condition:   Cancer
Interventions:   Drug: Liposomal paclitaxel;   Drug: Paclitaxel
Sponsors:   Shandong Luye Pharmaceutical Co., Ltd.;   Nanjing Sike Pharmaceutical Co., Ltd.
Completed

Mon, 04 Feb 2008 12:00:00 EST

A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Condition:   Biliary Tract Cancer
Interventions:   Drug: Nab-paclitaxel + Cisplatin;   Drug: Gemcitabine + Cisplatin
Sponsors:   Huazhong University of Science and Technology;   CSPC Ouyi Pharmaceutical Co., Ltd.
Recruiting

Thu, 31 Dec 2020 12:00:00 EST

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Conditions:   Anaplastic Thyroid Cancer;   Recurrent Thyroid Cancer
Interventions:   Drug: efatutazone;   Drug: paclitaxel
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Daiichi Sankyo, Inc.
Active, not recruiting

Mon, 02 Jun 2014 12:00:00 EDT

Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer

Condition:   Cholangiocarcinoma
Intervention:   Drug: nab-paclitaxel
Sponsor:   Istituto Clinico Humanitas
Recruiting

Thu, 09 May 2019 12:00:00 EDT

Belgian-Italian Trial to Evaluate the Efficacy and Safety of Below The Knee (BTK) Treatment With the Luminor 14 Paclitaxel Coated Percutaneous Transluminal Angioplasty Balloon Catheter of iVascular

Condition:   Peripheral Arterial Disease
Intervention:   Device: Luminor-14 Paclitaxel eluting balloon
Sponsor:   ID3 Medical
Recruiting

Tue, 19 Feb 2019 12:00:00 EST

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Condition:   Pancreatic Ductal Carcinoma
Interventions:   Other: Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20);   Drug: Placebo;   Drug: nab-Paclitaxel;   Drug: Gemcitabine
Sponsor:   Halozyme Therapeutics
Terminated

Tue, 22 Mar 2016 12:00:00 EDT

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine

Conditions:   Metastatic Pancreatic Cancer;   Adenocarcinoma of the Pancreas
Interventions:   Drug: nab-paclitaxel and gemcitabine;   Drug: gemcitabine mono and nab-paclitaxel and gemcitabine
Sponsors:   AIO-Studien-gGmbH;   ClinAssess GmbH;   Celgene Corporation
Active, not recruiting

Wed, 30 Sep 2015 12:00:00 EDT

Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: LY2780301 + paclitaxel
Sponsor:   Institut Paoli-Calmettes
Terminated

Fri, 08 Nov 2013 12:00:00 EST

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Conditions:   Esophageal Cancer;   Gastric Cancer
Intervention:   Drug: Afatinib and Paclitaxel
Sponsors:   Memorial Sloan Kettering Cancer Center;   Boehringer Ingelheim;   University of Southern California;   Dana-Farber Cancer Institute;   United States Department of Defense
Active, not recruiting

Wed, 01 Feb 2012 12:00:00 EST

The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions

Conditions:   Coronary Artery Disease;   Chronic Total Occlusion;   Native Coronary Artery
Interventions:   Device: paclitaxel eluting PTCA balloon catheter (SeQuent Please);   Device: paclitaxel eluting Taxus stent (Boston Scientific)
Sponsors:   University of Ulm;   B. Braun Melsungen AG
Completed

Thu, 01 May 2008 12:00:00 EDT

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

Conditions:   Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention:   Drug: Dasatinib, Paclitaxel, and Carboplatin
Sponsor:   AA Secord
Completed

Tue, 06 May 2008 12:00:00 EDT

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Conditions:   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Raltitrexed;   Drug: Paclitaxel
Sponsor:   Chinese Academy of Medical Sciences
Completed

Mon, 20 Mar 2017 12:00:00 EDT

Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

Condition:   Unresectable Pancreatic Carcinoma
Interventions:   Drug: Tocilizumab;   Drug: Gemcitabine;   Drug: nab-Paclitaxel
Sponsors:   Herlev Hospital;   Celgene
Active, not recruiting

Tue, 10 May 2016 12:00:00 EDT

Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer

Condition:   Pancreatic Cancer
Intervention:   Drug: GAX - Gemcitabine, Abraxane and Xeloda
Sponsor:   Stamford Hospital
Withdrawn

Wed, 21 Oct 2015 12:00:00 EDT

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)

Condition:   Muscle-Invasive Bladder Carcinoma
Interventions:   Drug: Nivolumab + Nab-paclitaxel;   Drug: Nivolumab
Sponsors:   IRCCS San Raffaele;   Bristol-Myers Squibb
Not yet recruiting

Thu, 06 May 2021 12:00:00 EDT

Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers

Condition:   Advanced Biliary Tract Cancers
Intervention:   Drug: cisplatin and nab-paclitaxel
Sponsors:   Henan Provincial People's Hospital;   CSPC Ouyi Pharmaceutical Co., Ltd.
Recruiting

Tue, 01 Oct 2019 12:00:00 EDT

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Conditions:   Non-Small-Cell Lung Cancer Metastatic;   Non-Small Cell Carcinoma of Lung, TNM Stage 4;   Nonsmall Cell Lung Cancer;   Non Small Cell Lung Cancer Recurrent
Interventions:   Drug: Nivolumab;   Drug: nab-paclitaxel
Sponsors:   Alliance Foundation Trials, LLC.;   Celgene Corporation;   Bristol-Myers Squibb
Unknown status

Fri, 18 Nov 2016 12:00:00 EST

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Durvalumab
Sponsors:   King Faisal Specialist Hospital & Research Center;   AstraZeneca
Completed

Fri, 11 Dec 2015 12:00:00 EST

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: paclitaxel + carboplatin + bevacizumab;   Drug: carboplatin + paclitaxel + bevacizumab + PF-3512676
Sponsor:   Pfizer
Terminated

Wed, 12 Apr 2006 12:00:00 EDT

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)

Conditions:   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Biological: pembroliziumab;   Drug: paclitaxel
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Wed, 25 Feb 2015 12:00:00 EST

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Condition:   Small Cell Lung Cancer
Interventions:   Drug: APG-1252;   Drug: Paclitaxel
Sponsor:   Ascentage Pharma Group Inc.
Active, not recruiting

Tue, 24 Dec 2019 12:00:00 EST

Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Conditions:   Ovarian Cancer;   Relapsed or Refractory;   Chiauranib;   Paclitaxel
Interventions:   Drug: chiauranib;   Drug: Placebo;   Drug: Paclitaxel
Sponsor:   Chipscreen Biosciences, Ltd.
Not yet recruiting

Thu, 10 Jun 2021 12:00:00 EDT

Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Paclitaxel;   Radiation: LDWART (Low Dose Whole Abdominal Radiation Therapy)
Sponsor:   National University Hospital, Singapore
Unknown status

Wed, 09 Sep 2015 12:00:00 EDT

Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).

Conditions:   Fallopian Tube Cancer;   Peritoneum Cancer;   Epithelial Ovarian Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Marilyn Huang, MD, MS;   Merck Sharp & Dohme Corp.
Recruiting

Fri, 15 Jul 2016 12:00:00 EDT

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: paclitaxel;   Genetic: microarray analysis;   Procedure: biopsy;   Procedure: neoadjuvant therapy;   Drug: Paclitaxel
Sponsors:   Georgetown University;   National Cancer Institute (NCI)
Terminated

Thu, 05 Aug 2004 12:00:00 EDT

A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Vantictumab combined with paclitaxel
Sponsor:   OncoMed Pharmaceuticals, Inc.
Completed

Thu, 31 Oct 2013 12:00:00 EDT

Paclitaxel Detection in NSCLC Treated With TC Regimen

Condition:   Non-small Cell Lung Cancer
Intervention:   Drug: Paclitaxel and Carboplatin regimen
Sponsor:   Sun Yat-sen University
Terminated

Thu, 14 Apr 2016 12:00:00 EDT

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Condition:   Breast Cancer
Intervention:   Drug: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
Sponsor:   Fudan University
Recruiting

Thu, 03 Sep 2020 12:00:00 EDT

Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Paclitaxel, Carboplatin;   Drug: Paclitaxel, Epirubicin
Sponsor:   Tianjin Medical University Cancer Institute and Hospital
Unknown status

Mon, 04 Aug 2014 12:00:00 EDT

A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer

Conditions:   Advanced Adenocarcinoma;   Metastatic Adenocarcinoma
Interventions:   Drug: Hydroxychloroquine (HCQ);   Drug: Gemcitabine;   Drug: Abraxane
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting

Tue, 10 Jan 2012 12:00:00 EST

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: LCL161;   Drug: paclitaxel
Sponsor:   Novartis Pharmaceuticals
Completed

Tue, 12 Jun 2012 12:00:00 EDT

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Condition:   Borderline Resectable Pancreatic Cancer
Interventions:   Drug: gemcitabine/nab-paclitaxel;   Drug: mFOLFIRINOX
Sponsor:   Nathan Bahary, MD
Terminated

Tue, 16 Sep 2014 12:00:00 EDT

Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC

Condition:   Small Cell Lung Cancer
Intervention:   Drug: Nabpaclitaxel
Sponsors:   Gruppo Oncologico Italiano di Ricerca Clinica;   Temas srl;   Clirest s.r.l.;   Mipharm S.p.A.;   Istituto Toscano Tumori
Unknown status

Tue, 18 Jul 2017 12:00:00 EDT

Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)

Condition:   Colorectal Cancer
Intervention:   Drug: Abraxane
Sponsors:   Mt. Sinai Medical Center, Miami;   Celgene Corporation
Completed

Thu, 28 Feb 2008 12:00:00 EST

Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer

Condition:   Head and Neck Cancer
Intervention:   Drug: Panitumumab + paclitaxel
Sponsors:   Grupo Español de Tratamiento de Tumores de Cabeza y Cuello;   Amgen;   Trial Form Support S.L.
Completed

Tue, 21 Dec 2010 12:00:00 EST

Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib

Condition:   Gastrointestinal Stromal Tumors
Intervention:   Drug: Paclitaxel
Sponsor:   Asan Medical Center
Completed

Wed, 18 Nov 2015 12:00:00 EST

Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC)

Condition:   Non-Small Cell Lung Cancer
Intervention:   Other: dosage of paclitaxel
Sponsor:   Caicun Zhou
Unknown status

Mon, 10 Feb 2014 12:00:00 EST

Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Paclitaxel/Carboplatin/Gefitinib;   Drug: Paclitaxel/Carboplatin
Sponsors:   Asan Medical Center;   AstraZeneca
Completed

Wed, 08 Sep 2010 12:00:00 EDT

Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients

Condition:   Gastric Adenocarcinoma
Intervention:   Drug: Nanoparticle Albumin-Bound Paclitaxel
Sponsor:   Peking University
Completed

Fri, 15 Apr 2011 12:00:00 EDT

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Condition:   Nasopharyngeal Carcinoma
Intervention:   Combination Product: Paclitaxel(Albumin-bound)
Sponsor:   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not yet recruiting

Wed, 24 Feb 2021 12:00:00 EST

QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

Condition:   Advanced Pancreatic Cancer
Interventions:   Biological: Gemcitabine;   Biological: Nab-paclitaxel;   Biological: ALT-803
Sponsor:   Altor BioScience
Completed

Thu, 24 Sep 2015 12:00:00 EDT

Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Albumin-bound paclitaxel plus capecitabine;   Drug: capecitabine
Sponsor:   Fudan University
Recruiting

Wed, 03 Mar 2021 12:00:00 EST

Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)

Condition:   Breast Cancer
Interventions:   Drug: Pre operativeTrastuzumab;   Drug: ABI-007 (Abraxane);   Drug: Vinorelbine
Sponsor:   Emory University
Completed

Thu, 19 Jul 2007 12:00:00 EDT

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

Conditions:   Urothelial Cancer;   Bladder Cancer
Intervention:   Drug: Lapatinib and Paclitaxel
Sponsors:   University of Michigan Rogel Cancer Center;   GlaxoSmithKline
Withdrawn

Thu, 04 Oct 2012 12:00:00 EDT

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Eftilagimod Alpha;   Drug: Paclitaxel
Sponsor:   Immutep S.A.S.
Not yet recruiting

Wed, 05 Feb 2020 12:00:00 EST

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Drug: Paricalcitol;   Other: Placebo
Sponsors:   Dana-Farber Cancer Institute;   Stand Up To Cancer;   Lustgarten Foundation;   American Association for Cancer Research
Recruiting

Fri, 11 May 2018 12:00:00 EDT

Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: TOCOSOL(R) Paclitaxel
Sponsor:   Achieve Life Sciences
Completed

Mon, 15 Nov 2004 12:00:00 EST

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Condition:   Metastatic Melanoma
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Everolimus
Sponsors:   SCRI Development Innovations, LLC;   Novartis
Completed

Tue, 17 Nov 2009 12:00:00 EST

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma

Condition:   Refractory Plasma Cell Myeloma
Interventions:   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Laboratory Biomarker Analysis
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Terminated

Fri, 20 Jul 2012 12:00:00 EDT

Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

Condition:   Advanced Gastric Cancer
Intervention:   Drug: Camrelizumab, Apatinib and Nab-paclitaxel
Sponsor:   Chinese PLA General Hospital
Recruiting

Mon, 02 Dec 2019 12:00:00 EST

A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy

Conditions:   Advanced Gastric Cancer;   Esophagogastric Junction Cancer
Interventions:   Drug: Paclitaxel;   Drug: RAD001
Sponsor:   Krankenhaus Nordwest
Completed

Thu, 25 Nov 2010 12:00:00 EST

Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma

Conditions:   Esophageal Neoplasms;   Stomach Neoplasms;   Neoplasm Metastasis
Interventions:   Drug: Regorafenib;   Drug: Paclitaxel
Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Completed

Thu, 02 Apr 2015 12:00:00 EDT

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: BIIB022 With Paclitaxel and Carboplatin
Sponsor:   Biogen
Completed

Wed, 02 Sep 2009 12:00:00 EDT

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer

Conditions:   Advanced or Metastatic Solid Tumors;   Advanced or Metastatic Breast Cancer
Interventions:   Drug: Azacitidine (Vidaza);   Drug: Nab-paclitaxel (Abraxane)
Sponsors:   University of Utah;   Celgene Corporation
Completed

Mon, 08 Sep 2008 12:00:00 EDT

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Condition:   Advanced Solid Tumors
Interventions:   Drug: TAS-119;   Drug: Paclitaxel
Sponsor:   Taiho Oncology, Inc.
Terminated

Thu, 08 May 2014 12:00:00 EDT

Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: Paclitaxel;   Drug: Cetuximab
Sponsor:   Medical University of Vienna
Recruiting

Thu, 20 Feb 2020 12:00:00 EST

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: MPDL3280A;   Drug: Carboplatin;   Drug: Nab-paclitaxel
Sponsors:   Columbia University;   Genentech, Inc.;   Celgene Corporation
Active, not recruiting

Tue, 22 Mar 2016 12:00:00 EDT

CDK4/6 Tumor, Abemaciclib, Paclitaxel

Condition:   Tumors
Intervention:   Drug: abemaciclib+paclitaxel
Sponsor:   Yonsei University
Recruiting

Tue, 20 Oct 2020 12:00:00 EDT

Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma

Conditions:   Glioblastoma;   Gliosarcoma;   GBM;   Glioblastoma Multiforme;   Glioblastoma, IDH-wildtype;   Recurrent Glioblastoma
Interventions:   Device: Sonication for opening of blood-brain barrier;   Drug: Chemotherapy, albumin-bound paclitaxel
Sponsors:   Northwestern University;   CarThera;   Bristol-Myers Squibb;   Lantheus Medical Imaging
Recruiting

Thu, 27 Aug 2020 12:00:00 EDT

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Conditions:   Chemotherapeutic Agent Toxicity;   Endometrial Adenocarcinoma;   Fallopian Tube Carcinoma;   Gastrointestinal Complication;   Malignant Ovarian Mixed Epithelial Tumor;   Neurotoxicity Syndrome;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Primary Peritoneal Carcinoma;   Stage II Ovarian Cancer;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer;   Undifferentiated Ovarian Carcinoma
Interventions:   Drug: Paclitaxel;   Drug: Cisplatin
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed

Tue, 23 Dec 2008 12:00:00 EST

Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer

Condition:   Carcinoma, Pancreatic Ductal
Intervention:   Drug: Paclitaxel and gemcitabine
Sponsor:   New York Presbyterian Brooklyn Methodist Hospital
Withdrawn

Tue, 27 Sep 2005 12:00:00 EDT

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: Carboplatin;   Drug: ABI-007
Sponsors:   Loyola University;   Genentech, Inc.;   Celgene Corporation
Completed

Wed, 09 Apr 2008 12:00:00 EDT

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Conditions:   Advanced Pancreatic Adenocarcinoma;   Pancreatic Cancer;   Pancreatic Ductal Adenocarcinoma
Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Drug: L-glutamine
Sponsors:   Jun Gong, MD;   Emmaus Medical, Inc.
Recruiting

Wed, 18 Nov 2020 12:00:00 EST

A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen

Condition:   Cancer
Intervention:   Drug: Custirsen, paclitaxel and carboplatin
Sponsors:   Achieve Life Sciences;   Teva Pharmaceutical Industries
Completed

Thu, 22 Dec 2011 12:00:00 EST

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Recurrent Ovarian Cancer;   Recurrent Fallopian Tube Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Drug: Relacorilant, 100mg QD;   Drug: Nab-paclitaxel, 80mg/m^2;   Drug: Nab-paclitaxel, 100mg/m^2;   Drug: Relacorilant, 150mg QD
Sponsor:   Corcept Therapeutics
Active, not recruiting

Mon, 17 Dec 2018 12:00:00 EST

Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer

Condition:   Advanced Biliary Tract Cancer
Intervention:   Drug: Toripalimab Combined With S1 and Albumin Paclitaxel
Sponsor:   Dai, Guanghai
Unknown status

Mon, 22 Jul 2019 12:00:00 EDT

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Conditions:   ER Positive, Her2 Negative Breast Cancer Patients;   Triple Negative Breast Cancer Patients
Interventions:   Drug: MM-121;   Drug: Paclitaxel
Sponsors:   Merrimack Pharmaceuticals;   Sanofi
Completed

Mon, 22 Aug 2011 12:00:00 EDT

Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)

Condition:   Advanced Non-small Cell Lung Cancer
Intervention:   Drug: paclitaxel poliglumex, pemetrexed
Sponsors:   Dartmouth-Hitchcock Medical Center;   CTI BioPharma
Completed

Mon, 18 Jun 2007 12:00:00 EDT

Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients

Condition:   Metastatic Pancreatic Ductal Adenocarcinoma
Interventions:   Drug: PF-04136309;   Drug: Nab-paclitaxel;   Drug: Gemcitabine
Sponsor:   Pfizer
Terminated

Mon, 11 Apr 2016 12:00:00 EDT

A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Napabucasin;   Drug: Paclitaxel
Sponsor:   Sumitomo Dainippon Pharma Oncology, Inc
Terminated

Thu, 07 Jul 2016 12:00:00 EDT

Clinical Study of Liposomal Paclitaxel in Chinese Patients

Condition:   Solid Tumor
Intervention:   Drug: Liposomal paclitaxel
Sponsor:   Nanjing Sike Pharmaceutical Co., Ltd.
Unknown status

Wed, 15 Apr 2009 12:00:00 EDT

Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study

Condition:   HER2-positive Breast Cancer
Intervention:   Combination Product: pyrotinib maleate tablets+nab-paclitaxel
Sponsor:   Hebei Medical University Fourth Hospital
Not yet recruiting

Thu, 18 Apr 2019 12:00:00 EDT

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: JS001,an engineered anti-PD-1 antibody;   Drug: Nab-Paclitaxel;   Drug: Placebo
Sponsor:   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Suspended

Mon, 17 Dec 2018 12:00:00 EST

Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer

Condition:   Esophageal Cancer
Intervention:   Drug: nab-paclitaxel group
Sponsor:   Tianjin Medical University Cancer Institute and Hospital
Unknown status

Thu, 05 May 2016 12:00:00 EDT

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

Condition:   Metastatic Urothelial Carcinoma
Intervention:   Drug: Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel
Sponsor:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Completed

Wed, 14 Mar 2018 12:00:00 EDT

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Condition:   Triple-negative Breast Cancer
Intervention:   Drug: SHR-1210+Albumin-bound paclitaxel + epirubicin
Sponsor:   Henan Cancer Hospital
Not yet recruiting

Mon, 30 Dec 2019 12:00:00 EST

PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer

Conditions:   Peritoneal Carcinomatosis;   Ovarian Cancer Stage IIIB;   Ovarian Cancer Stage IIIC;   Ovarian Cancer Stage IV;   Breast Cancer Stage IIIB;   Breast Cancer Stage IIIc;   Breast Cancer Stage IV;   Stomach Cancer Stage III;   Stomach Cancer Stage IV With Metastases;   Pancreas Cancer, Stage III;   Pancreas Cancer, Stage IV
Intervention:   Drug: PIPAC with Abraxane
Sponsors:   University Hospital, Ghent;   Kom Op Tegen Kanker;   University Ghent;   Hopital Lariboisière;   University Women's Hospital Tübingen;   Candiolo Cancer Institute - IRCCS;   Centre Hospitalier Universitaire Vaudois
Completed

Fri, 06 Oct 2017 12:00:00 EDT

Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer

Condition:   Pancreatic Adenocarcinoma
Intervention:   Drug: Nab-paclitaxel + Gemcitabine
Sponsor:   Institut Paoli-Calmettes
Completed

Thu, 26 Jun 2014 12:00:00 EDT

Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer

Conditions:   Surgically-Created Resection Cavity;   Drug Safety
Intervention:   Drug: S-1 + Paclitaxel Chemotherapy
Sponsor:   Zhejiang Cancer Hospital
Unknown status

Tue, 25 Dec 2012 12:00:00 EST

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Pertuzumab
Sponsors:   Dana-Farber Cancer Institute;   Susan G. Komen Breast Cancer Foundation;   Breast Cancer Research Foundation;   Terri Brodeur Breast Cancer Foundation
Active, not recruiting

Tue, 23 Oct 2018 12:00:00 EDT

Neoadjuvant Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma

Conditions:   Muscle Invasive Bladder Cancer;   Urothelial Carcinoma
Interventions:   Drug: Tislelizumab;   Drug: Nab paclitaxel
Sponsor:   Tianjin Medical University Second Hospital
Recruiting

Fri, 29 Jan 2021 12:00:00 EST

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

Condition:   Refractory Cancer
Interventions:   Drug: AZD6738;   Drug: Paclitaxel
Sponsor:   Samsung Medical Center
Recruiting

Tue, 15 Dec 2015 12:00:00 EST

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

Conditions:   Fallopian Tube Carcinoma;   Recurrent Ovarian Cancer;   Primary Peritoneal Carcinoma;   Recurrent Endometrial Cancer
Interventions:   Drug: Lenvatinib Mesylate;   Drug: Paclitaxel;   Other: Pharmacological Study
Sponsors:   Floor Backes;   Eisai Inc.
Active, not recruiting

Thu, 02 Jun 2016 12:00:00 EDT

Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Condition:   Locally Advanced Cervical Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Taxol
Sponsors:   Fondazione Policlinico Universitario Agostino Gemelli IRCCS;   Merck Sharp & Dohme Corp.
Recruiting

Thu, 23 Jan 2020 12:00:00 EST

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Conditions:   Salivary Gland Malignant Neoplasms;   Salivary Gland Tumors
Intervention:   Drug: Sintilimab , Carboplatin, Nab-paclitaxel
Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not yet recruiting

Wed, 11 Aug 2021 12:00:00 EDT

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

Condition:   Solid Tumors
Interventions:   Drug: PLX3397;   Drug: Paclitaxel
Sponsors:   Daiichi Sankyo, Inc.;   Plexxikon
Completed

Fri, 03 Feb 2012 12:00:00 EST

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Condition:   Advanced Pancreatic Cancer
Interventions:   Drug: Paclitaxel liposome;   Drug: S-1
Sponsor:   Fudan University
Not yet recruiting

Fri, 03 Jan 2020 12:00:00 EST

Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy

Condition:   Gastric Cancer
Interventions:   Drug: Paclitaxel;   Drug: Irinotecan
Sponsors:   Korean Cancer Study Group;   Boryung Pharmaceutical Co., Ltd
Unknown status

Wed, 20 Oct 2010 12:00:00 EDT

Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma

Condition:   Nasopharyngeal Carcinoma
Intervention:   Drug: Albumin-Bound Paclitaxel
Sponsor:   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not yet recruiting

Tue, 23 Feb 2021 12:00:00 EST

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC

Condition:   Malignant Neoplasm of Breast
Interventions:   Drug: Pembrolizumab;   Drug: nab-paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide
Sponsors:   Institut fuer Frauengesundheit;   Merck Sharp & Dohme Corp.;   Celgene Corporation
Completed

Thu, 21 Sep 2017 12:00:00 EDT

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Conditions:   Salivary Gland Malignant Neoplasms;   Salivary Gland Tumors
Intervention:   Drug: Toripalimab , Carboplatin, Nab-paclitaxel
Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not yet recruiting

Thu, 01 Apr 2021 12:00:00 EDT

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: SG001;   Drug: Nab-paclitaxel
Sponsor:   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Not yet recruiting

Tue, 05 Oct 2021 12:00:00 EDT

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

Condition:   Stage IIIA Non-Small Cell Lung Cancer
Interventions:   Drug: Neoadjuvant Cisplatin, nab-paclitaxel;   Drug: Adjuvant Cisplatin,nab-paclitaxel;   Drug: Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine
Sponsor:   UNC Lineberger Comprehensive Cancer Center
Terminated

Tue, 28 Oct 2014 12:00:00 EDT

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Conditions:   Solid Tumour,;   Breast Cancer,;   Metastatic Melanoma,;   Non-small Cell Lung Cancer (NSCLC),
Intervention:   Drug: F16IL2 in combination with paclitaxel
Sponsor:   Philogen S.p.A.
Unknown status

Mon, 31 May 2010 12:00:00 EDT

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions:   Drug: MM-121;   Drug: Paclitaxel
Sponsors:   Merrimack Pharmaceuticals;   Sanofi
Completed

Thu, 06 Oct 2011 12:00:00 EDT

Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer

Condition:   Gastric Cancer
Intervention:   Drug: paclitaxel-albumin and S-1
Sponsor:   Beijing Friendship Hospital
Not yet recruiting

Thu, 06 Feb 2020 12:00:00 EST

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Conditions:   Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: nab-Paclitaxel;   Drug: Carboplatin;   Drug: Gemcitabine
Sponsor:   Celgene
Completed

Wed, 19 Jun 2013 12:00:00 EDT

Study of Vemurafenib, Carboplatin, and Paclitaxel

Condition:   Advanced Cancers
Interventions:   Drug: Vemurafenib;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   M.D. Anderson Cancer Center
Completed

Tue, 10 Jul 2012 12:00:00 EDT

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

Condition:   Esophageal Squamous Cell Carcinoma
Interventions:   Drug: Sintilimab;   Drug: Nab paclitaxel;   Drug: Cisplatin
Sponsors:   Sun Yat-sen University;   Innovent Biologics (Suzhou) Co. Ltd.;   CSPC Pharmaceutical Group Limited
Recruiting

Mon, 14 Sep 2020 12:00:00 EDT

A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: FOLFIRINOX or gemcitabine/abraxane;   Radiation: SBRT
Sponsor:   University of Colorado, Denver
Active, not recruiting

Fri, 19 Aug 2016 12:00:00 EDT

Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel

Condition:   Cancer
Interventions:   Drug: Paclitaxel dose escalation;   Drug: Paclitaxel;   Drug: Cyclophosphamide;   Biological: Blood collection
Sponsor:   Centre Oscar Lambret
Completed

Thu, 16 Jun 2011 12:00:00 EDT

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Adriamycin and Cytoxan (AC);   Drug: ABI-007;   Drug: Taxol;   Drug: Bevacizumab;   Drug: pegfilgrastim
Sponsor:   Celgene
Completed

Tue, 31 Oct 2006 12:00:00 EST

Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor

Condition:   Squamous Cell Carcinoma of Head and Neck
Intervention:   Drug: albumin-bound paclitaxel
Sponsor:   Tianjin Medical University Cancer Institute and Hospital
Recruiting

Tue, 23 Feb 2021 12:00:00 EST

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: gemcitabine hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed

Mon, 27 Mar 2006 12:00:00 EST

Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like Nanoparticles

Conditions:   Coronary Artery Disease;   Atherosclerosis;   Inflammation
Interventions:   Drug: LDE-Paclitaxel;   Drug: LDE-Placebo
Sponsor:   University of Sao Paulo General Hospital
Active, not recruiting

Mon, 04 Nov 2019 12:00:00 EST

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

Condition:   Prostatic Neoplasms
Interventions:   Drug: Abraxane;   Drug: Leuprolide;   Drug: Bicalutamide
Sponsors:   The Methodist Hospital Research Institute;   Celgene Corporation
Terminated

Tue, 28 Aug 2007 12:00:00 EDT

Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy

Condition:   Small Cell Lung Cancer
Interventions:   Drug: Albumin Paclitaxel;   Drug: Simvastatin
Sponsors:   Shanghai Pulmonary Hospital, Shanghai, China;   Chinese Academy of Sciences
Recruiting

Thu, 07 Jan 2021 12:00:00 EST

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Conditions:   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Neoplasms by Site;   Genital Neoplasms, Female;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Carcinoma, Ovarian Epithelial;   Ovarian Diseases;   Genital Diseases, Female;   Endocrine System Diseases;   Carcinoma;   Anlotinib;   Angiogenesis;   Antineoplastic Agents;   Tyrosine Kinase Inhibitor
Interventions:   Drug: Drug: Anlotinib;   Drug: Drug: Carboplatin/Paclitaxel
Sponsor:   Wenjun Cheng
Not yet recruiting

Fri, 19 Mar 2021 12:00:00 EDT

SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Condition:   Pancreatic Cancer Stage IV
Intervention:   Drug: Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin
Sponsors:   RenJi Hospital;   Jiangsu HengRui Medicine Co., Ltd.
Recruiting

Fri, 29 Nov 2019 12:00:00 EST

Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer

Condition:   Recurrent Ovarian Cancer
Intervention:   Drug: LDE225
Sponsors:   University of Alabama at Birmingham;   Novartis Pharmaceuticals
Completed

Mon, 21 Jul 2014 12:00:00 EDT

Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Paclitaxel + Carboplatin + ASLAN001
Sponsor:   National University Hospital, Singapore
Unknown status

Tue, 24 Mar 2015 12:00:00 EDT

Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer

Condition:   Esophageal Cancer
Interventions:   Drug: S-1 and Paclitaxel;   Drug: Paclitaxel and Cisplatin;   Drug: 5-FU and Cisplatin
Sponsor:   Peking University
Terminated

Thu, 11 Oct 2012 12:00:00 EDT

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

Conditions:   Metastatic Breast Cancer;   Locally Recurrent Breast Cancer
Interventions:   Drug: Nab-paclitaxel;   Drug: IG-001
Sponsor:   Sorrento Therapeutics, Inc.
Completed

Mon, 17 Feb 2014 12:00:00 EST

Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer

Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Carcinoma;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions:   Drug: Paclitaxel;   Drug: Oxaliplatin
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 09 Apr 2003 12:00:00 EDT

Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Paclitaxel
Sponsors:   SOLTI Breast Cancer Research Group;   Merck Sharp & Dohme Corp.
Recruiting

Fri, 31 Jan 2020 12:00:00 EST

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Conditions:   Pancreatic Cancer;   Cancer of Pancreas;   Cancer of the Pancreas;   Pancreas Cancer
Interventions:   Drug: BVD-523;   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Procedure: Tumor biopsy
Sponsors:   Washington University School of Medicine;   BioMed Valley Discoveries, Inc;   National Cancer Institute (NCI)
Terminated

Wed, 18 Nov 2015 12:00:00 EST

Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma

Conditions:   Angiosarcomas;   Soft Tissue Sarcoma
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   Stanford University;   Genentech, Inc.
Terminated

Mon, 25 Jan 2010 12:00:00 EST

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Conditions:   Gastric Cancer;   Gastroesophageal Junction Cancer
Interventions:   Drug: afatinib;   Drug: paclitaxel
Sponsor:   Yonsei University
Active, not recruiting

Fri, 17 Jul 2015 12:00:00 EDT

A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsor:   Theodoros Foukakis
Completed

Wed, 07 Nov 2012 12:00:00 EST

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Sponsors:   University of Washington;   National Cancer Institute (NCI);   Celgene Corporation
Completed

Fri, 15 Jun 2012 12:00:00 EDT

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Condition:   Non-small-cell Lung Cancer
Intervention:   Drug: Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
Sponsor:   Taipei Veterans General Hospital, Taiwan
Completed

Thu, 29 May 2008 12:00:00 EDT

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Conditions:   Metastatic Pancreatic Adenocarcinoma;   Metastatic Pancreatic Cancer
Interventions:   Drug: Nab-Paclitaxel;   Drug: Gemcitabine;   Drug: Indoximod
Sponsor:   NewLink Genetics Corporation
Completed

Tue, 04 Mar 2014 12:00:00 EST

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: nab-paclitaxel
Sponsor:   Chinese Academy of Medical Sciences
Not yet recruiting

Wed, 11 Dec 2019 12:00:00 EST

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Conditions:   Advanced Malignant Solid Neoplasm;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Metastatic Malignant Solid Neoplasm;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Recurrent Breast Carcinoma;   TP53 wt Allele;   Unresectable Malignant Solid Neoplasm
Interventions:   Drug: MDM2/MDMX Inhibitor ALRN-6924;   Drug: Paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Wed, 31 Oct 2018 12:00:00 EDT

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

Condition:   Recurrent Platinum Resistant Ovarian Cancer
Interventions:   Drug: VB-111 + Paclitaxel;   Drug: Placebo + Paclitaxel
Sponsors:   Vascular Biogenics Ltd. operating as VBL Therapeutics;   GOG Foundation, Inc.
Recruiting

Fri, 12 Jan 2018 12:00:00 EST

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

Conditions:   Gastric Cancer;   GastroEsophageal Cancer
Interventions:   Drug: Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor);   Drug: Albumin-bound Paclitaxel
Sponsor:   Huazhong University of Science and Technology
Not yet recruiting

Wed, 04 Mar 2020 12:00:00 EST

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: pertuzumab in combination with trastuzumab and paclitaxel
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.;   University of Pennsylvania
Completed

Thu, 13 Jan 2011 12:00:00 EST

Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC

Condition:   STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Interventions:   Drug: NAB-PACLITAXEL;   Drug: PACLITAXEL
Sponsors:   University of Texas Southwestern Medical Center;   Celgene
Completed

Fri, 28 Dec 2012 12:00:00 EST

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Condition:   Neoplasms, Breast
Interventions:   Drug: Lapatinib oral tablets;   Drug: Paclitaxel infusion
Sponsor:   GlaxoSmithKline
Completed

Wed, 26 Jul 2006 12:00:00 EDT

POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer

Condition:   Advanced Breast Cancer
Interventions:   Drug: POL6326;   Drug: Eribulin;   Drug: Nab paclitaxel
Sponsor:   MedSIR
Not yet recruiting

Thu, 01 Apr 2021 12:00:00 EDT

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Condition:   Cancer
Interventions:   Drug: Afuresertib;   Drug: Paclitaxel
Sponsor:   Novartis Pharmaceuticals
Completed

Mon, 15 Sep 2014 12:00:00 EDT

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Conditions:   Metastatic Breast Cancer;   Metastatic Triple Negative Breast Cancer
Interventions:   Drug: Combination therapy (S81694 + paclitaxel) phase I;   Drug: Paclitaxel;   Drug: Combination therapy (S81694 + paclitaxel) phase II
Sponsors:   Institut de Recherches Internationales Servier;   ADIR, a Servier Group company
Completed

Fri, 26 Jan 2018 12:00:00 EST

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Paclitaxel
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Merck Sharp & Dohme Corp.
Active, not recruiting

Tue, 12 May 2015 12:00:00 EDT

Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab

Condition:   Breast Cancer
Intervention:   Drug: Paclitaxel/Gemcitabine/Trastuzumab
Sponsor:   Jungsil Ro
Completed

Thu, 20 Sep 2007 12:00:00 EDT

Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: nab-paclitaxel;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Unknown status

Mon, 28 Aug 2017 12:00:00 EDT

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Conditions:   Inoperable Locally Advanced Breast Cancer;   Metastatic Breast Cancer (MBC)
Interventions:   Drug: BEZ235;   Drug: Paclitaxel
Sponsor:   Novartis Pharmaceuticals
Terminated

Mon, 19 Dec 2011 12:00:00 EST

A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Radiation: Radiation Therapy;   Procedure: Surgical Resection
Sponsor:   University Health Network, Toronto
Active, not recruiting

Thu, 25 Jun 2015 12:00:00 EDT

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
Sponsor:   West China Hospital
Recruiting

Tue, 08 Jun 2021 12:00:00 EDT

Taxol Carboplatin and Erythropoetin

Condition:   Ovarian Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   North Eastern German Society of Gynaecological Oncology
Completed

Mon, 12 Sep 2005 12:00:00 EDT

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Hormone Receptor-Positive Breast Carcinoma;   Metastatic Breast Carcinoma;   Metastatic HER2-Negative Breast Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Triple-Negative Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8
Interventions:   Drug: Paclitaxel;   Radiation: Radium Ra 223 Dichloride
Sponsor:   National Cancer Institute (NCI)
Recruiting

Mon, 16 Sep 2019 12:00:00 EDT

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Condition:   Melanoma
Interventions:   Drug: Genasense;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   M.D. Anderson Cancer Center;   Genta Incorporated
Terminated

Mon, 13 Sep 2010 12:00:00 EDT

Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: nab-Paclitaxel;   Drug: Gemcitabine;   Radiation: Intensity modulated radiation
Sponsor:   Washington University School of Medicine
Completed

Wed, 05 Nov 2014 12:00:00 EST

A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)

Condition:   Unknown Primary Tumors
Interventions:   Drug: nab-paclitaxel;   Drug: Carboplatin;   Drug: Gemcitabine
Sponsor:   Fondazione del Piemonte per l'Oncologia
Unknown status

Tue, 17 Nov 2015 12:00:00 EST

Paclitaxel in Treating Older Patients With Solid Tumors

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: paclitaxel
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Mon, 27 Jan 2003 12:00:00 EST

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Conditions:   Lung Cancer Stage II;   PD-1 Antibody;   Non-small Cell Lung Cancer
Interventions:   Drug: SHR-1210;   Drug: Carboplatin and Paclitaxel-albumin
Sponsor:   Xuanwu Hospital, Beijing
Unknown status

Fri, 27 Sep 2019 12:00:00 EDT

Paclitaxel in Treating Women With Recurrent Solid Tumors

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: paclitaxel
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Tue, 25 Nov 2003 12:00:00 EST

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

Condition:   Triple Negative Breast Neoplasms
Interventions:   Drug: alpelisib;   Drug: placebo;   Drug: nab-paclitaxel
Sponsor:   Novartis Pharmaceuticals
Recruiting

Wed, 05 Feb 2020 12:00:00 EST

Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma

Conditions:   Thymoma;   Thymic Carcinoma
Interventions:   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Completed

Mon, 27 Jan 2003 12:00:00 EST

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: AZD1775
Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
Recruiting

Fri, 31 Jul 2015 12:00:00 EDT

Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: Paclitaxel for injection (albumin-bound)
Sponsor:   Huazhong University of Science and Technology
Not yet recruiting

Mon, 28 Jan 2019 12:00:00 EST

Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies

Condition:   Advanced Nonhaematologic Malignancies
Interventions:   Drug: BOS172722;   Drug: Paclitaxel
Sponsor:   Boston Pharmaceuticals
Completed

Wed, 01 Nov 2017 12:00:00 EDT

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Conditions:   Squamous Cell Cancer;   Head and Neck Cancer
Intervention:   Drug: Temsirolimus + Weekly Paclitaxel + Carboplatin
Sponsors:   Memorial Sloan Kettering Cancer Center;   NATL COMP CA NETWORK;   Pfizer
Completed

Thu, 19 Nov 2009 12:00:00 EST

A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer

Condition:   Pancreatic Cancer (Unresectable)
Interventions:   Drug: FG-3019;   Drug: Gemcitabine;   Drug: Nab-paclitaxel
Sponsor:   FibroGen
Active, not recruiting

Wed, 06 Aug 2014 12:00:00 EDT

Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients

Condition:   Adenocarcinoma Pancreas
Interventions:   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Other: Best Supportive Care
Sponsor:   AIO-Studien-gGmbH
Completed

Fri, 24 Jun 2016 12:00:00 EDT

Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Drug: Paclitaxel+Nedaplatin+Endostar
Sponsor:   Yuhong Li
Recruiting

Thu, 29 Jan 2015 12:00:00 EST

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

Conditions:   NSCLC, Recurrent;   Adenocarcinoma of Lung
Interventions:   Drug: Vargatef;   Drug: Abraxane;   Other: placebo
Sponsors:   Royal Marsden NHS Foundation Trust;   Boehringer Ingelheim;   Celgene
Withdrawn

Mon, 04 Dec 2017 12:00:00 EST

PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma

Condition:   Advanced Gastric Adenocarcinoma
Interventions:   Drug: GSK2636771;   Drug: Paclitaxel
Sponsor:   Yonsei University
Completed

Thu, 26 Nov 2015 12:00:00 EST

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   No Prior Chemotherapy
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab
Sponsors:   David O'Malley;   Genentech, Inc.
Unknown status

Wed, 13 Oct 2010 12:00:00 EDT

Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma

Condition:   Advanced Gastric Carcinoma
Intervention:   Drug: Liposomal paclitaxel plus capecitabine
Sponsor:   Nanjing Sike Pharmaceutical Co., Ltd.
Unknown status

Wed, 15 Apr 2009 12:00:00 EDT

A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: paclitaxel
Sponsors:   University of Kansas;   Novartis
Withdrawn

Fri, 16 Jul 2010 12:00:00 EDT

Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Condition:   Nasopharyngeal Carcinoma
Interventions:   Drug: Paclitaxel;   Drug: Cisplatin
Sponsor:   Sun Yat-sen University
Active, not recruiting

Wed, 08 Feb 2017 12:00:00 EST

Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)

Condition:   Pancreatic Adenocarcinoma
Interventions:   Device: NovoTTF-100L;   Drug: Gemcitabine;   Drug: nab-Paclitaxel
Sponsor:   NovoCure Ltd.
Unknown status

Tue, 29 Oct 2013 12:00:00 EDT

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

Conditions:   Breast Cancer;   Estrogen Receptor Negative Neoplasm;   HER-2 Positive Breast Cancer
Interventions:   Drug: nab-paclitaxel;   Drug: Trastuzumab
Sponsor:   Osaka Medical College
Terminated

Thu, 05 Nov 2015 12:00:00 EST

Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer

Conditions:   Ovarian Cancer Stage IIIC;   Ovarian Cancer Stage IV
Interventions:   Drug: CS-1008;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Daiichi Sankyo, Inc.
Completed

Fri, 24 Jul 2009 12:00:00 EDT

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: albumin-bound paclitaxel;   Drug: Apatinib
Sponsor:   Henan Cancer Hospital
Unknown status

Wed, 08 May 2019 12:00:00 EDT

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Conditions:   Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions:   Drug: gemcitabine hydrochloride;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Terminated

Mon, 27 Jan 2003 12:00:00 EST

Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

Condition:   Advanced Cancer
Interventions:   Drug: Nab-paclitaxel;   Drug: Bevacizumab;   Drug: Gemcitabine
Sponsor:   M.D. Anderson Cancer Center
Unknown status

Fri, 30 Apr 2010 12:00:00 EDT

Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition:   Lung Cancer
Intervention:   Drug: paclitaxel
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Wed, 17 Dec 2003 12:00:00 EST

Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

Condition:   Breast Neoplasms
Intervention:   Drug: cetuximab paclitaxel
Sponsor:   Hadassah Medical Organization
Unknown status

Wed, 19 Jul 2006 12:00:00 EDT

Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct Obstruction

Condition:   Bile Duct Obstruction
Intervention:   Device: Paclitaxel eluting covered metal stent and control covered metal stent
Sponsor:   Asan Medical Center
Completed

Wed, 28 Mar 2007 12:00:00 EDT

Efficacy and Safety of TPFinduction Chemotherapy Boundary Resectable Local Advanced Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Drug: Paclitaxel+Cisplatin+5fluorouracil
Sponsor:   Yuhong Li
Unknown status

Tue, 29 Nov 2016 12:00:00 EST

Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib

Condition:   Breast Cancer
Intervention:   Drug: Paclitaxel,Gemcitabine,Sunitinib
Sponsors:   Jungsil Ro;   Pfizer;   HK inno.N Corporation
Completed

Thu, 18 Feb 2010 12:00:00 EST

ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Gemcitabine;   Drug: Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Completed

Wed, 04 May 2005 12:00:00 EDT

Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

Condition:   Squamous Cell Carcinoma
Interventions:   Drug: Onivyde;   Drug: Paclitaxel
Sponsors:   Federation Francophone de Cancerologie Digestive;   Shire
Recruiting

Thu, 25 Oct 2018 12:00:00 EDT

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Conditions:   Breast Cancer;   Breast Adenocarcinoma;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions:   Drug: Rebastinib;   Drug: Paclitaxel;   Drug: Eribulin Mesylate
Sponsors:   Montefiore Medical Center;   Deciphera Pharmaceuticals LLC;   Albert Einstein College of Medicine
Recruiting

Wed, 06 Jul 2016 12:00:00 EDT

Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer

Condition:   Lung Cancer
Intervention:   Drug: Paclitaxel, Carboplatin and Irinotecan
Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Terminated

Wed, 25 Apr 2007 12:00:00 EDT

Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter

Condition:   In-stent Restenosis
Interventions:   Device: paclitaxel controlled release balloon catheter Vasoguard TM;   Device: paclitaxel release coronary balloon catheter SeQuent Please
Sponsors:   Shandong Branden Med.Device Co.,Ltd;   Fudan University
Unknown status

Wed, 07 Sep 2016 12:00:00 EDT

Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin

Condition:   Neoplasms, Germ Cell and Embryonal
Intervention:   Drug: Oxaliplatin, Paclitaxel
Sponsor:   Sanofi
Completed

Mon, 11 Feb 2008 12:00:00 EST

Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment in China

Condition:   Coronary Disease
Intervention:   Device: Paclitaxel Eluting Balloon Catheter
Sponsors:   Xijing Hospital;   The First Affiliated Hospital of Zhengzhou University;   First Affiliated Hospital of Zhejiang University;   Second Affiliated Hospital, School of Medicine, Zhejiang University;   Second Hospital of Jilin University;   First Affiliated Hospital of Xinjiang Medical University;   Tang-Du Hospital;   China-Japan Union Hospital, Jilin University;   Xuzhou Third People's Hospital
Unknown status

Thu, 15 Mar 2018 12:00:00 EDT

Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery

Condition:   Sarcoma
Intervention:   Drug: paclitaxel
Sponsor:   UNICANCER
Completed

Thu, 22 Sep 2005 12:00:00 EDT

Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor

Conditions:   Breast Cancer;   NSCLC;   Ovary Cancer;   Endometrial Cancer;   Small Cell Lung Cancer (SCLC);   Head and Neck (HNSCC)
Interventions:   Drug: PF-05212384;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Cristiana Sessa
Completed

Mon, 24 Feb 2014 12:00:00 EST

Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas

Condition:   Adenocarcinoma Pancreas
Interventions:   Procedure: Surgery;   Genetic: Genetic Expression;   Drug: Chemotherapy
Sponsor:   Medical University of South Carolina
Terminated

Mon, 04 Feb 2013 12:00:00 EST

Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis

Conditions:   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Ramucirumab;   Drug: Paclitaxel
Sponsor:   Samsung Medical Center
Completed

Fri, 11 Dec 2015 12:00:00 EST

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Condition:   Malignant Solid Tumor
Interventions:   Biological: ramucirumab (IMC-1121B);   Drug: paclitaxel
Sponsor:   Eli Lilly and Company
Completed

Tue, 24 Jan 2012 12:00:00 EST

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Completed

Fri, 20 Feb 2004 12:00:00 EST

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Condition:   Squamous Cell Carcinoma of Head and Neck
Interventions:   Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting

Tue, 28 Jul 2020 12:00:00 EDT

Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Condition:   Pancreatic Ductal Adenocarcinoma
Interventions:   Drug: nab-paclitaxel;   Drug: gemcitabine
Sponsor:   Samsung Medical Center
Unknown status

Fri, 24 Apr 2015 12:00:00 EDT

Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Condition:   Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma
Interventions:   Drug: sintilimab;   Drug: nab-paclitaxel
Sponsors:   Chinese Academy of Medical Sciences;   Chinese PLA General Hospital;   Beijing Friendship Hospital;   Beijing Hospital
Recruiting

Fri, 25 Oct 2019 12:00:00 EDT

Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer

Conditions:   Tubular Breast Cancer;   Mucinous Breast Cancer;   Invasive Ductal Breast Cancer;   Inflammatory Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Cisplatin
Sponsor:   RenJi Hospital
Completed

Thu, 24 Jul 2014 12:00:00 EDT

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Tak-228 & Tak-117;   Drug: Cisplatin & Nab Paclitaxel
Sponsors:   Baylor Research Institute;   Takeda
Active, not recruiting

Wed, 21 Jun 2017 12:00:00 EDT

Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy

Condition:   Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
Interventions:   Drug: Abraxane;   Drug: Gemcitabine
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
Completed

Mon, 01 Dec 2014 12:00:00 EST

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Conditions:   Locally Advanced Breast Carcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Nab-paclitaxel;   Other: Questionnaire Administration
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Active, not recruiting

Tue, 01 Nov 2011 12:00:00 EDT

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: CS-7017;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsors:   Daiichi Sankyo Co., Ltd.;   ICON Clinical Research
Completed

Fri, 10 Sep 2010 12:00:00 EDT

Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Epirubicin;   Drug: Paclitaxel;   Drug: Capecitabine
Sponsor:   Thomas Hatschek
Completed

Wed, 14 Sep 2011 12:00:00 EDT

ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer

Conditions:   Metastatic Breast Cancer;   Breast Carcinoma
Interventions:   Drug: ACY-1215;   Drug: Nab-paclitaxel
Sponsors:   Columbia University;   Acetylon Pharmaceuticals Incorporated;   National Cancer Institute (NCI)
Completed

Wed, 16 Dec 2015 12:00:00 EST

Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery

Condition:   Peripheral Artery Disease
Interventions:   Device: Paclitaxel Eluting Stent;   Device: Paclitaxel Eluting Balloon
Sponsors:   Provascular GmbH;   William Cook Europe
Completed

Mon, 19 Nov 2012 12:00:00 EST

Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Condition:   Advanced Triple Negative Breast Cancer
Interventions:   Drug: Apatinib Mesylate;   Drug: Albumin-Bound Paclitaxel
Sponsor:   Fujian Cancer Hospital
Not yet recruiting

Wed, 25 Aug 2021 12:00:00 EDT

A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients

Condition:   Solid Tumor
Intervention:   Drug: Oraxol
Sponsors:   Athenex, Inc.;   Zenith Technology Corporation Limited;   PharmaEssentia
Completed

Wed, 27 Nov 2019 12:00:00 EST

Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma

Condition:   Pancreatic Cancer
Interventions:   Drug: Chemotherapy;   Drug: Chemotherapy + ChemoRadiotherapy
Sponsor:   University of Florida
Completed

Fri, 11 Nov 2011 12:00:00 EST

Prevention of Paclitaxel Neuropathy With Cryotherapy

Condition:   Breast Cancer
Interventions:   Other: Cryotherapy;   Drug: Paclitaxel
Sponsors:   Medical Oncology & Hematology Associates of Northern Virginia;   Inova Health System
Unknown status

Wed, 03 Sep 2014 12:00:00 EDT

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Conditions:   Ovarian Cancer;   Peritoneal Cavity Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI);   National Comprehensive Cancer Network
Completed

Mon, 19 Jan 2009 12:00:00 EST

Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer

Condition:   Breast Neoplasm
Interventions:   Drug: Taxol;   Drug: TOCOSOL Paclitaxel
Sponsor:   Achieve Life Sciences
Terminated

Wed, 09 Nov 2005 12:00:00 EST

Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty

Condition:   Ischemia
Interventions:   Device: Angiogram, Medtronic DCB (paclitaxel)/stent;   Device: Angiogram, Bard DCB (paclitaxel)/stent
Sponsor:   Rabih A. Chaer
Recruiting

Tue, 03 May 2016 12:00:00 EDT

Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer

Condition:   Locally Advanced Pancreatic Cancer
Intervention:   Drug: Nab-paclitaxel and S-1
Sponsor:   Chinese Academy of Medical Sciences
Not yet recruiting

Thu, 24 Jan 2019 12:00:00 EST

FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: FOLFIRI.3;   Drug: nab-paclitaxel+ gemcitabine
Sponsors:   Federation Francophone de Cancerologie Digestive;   UNICANCER;   GERCOR - Multidisciplinary Oncology Cooperative Group
Active, not recruiting

Mon, 11 Jul 2016 12:00:00 EDT

AZD8186 and Paclitaxel in Advanced Gastric Cancer

Conditions:   Solid Tumor;   Stomach Cancer
Intervention:   Drug: AZD8186 in combination with paclitaxel
Sponsor:   Seoul National University Bundang Hospital
Recruiting

Fri, 28 Jun 2019 12:00:00 EDT

[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer

Condition:   Ovarian Neoplasm
Intervention:   Drug: Pazopanib and paclitaxel
Sponsors:   Imperial College London;   GlaxoSmithKline
Completed

Wed, 30 May 2012 12:00:00 EDT

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: Paclitaxel bound albumine
Sponsor:   Gruppo Oncologico Italiano di Ricerca Clinica
Completed

Wed, 09 Apr 2014 12:00:00 EDT

Paclitaxel-coated Balloon Angioplasty Versus Standard Angioplasty for the Treatment of Stenosis of Arteriovenous Fistula

Conditions:   Angioplasty;   Stenosis of Arteriovenous Fistula
Interventions:   Combination Product: Additional angioplasty with paclitaxel-coated balloon;   Combination Product: Additional angioplasty with placebo balloon;   Procedure: Conventional angioplasty
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Bard Peripheral Vascular, Inc.
Active, not recruiting

Thu, 28 Apr 2016 12:00:00 EDT

Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions

Condition:   Coronary Artery Disease
Interventions:   Procedure: Balloon angioplasty;   Procedure: Stent implantation
Sponsors:   B.Braun Surgical SA;   Hospital Universitario Infanta Cristina de Badajoz
Unknown status

Mon, 17 Jan 2011 12:00:00 EST

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Tumor;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Drug: Elesclomol Sodium;   Drug: Paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed

Mon, 27 Apr 2009 12:00:00 EDT

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma

Conditions:   Oral Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma
Interventions:   Drug: sintilimab, paclitaxel, carboplatin;   Procedure: Surgical resection
Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting

Fri, 22 Jan 2021 12:00:00 EST

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions:   Drug: paclitaxel;   Drug: ganetespib;   Other: laboratory biomarker analysis
Sponsors:   Fox Chase Cancer Center;   National Cancer Institute (NCI)
Terminated

Wed, 16 Oct 2013 12:00:00 EDT

Paclitaxel and Cisplatin for Thymic Neoplasm

Conditions:   Thymoma;   Thymic Carcinoma
Intervention:   Drug: paclitaxel and cisplatin
Sponsor:   Korean Cancer Study Group
Terminated

Wed, 07 Jan 2009 12:00:00 EST

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

Condition:   Locally Advanced Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Radiation: Hypofractionated Ablative Proton Therapy
Sponsor:   University of Maryland, Baltimore
Recruiting

Wed, 29 Aug 2018 12:00:00 EDT

Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer

Conditions:   Carcinoma;   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Intervention:   Drug: AMG 386, paclitaxel and carboplatin
Sponsor:   Amgen
Completed

Fri, 03 Dec 2010 12:00:00 EST

Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer

Conditions:   Pancreatic Neoplasm;   Metastatic Pancreatic Cancer;   Locally Advanced Pancreatic Adenocarcinoma
Intervention:   Drug: Anlotinib+Toripalimab+Nab-paclitaxel
Sponsor:   The First Affiliated Hospital with Nanjing Medical University
Recruiting

Fri, 22 Jan 2021 12:00:00 EST

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Condition:   Breast Cancer
Interventions:   Drug: T-DM1;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel;   Drug: Pertuzumab
Sponsors:   The Methodist Hospital Research Institute;   Celgene Corporation;   Novartis
Completed

Thu, 27 Feb 2014 12:00:00 EST

Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: paclitaxel plus trastuzumab
Sponsors:   WiSP Wissenschaftlicher Service Pharma GmbH;   Bristol-Myers Squibb;   Roche Pharma AG
Completed

Fri, 26 Aug 2011 12:00:00 EDT

Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma

Condition:   Small Cell Carcinoma
Interventions:   Drug: Nortriptyline Hydrochloride;   Drug: Paclitaxel
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Completed

Fri, 26 Aug 2016 12:00:00 EDT

First Line Chemotherapy for Advanced Cancer

Condition:   Gastric Cancer
Interventions:   Drug: albumin-bounded paclitaxel;   Drug: S-1
Sponsor:   Chinese Academy of Medical Sciences
Terminated

Mon, 11 Nov 2013 12:00:00 EST

Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy
Sponsor:   Yonsei University
Unknown status

Wed, 18 Apr 2018 12:00:00 EDT

Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)

Condition:   Coronary Artery Disease
Interventions:   Device: Device: Paclitaxel-Coated PTCA Balloon Catheter;   Device: SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel
Sponsor:   Boston Scientific Corporation
Active, not recruiting

Fri, 16 Aug 2019 12:00:00 EDT

Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Pancreatic Adenocarcinoma

Condition:   Pancreatic Adenocarcinoma
Interventions:   Drug: AVB-S6-500;   Drug: Nab paclitaxel;   Drug: Gemcitabine
Sponsor:   Aravive, Inc.
Recruiting

Fri, 30 Jul 2021 12:00:00 EDT

Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6

Conditions:   Gastric Cancer Stage IV;   Peritoneal Carcinomatosis;   Intraperitoneal Paclitaxel;   mFOLFOX6
Interventions:   Drug: Paclitaxel;   Drug: mFOLFOX6 regimen
Sponsors:   Seoul National University Bundang Hospital;   Boryung Pharmaceutical Co., Ltd;   B. Braun Korea Co., Ltd.
Recruiting

Tue, 07 Aug 2018 12:00:00 EDT

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Conditions:   Adult Type Ovarian Granulosa Cell Tumor;   Ovarian Gynandroblastoma;   Ovarian Sertoli-Leydig Cell Tumor;   Ovarian Sex Cord Tumor With Annular Tubules;   Ovarian Steroid Cell Tumor
Intervention:   Drug: Paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed

Mon, 27 Jan 2003 12:00:00 EST

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: SI-B001;   Drug: Paclitaxel
Sponsor:   Sichuan Baili Pharmaceutical Co., Ltd.
Recruiting

Thu, 23 Sep 2021 12:00:00 EDT

Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial

Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions:   Drug: Paclitaxel(intravenous) + Carboplatin(intravenous);   Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
Sponsors:   Gynecologic Oncology Trial & Investigation Consortium;   Japanese Gynecologic Oncology Group
Active, not recruiting

Tue, 10 Jan 2012 12:00:00 EST

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Condition:   Transitional Cell Carcinoma
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Pembrolizumab
Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
Active, not recruiting

Wed, 21 Oct 2015 12:00:00 EDT

Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: nab-paclitaxel regimen1;   Drug: nab-paclitaxel regimen2
Sponsor:   Beijing Cancer Hospital
Recruiting

Tue, 10 Dec 2019 12:00:00 EST

Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer

Condition:   Esophageal Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   Bristol-Myers Squibb
Completed

Tue, 27 Jun 2006 12:00:00 EDT

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

Condition:   HER-2 Positive Advanced Gastric Cancer
Interventions:   Drug: HM781-36B(Poziotinib);   Drug: Paclitaxel;   Drug: Trastuzumab
Sponsors:   Hanmi Pharmaceutical Company Limited;   National OncoVenture
Completed

Tue, 11 Dec 2012 12:00:00 EST

A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer

Condition:   Unresectable Biliary Tract Cancer
Intervention:   Drug: nab-paclitaxel in combination with gemcitabine + cisplatin
Sponsors:   AHS Cancer Control Alberta;   Celgene
Unknown status

Wed, 16 Dec 2015 12:00:00 EST

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer

Conditions:   Breast - Female;   Male Breast Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Paclitaxel
Sponsors:   Antoinette Tan, MD;   Merck Sharp & Dohme Corp.
Active, not recruiting

Wed, 11 Jan 2017 12:00:00 EST

Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC

Conditions:   Esophageal Cancer Stage IIB;   Esophageal Cancer Stage III
Interventions:   Combination Product: Paclitaxel, Cisplatin Plus 5-FU (TCF);   Radiation: radiochemotherapy
Sponsors:   Tianjin Medical University Cancer Institute and Hospital;   Shanghai Chest Hospital;   Henan Cancer Hospital;   The First Affiliated Hospital with Nanjing Medical University;   First Affiliated Hospital of Chongqing Medical University;   The First Affiliated Hospital of Anhui Medical University
Not yet recruiting

Fri, 08 Dec 2017 12:00:00 EST

Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer

Conditions:   Solid Tumor;   Stomach Cancer
Interventions:   Drug: Alpelisib;   Drug: Paclitaxel
Sponsor:   Seoul National University Bundang Hospital
Recruiting

Tue, 25 Aug 2020 12:00:00 EDT

A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Sorafenib + Paclitaxel + Carboplatin;   Drug: Placebo + Paclitaxel + Carboplatin
Sponsor:   Bayer
Terminated

Thu, 15 Nov 2007 12:00:00 EST

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Conditions:   Lung Cancer;   Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Interventions:   Drug: albumin-bound paclitaxel;   Drug: gemcitabine
Sponsors:   Memorial Sloan Kettering Cancer Center;   Celgene Corporation;   Miami Cancer Institute
Completed

Mon, 17 Aug 2015 12:00:00 EDT

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Refractory Breast Carcinoma;   Triple-Negative Breast Carcinoma
Interventions:   Drug: Alpelisib;   Drug: Nab-paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Thu, 02 Jan 2020 12:00:00 EST

Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

Conditions:   Gastric Cancer;   Gastroesophageal Cancer
Interventions:   Drug: KH903 + Paclitaxel;   Drug: Placebo + Paclitaxel
Sponsor:   Chengdu Kanghong Biotech Co., Ltd.
Not yet recruiting

Fri, 18 Sep 2020 12:00:00 EDT

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

Condition:   Pancreatic Cancer
Interventions:   Drug: Demcizumab;   Drug: Abraxane®;   Drug: gemcitabine;   Drug: Placebo
Sponsors:   OncoMed Pharmaceuticals, Inc.;   Celgene Corporation
Completed

Thu, 13 Nov 2014 12:00:00 EST

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Condition:   Triple-Negative Breast Cancer
Intervention:   Drug: camrelizumab in combination with nab-paclitaxel and famitinib
Sponsor:   Fudan University
Recruiting

Thu, 17 Oct 2019 12:00:00 EDT

A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Condition:   Advanced Gastric or Gastroesophageal Junction Cancer
Interventions:   Drug: Gentuximab;   Drug: Paclitaxel
Sponsors:   GeneScience Pharmaceuticals Co., Ltd.;   Shanghai East Hospital;   The First Affiliated Hospital, Zhejiang University School of Medicine;   Fujian Tumor Hospital;   Sir Run Run Shaw Hospital;   The Affiliated Tumor Hospital of Harbin Medical University;   Union Hospital of Tongji Medical College, Huazhong University of Science and Technology;   Sixth Affiliated Hospital, Sun Yat-sen University;   Tongji Hospital;   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine;   The First Hospital of Jilin University;   The First Affiliated Hospital with Nanjing Medical University;   The First Affiliated Hospital of Zhengzhou University
Unknown status

Mon, 12 Aug 2019 12:00:00 EDT

Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Condition:   HER2 Negative Metastatic Breast Cancer
Interventions:   Drug: Cabazitaxel;   Drug: Paclitaxel
Sponsor:   University Hospitals Bristol and Weston NHS Foundation Trust
Recruiting

Thu, 09 Feb 2017 12:00:00 EST

Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy

Condition:   Advanced Pancreatic Cancer
Interventions:   Drug: cisplatin+Nab-paclitaxel+GEM;   Drug: Nab-paclitaxel+GEM
Sponsor:   Fudan University
Not yet recruiting

Wed, 13 Jan 2021 12:00:00 EST

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Conditions:   Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions:   Drug: paclitaxel;   Drug: bryostatin 1
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 27 Jan 2003 12:00:00 EST

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Conditions:   Metastatic Pancreatic Adenocarcinoma;   Stage IV Pancreatic Cancer AJCC v8
Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel
Sponsors:   Laith Abushahin;   National Cancer Institute (NCI)
Recruiting

Thu, 03 Oct 2019 12:00:00 EDT

Phase II Study of ABI-007 for Gastric Cancer

Condition:   Gastric Cancer
Intervention:   Drug: ABI-007
Sponsor:   Taiho Pharmaceutical Co., Ltd.
Completed

Fri, 18 Apr 2008 12:00:00 EDT

Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors

Condition:   Advanced Hepatobiliary and Malignant Tumors
Intervention:   Drug: albumin-bound paclitaxel + oxaliplatin
Sponsor:   Dong Wang
Not yet recruiting

Mon, 19 Aug 2019 12:00:00 EDT

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

Conditions:   Endometrial Cancer;   Uterine Cancer;   Ovarian Cancer;   Carcinosarcoma
Interventions:   Drug: Paclitaxel;   Drug: 300mg DKN-01;   Drug: 600mg DKN-01
Sponsor:   Leap Therapeutics, Inc.
Completed

Wed, 10 Jan 2018 12:00:00 EST

Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin

Condition:   Invasive Breast Cancer
Intervention:   Drug: Doxil, Paclitaxel, Cyclophosphamide, Avastin
Sponsors:   University of Alabama at Birmingham;   Ortho Biotech, Inc.;   Genentech, Inc.
Completed

Thu, 13 Mar 2008 12:00:00 EDT

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

Conditions:   Carcinoma;   Non-Squamous Non-Small-Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: CDP791 10mg/kg;   Drug: CDP791 20mg/kg
Sponsor:   UCB Pharma
Completed

Fri, 09 Sep 2005 12:00:00 EDT

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Condition:   Squamous Cell Carcinoma of the Anal Canal
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: retifanlimab
Sponsor:   Incyte Corporation
Recruiting

Wed, 15 Jul 2020 12:00:00 EDT

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Veliparib;   Drug: Carboplatin;   Drug: Veliparib Placebo
Sponsor:   AbbVie
Active, not recruiting

Mon, 16 Jun 2014 12:00:00 EDT

Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4

Conditions:   Restenosis;   Stable Angina Pectoris;   Acute Coronary Syndrome
Interventions:   Device: Paclitaxel Eluting Balloon + Scoring Balloon;   Device: Paclitaxel Eluting Balloon
Sponsors:   Deutsches Herzzentrum Muenchen;   Biotronik AG
Completed

Mon, 02 Jul 2012 12:00:00 EDT

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

Condition:   Medical Oncology
Interventions:   Drug: BAY1161909;   Drug: Paclitaxel
Sponsor:   Bayer
Terminated

Thu, 15 May 2014 12:00:00 EDT

Paclitaxel and Irinotecan in Advanced Gastric Cancer

Condition:   Advanced Gastric Cancer
Intervention:   Drug: Paclitaxel and irinotecan
Sponsor:   Seoul National University Hospital
Completed

Thu, 03 Jun 2010 12:00:00 EDT

AVB-S6-500/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Condition:   Platinum-resistant Ovarian Cancer
Interventions:   Drug: AVB-S6-500;   Drug: Paclitaxel;   Other: Placebo
Sponsors:   Aravive, Inc.;   GOG Foundation;   European Network of Gynaecological Oncological Trial Groups (ENGOT)
Recruiting

Thu, 28 Jan 2021 12:00:00 EST

The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

Condition:   Head and Neck Cancer
Intervention:   Drug: Buparlisib & Paclitaxel
Sponsor:   Adlai Nortye Biopharma Co., Ltd.
Recruiting

Wed, 08 Apr 2020 12:00:00 EDT

RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty

Conditions:   Peripheral Artery Disease;   Atherosclerosis;   Artery Diseases, Peripheral;   Plaque, Atherosclerotic;   Occlusive Arterial Disease
Interventions:   Device: RANGER™ Paclitaxel Coated Balloon;   Drug: Paclitaxel;   Procedure: Standard Balloon Angioplasty
Sponsor:   Boston Scientific Corporation
Active, not recruiting

Fri, 24 Feb 2017 12:00:00 EST

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

Conditions:   Cancer;   Non Small Cell Lung Cancer;   Epithelial Ovarian Cancer
Interventions:   Drug: AZD0530;   Drug: Carboplatin;   Drug: paclitaxel
Sponsor:   AstraZeneca
Withdrawn

Fri, 23 Oct 2009 12:00:00 EDT

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Hoffmann-La Roche
Completed

Mon, 13 Jul 2009 12:00:00 EDT

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

Conditions:   Lung Cancer, Non-small Cell;   Artificial Intelligence
Intervention:   Drug: Camrelizumab + Nab-paclitaxel + Carboplatin
Sponsors:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;   Guangdong Provincial People's Hospital;   Third Affiliated Hospital, Sun Yat-Sen University
Recruiting

Wed, 09 Sep 2020 12:00:00 EDT

Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Conditions:   Ovarian Cancer;   Primary PERITONEUM;   Fallopian Tube Cancer
Intervention:   Drug: Paclitaxel,Cisplatin, Bevacizumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.
Completed

Tue, 08 Jan 2008 12:00:00 EST

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

Condition:   Breast Cancer
Interventions:   Drug: Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa;   Drug: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
Sponsors:   German Breast Group;   Pharmacia;   Amgen;   Bristol-Myers Squibb
Completed

Tue, 16 Oct 2007 12:00:00 EDT

Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer

Condition:   Epithelial Ovarian Cancer
Interventions:   Drug: Metformin;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   University Medical Center Groningen
Completed

Tue, 09 Dec 2014 12:00:00 EST

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: CFI-402257;   Drug: Paclitaxel
Sponsors:   Canadian Cancer Trials Group;   Stand Up To Cancer;   Canadian Breast Cancer Foundation;   Ontario Institute for Cancer Research
Recruiting

Tue, 26 Jun 2018 12:00:00 EDT

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

Conditions:   Resectable Pancreatic Cancer;   Ductal Adenocarcinoma of the Pancreas
Interventions:   Drug: perioperative nab-paclitaxel/gemcitabine;   Drug: adjuvant nab-paclitaxel/gemcitabine
Sponsors:   AIO-Studien-gGmbH;   Celgene;   ClinAssess GmbH
Active, not recruiting

Tue, 28 Jan 2014 12:00:00 EST

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

Conditions:   Head and Neck Cancer;   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: Cetuximab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   UNC Lineberger Comprehensive Cancer Center
Completed

Mon, 28 Apr 2014 12:00:00 EDT

Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel

Condition:   Pancreatic Cancer
Interventions:   Drug: Nab-paclitaxel;   Drug: Gemcitabine
Sponsors:   Universitaire Ziekenhuizen Leuven;   Celgene Corporation
Completed

Tue, 08 Apr 2014 12:00:00 EDT

Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

Condition:   Neoplasms, Breast
Interventions:   Drug: Paclitaxel;   Drug: GW572016 (Lapatinib)
Sponsor:   GlaxoSmithKline
Completed

Fri, 09 Jan 2004 12:00:00 EST

Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: vadimezan
Sponsor:   Swiss Group for Clinical Cancer Research
Completed

Wed, 27 Jan 2010 12:00:00 EST

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Albumin-bound paclitaxel;   Drug: Carboplatin;   Drug: Herceptin®
Sponsor:   Celgene
Completed

Tue, 05 Oct 2004 12:00:00 EDT

Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer

Condition:   Advanced Gastric Cancer
Interventions:   Drug: taxel plus raltitrexed;   Drug: taxol
Sponsor:   Fudan University
Unknown status

Wed, 26 Feb 2014 12:00:00 EST

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Conditions:   Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Avastin
Sponsors:   Massachusetts General Hospital;   Genentech, Inc.;   National Cancer Institute (NCI)
Active, not recruiting

Thu, 03 Apr 2008 12:00:00 EDT

Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma

Condition:   Metastatic Pancreatic Adenocarcinoma
Interventions:   Drug: Gemcitabine;   Drug: Paclitaxel
Sponsor:   UNICANCER
Active, not recruiting

Thu, 09 May 2019 12:00:00 EDT

Scheduling Nab-paclitaxel With Gemcitabine

Condition:   Pancreatic Adenocarcinoma Metastatic
Interventions:   Drug: Abraxane (nab-paclitaxel);   Drug: Gemcitabine
Sponsors:   CCTU- Cancer Theme;   Celgene
Completed

Fri, 18 May 2018 12:00:00 EDT

A Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

Condition:   Small Cell Lung Carcinoma
Interventions:   Drug: paclitaxel;   Biological: IBI318
Sponsor:   Innovent Biologics (Suzhou) Co. Ltd.
Recruiting

Thu, 17 Dec 2020 12:00:00 EST

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Conditions:   Resectable Cholangiocarcinoma;   Stage IB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage II Intrahepatic Cholangiocarcinoma AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions:   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Nab-paclitaxel
Sponsors:   Emory University;   Celgene
Recruiting

Mon, 09 Jul 2018 12:00:00 EDT

Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma

Condition:   Cutaneous Malignant Melanoma
Interventions:   Drug: Nintedanib;   Drug: Nintedanib-Placebo;   Drug: Paclitaxel
Sponsors:   Prof. Dr. med. Dirk Schadendorf;   Boehringer Ingelheim;   medac GmbH;   Alcedis GmbH
Completed

Thu, 04 Dec 2014 12:00:00 EST

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

Condition:   Cancer of Head and Neck
Interventions:   Drug: Erbitux, Paclitaxel & Carboplatin;   Radiation: Radiation
Sponsors:   University of Maryland, Baltimore;   Bristol-Myers Squibb
Completed

Thu, 22 Jun 2006 12:00:00 EDT

Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer

Condition:   Stage III-IV or Recurrent Endometrial Cancer
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
Sponsor:   Catholic University of the Sacred Heart
Unknown status

Thu, 17 Jan 2013 12:00:00 EST

Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   Weill Medical College of Cornell University
Terminated

Tue, 20 Mar 2012 12:00:00 EDT

Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   Hellenic Oncology Research Group;   University Hospital of Crete
Terminated

Mon, 10 May 2010 12:00:00 EDT

Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer

Condition:   Small Cell Lung Cancer
Intervention:   Drug: taxol plus everolimus
Sponsor:   Samsung Medical Center
Completed

Wed, 03 Mar 2010 12:00:00 EST

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Conditions:   Squamous Cell Carcinoma of the Head and Neck;   Basaloid Squamous Cell Carcinoma;   Undifferentiated Carcinoma;   Adenosquamous Cell Carcinoma
Interventions:   Drug: Abraxane;   Drug: Erbitux;   Drug: Carboplatin;   Radiation: Intensity Modulated Radiation Therapy
Sponsors:   Dana-Farber Cancer Institute;   Celgene Corporation
Terminated

Tue, 11 Dec 2007 12:00:00 EST

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Conditions:   Head and Neck Cancer;   Squamous Cell Cancer
Intervention:   Drug: Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Comprehensive Cancer Network;   Boehringer Ingelheim
Completed

Sun, 04 Nov 2012 12:00:00 EDT

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

Condition:   Medical Oncology
Interventions:   Drug: BAY1217389;   Drug: Paclitaxel
Sponsor:   Bayer
Completed

Thu, 19 Feb 2015 12:00:00 EST

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Condition:   Carcinoma of Unknown Primary
Interventions:   Drug: belinostat, carboplatin, paclitaxel;   Drug: carboplatin, paclitaxel
Sponsors:   Onxeo;   Spectrum Pharmaceuticals, Inc
Completed

Wed, 01 Apr 2009 12:00:00 EDT

Trial of NanoPac Intratumoral Injection in Lung Cancer

Conditions:   Lung Cancer, Nonsmall Cell;   Lung Cancer;   Lung Cancer, Small Cell;   Neoplasm of Lung
Intervention:   Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Sponsors:   NanOlogy, LLC;   US Biotest, Inc.
Recruiting

Thu, 19 Mar 2020 12:00:00 EDT

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: Camrelizumab;   Drug: Nab paclitaxel;   Drug: Gemcitabine Injection
Sponsor:   Fudan University
Recruiting

Tue, 04 Aug 2020 12:00:00 EDT

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

Condition:   Advanced Cancer
Interventions:   Drug: Dasatinib;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsor:   M.D. Anderson Cancer Center
Active, not recruiting

Wed, 18 Nov 2009 12:00:00 EST

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Condition:   HER2-Positive Early Stage Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Pegfilgrastim
Sponsors:   Memorial Sloan Kettering Cancer Center;   GlaxoSmithKline
Completed

Tue, 09 Apr 2013 12:00:00 EDT

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: MM-141;   Drug: Placebo;   Drug: Gemcitabine;   Drug: Nab-Paclitaxel
Sponsor:   Merrimack Pharmaceuticals
Completed

Thu, 26 Mar 2015 12:00:00 EDT

Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer

Condition:   Advanced Gastric Carcinoma
Intervention:   Drug: paclitaxel liposome
Sponsor:   Peking University
Unknown status

Fri, 13 Jun 2014 12:00:00 EDT

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

Conditions:   Neoplasms;   Breast Neoplasms;   Breast Cancer
Interventions:   Drug: AZD8931;   Drug: Paclitaxel;   Drug: Placebo
Sponsor:   AstraZeneca
Completed

Wed, 13 May 2009 12:00:00 EDT

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

Condition:   Adenocarcinoma Breast Stage IV
Interventions:   Biological: IMP321 (eftilagimod alpha);   Drug: Placebo;   Drug: Paclitaxel
Sponsor:   Immutep S.A.S.
Completed

Wed, 25 Nov 2015 12:00:00 EST

Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

Condition:   Solid Tumors
Interventions:   Drug: Dovitinib;   Drug: Dovitinib + Paclitaxel
Sponsors:   Centro Nacional de Investigaciones Oncologicas CARLOS III;   Hospital Universitario de Fuenlabrada;   M.D. Anderson Cancer Center;   Hospital Universitari de Bellvitge
Terminated

Thu, 08 Mar 2012 12:00:00 EST

Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Condition:   Gastric Cancer
Intervention:   Drug: Camrelizumab+Apatinib+Paclitaxel-albumin+S-1
Sponsor:   Beijing Friendship Hospital
Not yet recruiting

Thu, 06 Feb 2020 12:00:00 EST

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Condition:   Triple Negative Breast Neoplasms
Interventions:   Drug: Capivasertib;   Drug: Paclitaxel;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting

Tue, 25 Jun 2019 12:00:00 EDT

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

Condition:   Anaplastic Thyroid Cancer
Interventions:   Drug: CA4P;   Drug: paclitaxel;   Drug: carboplatin
Sponsor:   Mateon Therapeutics
Terminated

Thu, 26 Jul 2007 12:00:00 EDT

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

Condition:   Prostate Cancer
Interventions:   Drug: Estramustine;   Drug: Taxol
Sponsor:   M.D. Anderson Cancer Center
Completed

Thu, 30 May 2002 12:00:00 EDT

Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease

Conditions:   Peripheral Arterial Disease;   Stenotic Femoro-popliteal Arteries;   Occluded Femoro-popliteal Arteries;   Atherosclerosis
Intervention:   Device: Paclitaxel-coated balloon catheter angioplasty
Sponsor:   Bayer
Completed

Wed, 04 Nov 2009 12:00:00 EST

Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients

Condition:   Adrenocortical Carcinoma
Interventions:   Drug: Sorafenib;   Drug: Paclitaxel
Sponsor:   University of Turin, Italy
Unknown status

Thu, 06 Nov 2008 12:00:00 EST

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Condition:   Stomach Cancer
Interventions:   Drug: nab paclitaxel;   Drug: Tegafur;   Drug: Oxaliplatin;   Drug: Capecitabine
Sponsors:   Zhejiang Cancer Hospital;   CSPC Ouyi Pharmaceutical Co., Ltd.
Recruiting

Wed, 23 Oct 2019 12:00:00 EDT

Prevention of Restenosis Following Revascularization

Condition:   Vascular Disease, Peripheral
Intervention:   Drug: Nanoparticle Paclitaxel
Sponsor:   Celgene Corporation
Terminated

Mon, 20 Aug 2007 12:00:00 EDT

Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma

Condition:   Esophageal Carcinoma
Interventions:   Drug: Liposomal Paclitaxel;   Drug: Nedaplatin
Sponsor:   Sun Yat-sen University
Completed

Wed, 10 Aug 2016 12:00:00 EDT

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: paclitaxel;   Drug: Reparixin;   Drug: placebo
Sponsors:   Dompé Farmaceutici S.p.A;   PRA Health Sciences
Completed

Tue, 24 Feb 2015 12:00:00 EST

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: nab-paclitaxel;   Radiation: Radiation therapy
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Terminated

Tue, 16 Oct 2007 12:00:00 EDT

Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

Condition:   Neoplasms, Gastrointestinal Tract
Interventions:   Drug: Lapatinib;   Drug: Paclitaxel
Sponsor:   GlaxoSmithKline
Completed

Fri, 15 Jun 2007 12:00:00 EDT

Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma

Condition:   Epithelial Ovarian Carcinoma
Interventions:   Drug: Metformin;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Gynecologic Oncology Associates;   University of North Carolina, Chapel Hill
Unknown status

Fri, 08 May 2015 12:00:00 EDT

Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer

Condition:   Gastric Cancer
Intervention:   Drug: Nab-paclitaxel combined with oxaliplatin and S-1
Sponsors:   Jianjun Yang;   CSPC Ouyi Pharmaceutical Co., Ltd.
Recruiting

Wed, 22 Sep 2021 12:00:00 EDT

Angioplasty With Paclitaxel-coated Balloon Only Strategy for Coronary de Novo Lesions

Condition:   Coronary Disease
Intervention:   Device: Paclitaxel DCB
Sponsor:   Beijing Hospital
Recruiting

Wed, 17 Jul 2019 12:00:00 EDT

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Condition:   Triple-Negative Breast Cancer
Interventions:   Drug: JS001;   Drug: Nab-Paclitaxel;   Drug: Placebo
Sponsor:   Shanghai Junshi Bioscience Co., Ltd.
Recruiting

Wed, 11 Sep 2019 12:00:00 EDT

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

Conditions:   Neoplasms;   Pancreatic Neoplasms
Interventions:   Drug: LMB-100;   Drug: Nab-Paclitaxel;   Device: Mesothelin Expression
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Thu, 23 Jun 2016 12:00:00 EDT

Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer

Condition:   Recurrent Cervical Cancer
Intervention:   Drug: anti-PD-1+Albumin-Bound Paclitaxel
Sponsor:   Sun Yat-sen University
Recruiting

Fri, 10 Apr 2020 12:00:00 EDT

Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

Conditions:   Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer;   Bowel Obstruction
Interventions:   Drug: Cisplatin;   Drug: Paclitaxel
Sponsor:   University Health Network, Toronto
Terminated

Tue, 09 Mar 2010 12:00:00 EST

Dose-finding Study in Platinum-Resistant Ovarian Cancer

Condition:   Recurrent Platinum-resistant Ovarian Cancer
Intervention:   Drug: GSK2110183 in combination with carboplatin and paclitaxel
Sponsor:   Accenture
Completed

Tue, 31 Jul 2012 12:00:00 EDT

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Condition:   Melanoma
Interventions:   Drug: Genasense® (oblimersen);   Drug: Abraxane® (paclitaxel protein-bound particles for injectable suspension);   Drug: Temodar® (temozolomide)
Sponsor:   Genta Incorporated
Unknown status

Fri, 08 Dec 2006 12:00:00 EST

Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin

Condition:   Metastatic Breast Cancer
Interventions:   Drug: liposomal Doxorubicin;   Drug: Myocet / Paclitaxel
Sponsor:   Claudia Lorenz-Schlüter
Terminated

Fri, 06 Jun 2008 12:00:00 EDT

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

Condition:   Breast Neoplasms
Intervention:   Drug: Nanoparticle albumin bound paclitaxel followed by FEC
Sponsors:   NSABP Foundation Inc;   Celgene Corporation
Completed

Fri, 13 May 2005 12:00:00 EDT

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer

Condition:   HER2+ Early or Locally Advanced Breast Cancer
Interventions:   Drug: pyrotinib + trastuzumab + nab-paclitaxel;   Drug: pertuzumab + trastuzumab + nab-paclitaxel
Sponsors:   Tianjin Medical University Cancer Institute and Hospital;   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not yet recruiting

Tue, 25 May 2021 12:00:00 EDT

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Condition:   Advanced Gastric Adenocarcinoma
Interventions:   Drug: Paclitaxel;   Drug: Olaparib;   Drug: Pembrolizumab
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Merck Sharp & Dohme Corp.
Recruiting

Tue, 24 Dec 2019 12:00:00 EST

A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer

Conditions:   Pancreatic Adenocarcinoma;   Metastatic Pancreatic Adenocarcinoma
Interventions:   Genetic: VCN-01;   Drug: Gemcitabine;   Drug: Abraxane®
Sponsor:   VCN Biosciences, S.L.
Completed

Mon, 27 Jan 2014 12:00:00 EST

Pembro/Carbo/Taxol in Endometrial Cancer

Conditions:   Endometrial Cancer;   Endometrial Adenocarcinoma
Interventions:   Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Daniela Matei, MD;   Merck Sharp & Dohme Corp.;   Hoosier Cancer Research Network
Active, not recruiting

Tue, 15 Sep 2015 12:00:00 EDT

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Condition:   Solid Tumors
Intervention:   Drug: Nilotinib + Paclitaxel
Sponsor:   National Cancer Institute (NCI)
Recruiting

Thu, 05 Mar 2015 12:00:00 EST

Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2)

Condition:   Small Vessel Lesion
Interventions:   Device: paclitaxel controlled release balloon catheter (VasoguardTM);   Device: common balloon catheter (Maverick2)
Sponsor:   Shandong Branden Med.Device Co.,Ltd
Unknown status

Wed, 07 Sep 2016 12:00:00 EDT

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

Conditions:   Breast Cancer;   Ovarian Neoplasm;   Pain
Interventions:   Dietary Supplement: Omega-3 fatty acid;   Dietary Supplement: Placebo;   Drug: Paclitaxel
Sponsors:   New Mexico Cancer Care Alliance;   Alliance Healthcare Foundation
Active, not recruiting

Mon, 01 Apr 2013 12:00:00 EDT

Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer

Conditions:   Esophageal Squamous Cell Cancer;   Elderly Patients
Intervention:   Other: Sequential chemotherapy (paclitaxel 80mg/m2 d1,d8) and radiotherapy
Sponsor:   Shen Lin
Unknown status

Thu, 19 Dec 2013 12:00:00 EST

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Conditions:   Advanced Malignant Solid Neoplasm;   KRAS Gene Mutation;   Ovarian Carcinoma;   Refractory Malignant Solid Neoplasm;   Refractory Ovarian Carcinoma
Interventions:   Drug: Paclitaxel;   Other: Pharmacokinetic Study;   Drug: Spleen Tyrosine Kinase Inhibitor TAK-659
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Wed, 28 Nov 2018 12:00:00 EST

A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: tivozanib (AV-951) + paclitaxel
Sponsor:   AVEO Pharmaceuticals, Inc.
Completed

Thu, 17 Jul 2008 12:00:00 EDT

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer

Condition:   Carcinoma Breast Stage IV
Intervention:   Drug: Abraxane,Cyclophosphamide,Carboplatin
Sponsor:   Sun Yat-sen University
Terminated

Tue, 08 Jul 2014 12:00:00 EDT

A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR)

Conditions:   Stable Angina;   Unstable Angina
Interventions:   Procedure: Paclitaxel-coated Balloon;   Device: Paclitaxel-eluting Stent
Sponsor:   Ospedale San Donato
Terminated

Fri, 17 Sep 2010 12:00:00 EDT

Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Paclitaxel+Reparixin
Sponsors:   Dompé Farmaceutici S.p.A;   PRA Health Sciences
Completed

Thu, 05 Dec 2013 12:00:00 EST

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Condition:   Gastric Cancer
Interventions:   Drug: Albumin-bound Paclitaxel plus S-1;   Drug: Oxaliplatin plus S-1
Sponsors:   Huazhong University of Science and Technology;   CSPC Ouyi Pharmaceutical Co., Ltd.
Recruiting

Fri, 11 Jan 2019 12:00:00 EST

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Ipatasertib;   Drug: Paclitaxel;   Drug: Placebo
Sponsors:   Genentech, Inc.;   SOLTI Breast Cancer Research Group
Completed

Wed, 26 Nov 2014 12:00:00 EST

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Condition:   Non-Squamous Non-Small Cell Lung Cancer
Interventions:   Drug: Paclitaxel / Carboplatin;   Drug: bavituximab
Sponsor:   Peregrine Pharmaceuticals
Completed

Mon, 12 Jul 2010 12:00:00 EDT

Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)

Condition:   Primary Breast Cancer
Interventions:   Drug: Cabacitaxel;   Drug: Paclitaxel
Sponsor:   German Breast Group
Completed

Wed, 30 Jan 2013 12:00:00 EST

Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents

Condition:   Coronary Artery Bypass Grafting
Intervention:   Device: Paclitaxel eluting stent
Sponsors:   Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec;   Boston Scientific Corporation;   Canadian Institutes of Health Research (CIHR)
Terminated

Tue, 19 Oct 2010 12:00:00 EDT

Trial of NanoPac Focal Therapy for Prostate Cancer

Conditions:   Prostate Cancer;   Prostate Adenocarcinoma;   Prostate Cancer Adenocarcinoma;   Prostatic Neoplasm;   Urogenital Neoplasms;   Genital Neoplasms, Male;   Localized Cancer
Intervention:   Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Sponsors:   NanOlogy, LLC;   US Biotest, Inc.
Terminated

Thu, 09 Jan 2020 12:00:00 EST

Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer

Condition:   Advanced Breast Cancer
Intervention:   Drug: gemcitabine , paclitaxel
Sponsors:   Samsung Medical Center;   Korean Cancer Study Group
Completed

Tue, 20 Nov 2007 12:00:00 EST

Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis

Condition:   Peripheral Artery Disease
Interventions:   Device: Sirolimus-eluting balloon catheter;   Device: Paclitaxel-eluting balloon catheter
Sponsor:   Acotec Scientific Co., Ltd
Not yet recruiting

Thu, 29 Jul 2021 12:00:00 EDT

A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer

Conditions:   Solid Tumor;   Stage IV Gastric Cancer
Intervention:   Drug: Paclitaxel
Sponsor:   Daehwa Pharmaceutical Co., Ltd.
Completed

Wed, 07 Sep 2016 12:00:00 EDT

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Condition:   Metastatic Gastric Cancer
Intervention:   Drug: durvalumab, tremelimumab, paclitaxel
Sponsors:   Asan Medical Center;   Hallym University Medical Center;   Seoul National University Bundang Hospital
Recruiting

Fri, 23 Nov 2018 12:00:00 EST

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Condition:   Peritoneal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Paclitaxel
Sponsor:   M.D. Anderson Cancer Center
Completed

Tue, 26 Jun 2007 12:00:00 EDT

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

Conditions:   Pharmacokinetics of ASP9853;   Non-hematologic Malignancies
Interventions:   Drug: ASP9853;   Drug: Docetaxel;   Drug: Paclitaxel
Sponsor:   Astellas Pharma Global Development, Inc.
Terminated

Fri, 12 Oct 2012 12:00:00 EDT

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: nab paclitaxel;   Drug: Cyclophosphamide;   Drug: Trastuzumab
Sponsors:   SCRI Development Innovations, LLC;   Celgene Corporation
Completed

Thu, 06 Mar 2008 12:00:00 EST

A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy

Condition:   Cervical Cancer
Intervention:   Drug: HLX10+Albumin-Bound Paclitaxel
Sponsor:   Shanghai Henlius Biotech
Active, not recruiting

Tue, 05 Nov 2019 12:00:00 EST

Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsor:   Hellenic Oncology Research Group
Completed

Wed, 17 Sep 2008 12:00:00 EDT

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions:   Drug: Galunisertib;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting

Wed, 03 Feb 2016 12:00:00 EST

A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

Condition:   Solid Tumors
Interventions:   Drug: LCL161;   Drug: Paclitaxel
Sponsor:   Novartis Pharmaceuticals
Completed

Mon, 15 Nov 2010 12:00:00 EST

Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon

Condition:   Coronary Restenosis
Interventions:   Combination Product: Sirolimus coated balloon;   Combination Product: Paclitaxel coated balloon
Sponsor:   InnoRa GmbH
Completed

Tue, 08 Aug 2017 12:00:00 EDT

Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.

Condition:   Ovarian Cancer
Intervention:   Drug: Paclitaxel (albumin-bound)
Sponsors:   Chinese Academy of Medical Sciences;   CSPC Ouyi Pharmaceutical Co., Ltd.
Not yet recruiting

Thu, 10 Dec 2020 12:00:00 EST

Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide;   Drug: paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
Sponsor:   Hebei Medical University Fourth Hospital
Withdrawn

Mon, 26 Aug 2019 12:00:00 EDT

Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)

Conditions:   Esophageal Squamous Cell Carcinoma;   Stage III
Intervention:   Drug: Pembrolizumab Injection [Keytruda]
Sponsor:   Tianjin Medical University Cancer Institute and Hospital
Recruiting

Fri, 15 May 2020 12:00:00 EDT

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Condition:   Gastric Cancer
Interventions:   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Placebo
Sponsor:   AstraZeneca
Active, not recruiting

Fri, 16 Aug 2013 12:00:00 EDT

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Condition:   Gastric Cancer
Interventions:   Drug: olaparib;   Drug: paclitaxel;   Drug: Placebo
Sponsor:   AstraZeneca
Active, not recruiting

Fri, 05 Feb 2010 12:00:00 EST

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Conditions:   Recurrent Head and Neck Squamous Cell Carcinoma;   Head and Neck Cancer Stage IV
Interventions:   Drug: Nivolumab + Paclitaxel;   Drug: Cetuximab + Paclitaxel
Sponsors:   Grupo Español de Tratamiento de Tumores de Cabeza y Cuello;   Bristol-Myers Squibb;   Apices Soluciones S.L.
Recruiting

Mon, 24 Feb 2020 12:00:00 EST

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Condition:   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: Cetuximab;   Drug: Paclitaxel
Sponsors:   Grupo Español de Tratamiento de Tumores de Cabeza y Cuello;   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Recruiting

Thu, 17 Dec 2020 12:00:00 EST

EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer

Condition:   Ovarian Cancer Recurrent
Interventions:   Drug: EP-100;   Drug: Paclitaxel
Sponsor:   Esperance Pharmaceuticals Inc
Completed

Tue, 06 Dec 2011 12:00:00 EST

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Conditions:   Breast Cancer;   Triple Negative Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: AZD2281;   Drug: Paclitaxel
Sponsor:   AstraZeneca
Completed

Tue, 01 Jul 2008 12:00:00 EDT

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Condition:   Neoplasms
Interventions:   Drug: Paclitaxel;   Drug: Copanlisib (BAY80-6946)
Sponsor:   Bayer
Completed

Mon, 08 Aug 2011 12:00:00 EDT

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Pelareorep
Sponsors:   National Cancer Institute (NCI);   NRG Oncology
Completed

Fri, 10 Sep 2010 12:00:00 EDT

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Condition:   Small Cell Lung Cancer
Interventions:   Drug: Alisertib;   Drug: Placebo;   Drug: Paclitaxel
Sponsor:   Millennium Pharmaceuticals, Inc.
Completed

Thu, 16 Jan 2014 12:00:00 EST

EGFR-targeted Therapy for Gastric Cancer

Condition:   Adenocarcinoma of the Stomach
Intervention:   Drug: Anti-EGFR antibody in combination with weekly paclitaxel
Sponsors:   National Cancer Center, Korea;   Korean Cancer Study Group
Recruiting

Wed, 04 Sep 2019 12:00:00 EDT

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

Condition:   Breast Neoplasms
Interventions:   Drug: Ipatasertib;   Drug: Paclitaxel;   Drug: Placebo
Sponsor:   Genentech, Inc.
Completed

Fri, 13 Jun 2014 12:00:00 EDT

Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

Conditions:   Gastric Cancer;   Chemotherapy Effect;   Surgery;   Metastasis;   Survival
Interventions:   Drug: Paclitaxel;   Drug: Lobaplatin
Sponsor:   Wuhan Union Hospital, China
Recruiting

Mon, 22 Mar 2021 12:00:00 EDT

Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Device: Bare metal Stent plus Paclitaxel Balloon;   Device: Bare metal Stent
Sponsors:   Francisco Javier Goicolea;   Effice Servicios Para la Investigacion S.L.
Completed

Thu, 25 Apr 2013 12:00:00 EDT

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Conditions:   Stage IA Pancreatic Adenocarcinoma;   Stage IB Pancreatic Adenocarcinoma;   Stage IIA Pancreatic Adenocarcinoma;   Stage IIB Pancreatic Adenocarcinoma
Interventions:   Drug: nab-paclitaxel;   Drug: Gemcitabine;   Drug: tegafur
Sponsor:   Fudan University
Recruiting

Fri, 03 Jan 2020 12:00:00 EST

Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer

Condition:   Testicular Cancer
Interventions:   Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Gemcitabine
Sponsor:   Rigshospitalet, Denmark
Terminated

Wed, 19 Sep 2007 12:00:00 EDT

Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: OMP-54F28, Paclitaxel and Carboplatin
Sponsor:   OncoMed Pharmaceuticals, Inc.
Completed

Thu, 20 Mar 2014 12:00:00 EDT

Camrelizumab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of Resectable NSCLC

Condition:   Non-small-cell Lung Cancer (NSCLC)
Intervention:   Drug: camrelizumab combined with albumin-bound paclitaxel and cisplatin
Sponsor:   Tang-Du Hospital
Recruiting

Wed, 08 Apr 2020 12:00:00 EDT

STREAMER : STent Restenosis And MEdicaments Release

Condition:   Critical Ischemia
Intervention:   Drug: Paclitaxel
Sponsor:   Hospices Civils de Lyon
Completed

Mon, 18 Jul 2016 12:00:00 EDT

Phase II Trial of Standard Chemotherapy (Carboplatin & Paclitaxel) +Various Proton Beam Therapy (PBT) Doses

Condition:   Non Small Cell Lung Cancer
Interventions:   Device: Proton Beam Therapy;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   Mayo Clinic
Recruiting

Fri, 28 Apr 2017 12:00:00 EDT

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

Condition:   Esophageal Neoplasms
Interventions:   Drug: Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib;   Drug: Paclitaxel + Cisplatin + TQB2450 injection
Sponsors:   Henan Cancer Hospital;   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting

Thu, 19 Aug 2021 12:00:00 EDT

Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA)

Condition:   In-Stent Restenosis
Interventions:   Device: Rapamycin eluting stent implantation;   Device: Paclitaxel eluting balloon catheter
Sponsors:   Medical University of Warsaw;   KCRI
Unknown status

Wed, 08 Dec 2010 12:00:00 EST

A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer

Condition:   Advanced Breast Cancer
Interventions:   Drug: Vinflunine+Gemcitabine;   Drug: Paclitaxel+Gemcitabine
Sponsor:   Pierre Fabre Medicament
Terminated

Tue, 04 Feb 2014 12:00:00 EST

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Conditions:   Recurrent Bladder Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Quality-of-Life Assessment
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Withdrawn

Thu, 24 Mar 2016 12:00:00 EDT

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

Condition:   Non-Small Cell Lung Cancer(NSCLC)
Interventions:   Drug: Paclitaxel Micelles for Injection;   Drug: Paclitaxel Injection;   Drug: Cisplatin
Sponsor:   Shanghai Yizhong Biotechnology Co., Ltd.
Active, not recruiting

Fri, 29 Jan 2016 12:00:00 EST

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: ACP-196;   Drug: Nab-paclitaxel;   Drug: Gemcitabine
Sponsor:   Acerta Pharma BV
Terminated

Wed, 07 Oct 2015 12:00:00 EDT

Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon

Condition:   DES In-stent Stenosis
Interventions:   Device: Paclitaxel coated balloon (SeQuent Please);   Device: Sirolimus coated balloon
Sponsor:   InnoRa GmbH
Completed

Mon, 19 Dec 2016 12:00:00 EST

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

Condition:   Lung Cancer
Interventions:   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Bevacizumab
Sponsor:   Memorial Sloan Kettering Cancer Center
Completed

Fri, 12 Dec 2008 12:00:00 EST

Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.

Condition:   Gastric Cancer
Interventions:   Drug: Taxol;   Drug: Campt, Topotesin
Sponsors:   Hokkaido Gastrointestinal Cancer Study Group;   Hokkaido University Hospital
Withdrawn

Wed, 21 Sep 2005 12:00:00 EDT

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer

Condition:   Head and Neck Cancer
Interventions:   Biological: Cetuximab;   Drug: Cisplatin;   Drug: Nab-Paclitaxel;   Radiation: intensity-modulated radiation therapy
Sponsor:   University of Texas Southwestern Medical Center
Completed

Thu, 26 Feb 2009 12:00:00 EST

Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Paclitaxel;   Procedure: Radiation Therapy
Sponsor:   University of Rochester
Completed

Thu, 15 Sep 2005 12:00:00 EDT

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Condition:   Neoplasms
Interventions:   Drug: Nilotinib;   Drug: Paclitaxel
Sponsor:   National Cancer Institute (NCI)
Recruiting

Mon, 29 Jun 2020 12:00:00 EDT

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Condition:   Head and Neck Squamous Cell Carcinoma
Intervention:   Drug: Camrelizumab, nab-paclitaxel, cisplatin
Sponsors:   Sun Yat-sen University;   Jiangsu HengRui Medicine Co., Ltd.
Recruiting

Thu, 01 Apr 2021 12:00:00 EDT

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: Buparlisib;   Drug: Buparlisib matching Placebo;   Drug: Paclitaxel
Sponsor:   Novartis Pharmaceuticals
Terminated

Mon, 13 May 2013 12:00:00 EDT

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Conditions:   Breast Adenocarcinoma;   Invasive Breast Carcinoma;   Triple-Negative Breast Carcinoma
Interventions:   Drug: Atezolizumab;   Drug: Nab-paclitaxel
Sponsor:   M.D. Anderson Cancer Center
Active, not recruiting

Fri, 21 Aug 2015 12:00:00 EDT

Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions

Condition:   Coronary Atherosclerosis
Interventions:   Device: NEVO™ Sirolimus-eluting Coronary Stent System;   Device: Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)
Sponsors:   Cordis Corporation;   Conor Medsystems
Terminated

Fri, 01 Feb 2008 12:00:00 EST

Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

Conditions:   Gastric Cancer;   Peritoneal Carcinomatosis;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Paclitaxel;   Drug: Leucovorin;   Drug: Fluorouracil
Sponsor:   University of California, Irvine
Recruiting

Sun, 21 Feb 2021 12:00:00 EST

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Conditions:   Malignant Ovarian Epithelial Tumor;   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
Interventions:   Drug: Akt/ERK Inhibitor ONC201;   Drug: Paclitaxel;   Other: Questionnaire Administration
Sponsor:   Ira Winer
Recruiting

Wed, 14 Aug 2019 12:00:00 EDT

Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis Superficialis

Condition:   Peripheral Arterial Disease
Interventions:   Device: Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries;   Device: Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter
Sponsors:   Jena University Hospital;   iVascular S.L.U.;   KKS Netzwerk
Active, not recruiting

Thu, 03 Sep 2015 12:00:00 EDT

CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation

Condition:   Coronary Disease
Intervention:   Device: CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
Sponsor:   Conor Medsystems
Completed

Wed, 17 Jan 2007 12:00:00 EST

Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors

Conditions:   Neoplasm Metastasis;   Carcinoma
Intervention:   Drug: Paclitaxel plus PTK787
Sponsors:   Indiana University School of Medicine;   Novartis
Completed

Mon, 11 Aug 2008 12:00:00 EDT

A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Condition:   Ovarian Cancer
Interventions:   Drug: MK-1775;   Drug: Placebo;   Drug: paclitaxel;   Drug: carboplatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Fri, 20 May 2011 12:00:00 EDT

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Neratinib;   Drug: Trastuzumab;   Drug: Paclitaxel
Sponsor:   Puma Biotechnology, Inc.
Completed

Fri, 05 Jun 2009 12:00:00 EDT

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Conditions:   Adenocarcinoma;   Pancreatic Neoplasms
Interventions:   Drug: MLN8237;   Drug: nab-Paclitaxel
Sponsor:   Washington University School of Medicine
Completed

Mon, 03 Sep 2012 12:00:00 EDT

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: Lapatinib and Paclitaxel
Sponsor:   Frederick R. Ueland, M.D.
Recruiting

Thu, 29 Oct 2020 12:00:00 EDT

S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

Condition:   Head and Neck Cancer
Interventions:   Drug: gemcitabine;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Completed

Fri, 07 Jan 2005 12:00:00 EST

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Condition:   Endometrial Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: bevacizumab
Sponsors:   David O'Malley;   Genentech, Inc.
Completed

Thu, 09 Aug 2007 12:00:00 EDT

Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer

Condition:   Cervical Cancer
Intervention:   Drug: Phyxol(Paclitaxel)
Sponsors:   Chang Gung Memorial Hospital;   Sinphar Pharmaceutical Co., Ltd
Unknown status

Thu, 15 Jan 2009 12:00:00 EST

Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

Condition:   Extensive-Stage Small Cell Lung Cancer
Interventions:   Drug: Paclitaxel/Albumin-Bound Paclitaxel;   Drug: IBI308
Sponsor:   Junling Li
Recruiting

Wed, 14 Aug 2019 12:00:00 EDT

Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study

Condition:   Nasopharyngeal Cancer
Intervention:   Drug: Nab paclitaxel
Sponsor:   Sun Yat-sen University
Recruiting

Tue, 20 Apr 2021 12:00:00 EDT

A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: gemcitabine;   Drug: paclitaxel;   Drug: bevacizumab
Sponsors:   Eli Lilly and Company;   Genentech, Inc.
Completed

Wed, 03 May 2006 12:00:00 EDT

Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Enzalutamide;   Drug: Placebo;   Drug: Paclitaxel
Sponsors:   Pfizer;   Astellas Pharma Inc;   Medivation, Inc.
Withdrawn

Tue, 11 Oct 2016 12:00:00 EDT

Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus

Condition:   Esophageal Squamous Cell Carcinoma
Interventions:   Other: Paclitaxel plus Cisplatin with radiotherapy;   Other: S1 plus Cisplatin with radiotherapy
Sponsor:   Mianyang Central Hospital
Unknown status

Mon, 26 Oct 2015 12:00:00 EDT

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Condition:   Platinum-resistant Ovarian Cancer
Interventions:   Drug: Paclitaxel;   Drug: Afuresertib
Sponsor:   Laekna Limited
Recruiting

Tue, 05 May 2020 12:00:00 EDT

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

Condition:   Pancreatic Cancer
Interventions:   Drug: Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine;   Drug: Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine;   Drug: Part A- VS-4718, nab-paclitaxel, gemcitabine
Sponsor:   Verastem, Inc.
Terminated

Mon, 11 Jan 2016 12:00:00 EST

Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: bortezomib;   Drug: paclitaxel;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 09 Apr 2003 12:00:00 EDT

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Conditions:   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Ramucirumab;   Drug: Paclitaxel
Sponsor:   Eli Lilly and Company
Completed

Mon, 03 Aug 2015 12:00:00 EDT

Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Paclitaxel and Sorafenib;   Drug: Paclitaxel
Sponsors:   Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH;   iOMEDICO AG
Completed

Tue, 22 Mar 2011 12:00:00 EDT

ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: ARQ-761;   Drug: Gemcitabine;   Drug: nab-paclitaxel
Sponsor:   University of Texas Southwestern Medical Center
Suspended

Mon, 03 Aug 2015 12:00:00 EDT

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: MEDI-575
Sponsor:   MedImmune LLC
Terminated

Wed, 29 Dec 2010 12:00:00 EST

PD0332991/Paclitaxel in Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: PD0332991;   Drug: Paclitaxel
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
Completed

Tue, 22 Mar 2011 12:00:00 EDT

Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

Condition:   Advanced Gastric Cancer
Interventions:   Drug: Paclitaxel;   Drug: Olaparib;   Drug: Durvalumab
Sponsors:   Do-Youn Oh;   AstraZeneca
Active, not recruiting

Mon, 09 Jul 2018 12:00:00 EDT

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer
Interventions:   Drug: AVB-S6-500;   Drug: Paclitaxel;   Drug: Carboplatin;   Procedure: Tissue from Diagnostic Laparoscopy;   Procedure: Tissue from Core biopsy;   Procedure: Interval Debulking;   Procedure: Peripheral blood;   Procedure: Ascites collection
Sponsors:   Washington University School of Medicine;   Aravive, Inc.
Withdrawn

Tue, 31 Jul 2018 12:00:00 EDT

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Condition:   Locally Recurrent or Metastatic Breast Cancer
Interventions:   Drug: Imetelstat sodium;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsor:   Geron Corporation
Completed

Thu, 09 Dec 2010 12:00:00 EST

Stromal TARgeting for PAncreatic Cancer (STAR_PAC)

Condition:   Pancreatic Adenocarcinoma
Interventions:   Drug: ATRA;   Drug: Gemcitabine;   Drug: Nab-paclitaxel
Sponsors:   Barts & The London NHS Trust;   Medical Research Council;   Celgene Corporation;   Cancer Research UK Cambridge Institute;   King's College London;   Royal Free Hospital NHS Foundation Trust;   Imperial College Healthcare NHS Trust;   Institute of Cancer Research, United Kingdom;   Cambridge University Hospitals NHS Foundation Trust
Completed

Wed, 11 Oct 2017 12:00:00 EDT

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Condition:   Endometrial Cancer
Interventions:   Drug: Carboplatin/Paclitaxel;   Drug: Trastuzumab
Sponsors:   Yale University;   Genentech, Inc.
Active, not recruiting

Mon, 06 Jun 2011 12:00:00 EDT

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Dasatinib;   Drug: Trastuzumab;   Drug: Paclitaxel
Sponsors:   Spanish Breast Cancer Research Group;   Bristol-Myers Squibb
Completed

Wed, 02 Mar 2011 12:00:00 EST

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Condition:   Locally Advanced or Metastatic Gastric Adenocarcinoma
Interventions:   Drug: Camrelizumab;   Drug: Apatinib Mesylate;   Drug: nab-paclitaxel
Sponsor:   The First Affiliated Hospital of Xiamen University
Recruiting

Thu, 01 Oct 2020 12:00:00 EDT

A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

Condition:   Advanced Solid Tumors
Interventions:   Drug: Paclitaxel;   Drug: RO5509554
Sponsor:   Hoffmann-La Roche
Completed

Mon, 19 Dec 2011 12:00:00 EST

Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer

Conditions:   Ovarian Cancer;   Endometrial Cancer;   Recurrent Ovarian Cancer;   Recurrent Endometrial Cancer
Interventions:   Drug: BKM120;   Drug: Nabpaclitaxel
Sponsors:   Rutgers, The State University of New Jersey;   Rutgers Cancer Institute of New Jersey;   National Cancer Institute (NCI)
Withdrawn

Mon, 21 Apr 2014 12:00:00 EDT

Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)

Condition:   Ovarian Sex-cord Stromal Tumor
Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   ARCAGY/ GINECO GROUP;   Roche Pharma AG
Completed

Thu, 17 Jan 2013 12:00:00 EST

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Conditions:   Ovarian Carcinoma;   Fallopian Tube Cancer;   Peritoneal Cancer;   Breast Carcinoma
Interventions:   Drug: Alisertib;   Drug: Paclitaxel
Sponsor:   Millennium Pharmaceuticals, Inc.
Completed

Wed, 24 Mar 2010 12:00:00 EDT

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)

Condition:   Breast Cancer
Interventions:   Drug: Gemcitabine,cisplatin;   Drug: Gemcitabine, Paclitaxel
Sponsors:   Fudan University;   307 Hospital of PLA;   The Affiliated Hospital of the Chinese Academy of Military Medical Sciences;   Sun Yat-sen University;   Tianjin Medical University Cancer Institute and Hospital;   Zhejiang Cancer Hospital;   Changhai Hospital
Completed

Tue, 01 Feb 2011 12:00:00 EST

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

Condition:   Neoplasms, Breast
Intervention:   Drug: Lapatinib/nab-Paclitaxel
Sponsor:   Novartis Pharmaceuticals
Completed

Thu, 03 Jul 2008 12:00:00 EDT

Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer

Condition:   Esophageal Squamous Cell Cancer
Intervention:   Other: Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy
Sponsor:   Shen Lin
Unknown status

Thu, 19 Dec 2013 12:00:00 EST

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Conditions:   Inflammatory Breast Cancer;   Stage IIA Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer;   Stage IIB Breast Cancer;   Estrogen Receptor Negative;   Progesterone Receptor Negative;   HER2/Neu Negative
Interventions:   Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Active, not recruiting

Fri, 03 Feb 2012 12:00:00 EST

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

Condition:   Oropharynx Squamous Cell Carcinoma
Interventions:   Drug: Nivolumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation Therapy
Sponsors:   University of Michigan Rogel Cancer Center;   Bristol-Myers Squibb
Recruiting

Mon, 04 Feb 2019 12:00:00 EST

Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer

Conditions:   Esophageal Cancer;   Gastric Cancer
Interventions:   Drug: Bryostatin-1;   Drug: Paclitaxel (Taxol)
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Completed

Fri, 25 Jul 2003 12:00:00 EDT

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Apatinib;   Drug: Paclitaxel
Sponsor:   Tianjin Medical University Cancer Institute and Hospital
Unknown status

Mon, 20 Nov 2017 12:00:00 EST

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Sorafenib;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   SCRI Development Innovations, LLC;   Bayer
Completed

Fri, 20 Oct 2006 12:00:00 EDT

The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

Condition:   Solid Tumor, Adult
Intervention:   Drug: Oraxol
Sponsor:   Athenex, Inc.
Recruiting

Wed, 27 Mar 2019 12:00:00 EDT

Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)

Conditions:   Coronary Artery Disease;   Coronary Restenosis;   Coronary Atherosclerosis;   Coronary Arteriosclerosis
Interventions:   Device: Agent Paclitaxel-coated balloon;   Device: SeQuent® Please Paclitaxel-coated Balloon
Sponsor:   Hemoteq AG
Completed

Fri, 30 May 2014 12:00:00 EDT

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

Condition:   Gastric Cancer
Interventions:   Biological: Ramucirumab (IMC-1211B) DP;   Drug: Placebo;   Drug: Paclitaxel
Sponsor:   Eli Lilly and Company
Completed

Tue, 27 Jul 2010 12:00:00 EDT

A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: Paclitaxel, Carboplatin and Vorinostat
Sponsors:   Herlev Hospital;   Odense University Hospital
Unknown status

Wed, 15 Oct 2008 12:00:00 EDT

Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

Condition:   Urothelial Cancer
Interventions:   Drug: Nab-Paclitaxel;   Drug: Paclitaxel
Sponsors:   Canadian Cancer Trials Group;   Australian and New Zealand Urogenital and Prostate Cancer Trials Group;   Celgene
Completed

Mon, 13 Jan 2014 12:00:00 EST

A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology

Condition:   Squamous Non-Small Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: RO5479599
Sponsor:   Hoffmann-La Roche
Terminated

Wed, 30 Jul 2014 12:00:00 EDT

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Condition:   Locally Advanced or Metastatic Solid Tumor
Interventions:   Drug: rebastinib;   Drug: Paclitaxel
Sponsor:   Deciphera Pharmaceuticals LLC
Active, not recruiting

Thu, 26 Jul 2018 12:00:00 EDT

Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer

Condition:   Gastric Cancer
Intervention:   Drug: S1/Paclitaxel chemotherapy plus Apatinib
Sponsors:   The First Affiliated Hospital of Zhejiang Chinese Medical University;   Jiangsu HengRui Medicine Co., Ltd.
Unknown status

Thu, 20 Aug 2015 12:00:00 EDT

VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer

Condition:   Cervical Cancer
Intervention:   Drug: Drug: Cisplatin; nab-paclitaxel
Sponsor:   Peking University Third Hospital
Recruiting

Fri, 12 Jul 2019 12:00:00 EDT

Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

Conditions:   Kidney Diseases;   ESRD
Interventions:   Device: Vascular Wrap Paclitaxel-Eluting Mesh;   Device: Lifespan® ePTFE Vascular Graft
Sponsor:   Angiotech Pharmaceuticals
Terminated

Mon, 19 Mar 2007 12:00:00 EDT

Paclitaxel Eluting Balloon for SFA In-stent Restenosis

Condition:   In-stent Arterial Restenosis
Intervention:   Device: PTA with drug eluting balloon with paclitaxel
Sponsor:   University Health Network, Toronto
Unknown status

Tue, 12 Jun 2012 12:00:00 EDT

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Paclitaxel plus carboplatin;   Drug: Paclitaxel and epirubicin
Sponsor:   Chinese Academy of Medical Sciences
Unknown status

Thu, 13 Jan 2011 12:00:00 EST

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Tivozanib Hydrochloride;   Drug: paclitaxel;   Drug: Placebo
Sponsors:   AVEO Pharmaceuticals, Inc.;   Astellas Pharma Inc
Terminated

Mon, 10 Dec 2012 12:00:00 EST

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

Condition:   Sarcoma
Interventions:   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed

Fri, 03 Jun 2005 12:00:00 EDT

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer

Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions:   Drug: mifepristone;   Drug: placebo;   Drug: nab-paclitaxel
Sponsor:   University of Chicago
Completed

Thu, 15 Dec 2011 12:00:00 EST

Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts

Conditions:   Dysfunctional AV Graft;   Dysfunctional AV Fistula
Intervention:   Device: Lutonix Paclitaxel Drug Coated Balloon
Sponsor:   C. R. Bard
Withdrawn

Tue, 08 Jul 2014 12:00:00 EDT

Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: Afatinib 30Mg Tab;   Drug: Afatinib 40Mg Tab;   Drug: Gemzar;   Drug: Abraxane
Sponsors:   PD Dr. med. Volker Heinemann;   Technische Universität München;   University of Cologne
Unknown status

Tue, 29 Nov 2016 12:00:00 EST

Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: Genexol-PM;   Drug: Paclitaxel
Sponsor:   National Cancer Center, Korea
Withdrawn

Mon, 26 Jul 2010 12:00:00 EDT

Evaluation of Paclitaxel Coated Balloon in the Treatment of Dialysis Access Dysfunction

Conditions:   Dialysis Access Malfunction;   Kidney Failure
Intervention:   Drug: Paclitaxel Drug Coated Balloon
Sponsor:   Singapore General Hospital
Recruiting

Wed, 04 Aug 2021 12:00:00 EDT

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Conditions:   Breast Cancer;   Ovarian Cancer;   Gynecological Cancer;   Head and Neck Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Non-squamous Cell Lung Cancer
Intervention:   Drug: PM01183 + paclitaxel +/- bevacizumab
Sponsor:   PharmaMar
Completed

Mon, 15 Apr 2013 12:00:00 EDT

Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Condition:   Relapse/Refractory Multiple Myeloma
Interventions:   Drug: Paclitaxel;   Drug: Cyclophosphamide;   Drug: Dexamethasone
Sponsor:   Sun Yat-sen University
Withdrawn

Wed, 07 Dec 2016 12:00:00 EST

Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer

Condition:   Advanced Solid Tumors
Intervention:   Drug: Paclitaxel+HM30181
Sponsor:   Hanmi Pharmaceutical Company Limited
Completed

Tue, 13 Dec 2011 12:00:00 EST

EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Paclitaxel + Carboplatin every 3 weeks;   Drug: Carboplatin monotherapy every 3 weeks;   Drug: Weekly Paclitaxel and Carboplatin
Sponsor:   Hospices Civils de Lyon
Completed

Wed, 04 Dec 2013 12:00:00 EST

Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Drug: Lenvatinib;   Drug: Paclitaxel;   Biological: Pembrolizumab
Sponsor:   Floor Backes
Not yet recruiting

Thu, 04 Mar 2021 12:00:00 EST

LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors

Condition:   Advanced Solid Tumors
Intervention:   Drug: Panobinostat (LBH589), Carboplatin and Paclitaxel
Sponsors:   Southern Europe New Drug Organization;   Novartis
Unknown status

Fri, 09 Jul 2010 12:00:00 EDT

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Conditions:   Pancreatic Ductal Adenocarcinoma;   Metastatic Pancreatic Cancer
Interventions:   Drug: CEND-1;   Drug: Gemcitabine Injection;   Drug: Nab paclitaxel
Sponsors:   University of Sydney;   Australasian Gastro-Intestinal Trials Group
Not yet recruiting

Mon, 13 Sep 2021 12:00:00 EDT

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Condition:   Lung Cancer, Non-Small Cell
Interventions:   Drug: pazopanib;   Drug: paclitaxel
Sponsor:   GlaxoSmithKline
Completed

Fri, 20 Mar 2009 12:00:00 EDT

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Apatinib;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Chinese Academy of Medical Sciences
Unknown status

Thu, 08 Nov 2018 12:00:00 EST

Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

Conditions:   Breast Cancer;   Adenocarcinoma of the Breast
Intervention:   Drug: epirubicin, cyclophosphamide, Paclitaxel,
Sponsors:   Memorial Sloan Kettering Cancer Center;   Amgen;   Pfizer
Completed

Mon, 18 Feb 2008 12:00:00 EST

Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome

Condition:   Breast Carcinoma
Interventions:   Procedure: Cryotherapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
Completed

Mon, 28 Dec 2015 12:00:00 EST

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Conditions:   Urinary Bladder Neoplasms;   Carcinoma, Transitional Cell;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Pancreatic Ductal;   Tumor Virus Infections
Interventions:   Drug: CC-486;   Drug: Carboplatin;   Drug: ABI-007
Sponsor:   Celgene
Completed

Wed, 23 Nov 2011 12:00:00 EST

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

Condition:   Malignant Melanoma
Interventions:   Drug: Sorafenib (BAY 43-9006);   Drug: ABI-007(Abraxane)
Sponsors:   Mt. Sinai Medical Center, Miami;   Celgene Corporation;   Bayer
Completed

Thu, 07 Jun 2007 12:00:00 EDT

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Albumin-bound paclitaxel combined with carboplatin;   Drug: Epirubicin combined with docetaxel
Sponsor:   Shengjing Hospital
Recruiting

Wed, 23 Oct 2019 12:00:00 EDT

First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

Conditions:   Metastatic Breast Cancer;   Advanced Breast Cancer;   Triple Negative Breast Cancer
Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   MedSIR;   Hoffmann-La Roche
Recruiting

Fri, 29 May 2020 12:00:00 EDT

Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: Gemcitabine;   Drug: Adriamycine;   Drug: Paclitaxel
Sponsors:   Spanish Breast Cancer Research Group;   Eli Lilly and Company;   Bristol-Myers Squibb
Completed

Wed, 10 Aug 2005 12:00:00 EDT

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Condition:   Melanoma
Interventions:   Drug: Tasisulam-sodium;   Drug: Paclitaxel
Sponsor:   Eli Lilly and Company
Terminated

Sun, 01 Nov 2009 12:00:00 EDT

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition:   Lung Cancer (NSCLC)
Interventions:   Biological: Paclitaxel;   Biological: Carboplatin;   Biological: Ipilimumab;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 31 Oct 2014 12:00:00 EDT

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: Folfirinox alternating with Gemcitabine-nab-Paclitaxel
Sponsor:   Lyudmyla Berim
Recruiting

Thu, 17 Dec 2020 12:00:00 EST

The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee

Conditions:   Peripheral Arterial Disease;   Cardiovascular Disease;   Peripheral Vascular Disease
Intervention:   Other: Paclitaxel administration using the OPC
Sponsors:   Horizons International Peripheral Group;   Advanced Catheter Therapies, Inc.
Completed

Mon, 08 Jun 2015 12:00:00 EDT

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Abraxane;   Drug: Carboplatin;   Drug: Avastin
Sponsors:   William Sikov MD;   Yale University
Completed

Mon, 28 Jul 2008 12:00:00 EDT

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Conditions:   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer;   Uterine Cancer
Interventions:   Drug: Olaparib;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsors:   Swedish Medical Center;   AstraZeneca
Unknown status

Thu, 26 Jul 2012 12:00:00 EDT

Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in In-Stent Restenosis Lesions (DEBREST)

Condition:   In-stent Coronary Artery Restenosis
Intervention:   Device: Danubio paclitaxel-eluting balloon
Sponsors:   MINVASYS;   European Cardiovascular Research Center
Completed

Mon, 05 Dec 2011 12:00:00 EST

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

Conditions:   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions:   Drug: suramin;   Drug: paclitaxel;   Other: pharmacological study
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 06 Feb 2003 12:00:00 EST

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: irinotecan hydrochloride;   Drug: paclitaxel
Sponsors:   University of Chicago;   National Cancer Institute (NCI)
Completed

Thu, 29 Apr 2004 12:00:00 EDT

Balloon Elution and Late Loss Optimization (BELLO) Study

Condition:   Coronary Artery Disease
Interventions:   Device: IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon);   Device: Taxus (Paclitaxel eluting stent)
Sponsor:   Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
Unknown status

Mon, 15 Mar 2010 12:00:00 EDT

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

Condition:   Advanced Gastric Cancer
Interventions:   Drug: AZD5363;   Drug: paclitaxel
Sponsor:   Samsung Medical Center
Completed

Fri, 22 May 2015 12:00:00 EDT

Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer

Condition:   Pancreatic Neoplasm
Interventions:   Drug: Nab-paclitaxel;   Drug: Gemcitabine
Sponsors:   Hacettepe University;   Celgene
Completed

Thu, 17 Jan 2019 12:00:00 EST

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Conditions:   Fallopian Tube Carcinoma;   Infectious Disorder;   Neutropenia;   Ovarian Carcinosarcoma;   Primary Peritoneal Carcinoma;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions:   Procedure: Adjuvant Therapy;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Pegfilgrastim
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed

Fri, 14 Jul 2006 12:00:00 EDT

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Locally Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer Non-resectable
Interventions:   Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX;   Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
Sponsor:   FibroGen
Recruiting

Tue, 07 May 2019 12:00:00 EDT

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer

Conditions:   Gastro-oesophageal Junction Cancer;   Gastric Cancer
Interventions:   Drug: AZD4547;   Drug: paclitaxel
Sponsor:   AstraZeneca
Terminated

Mon, 24 Oct 2011 12:00:00 EDT

A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Conditions:   Pancreatic Cancer;   Metastatic Pancreatic Cancer;   Metastatic Pancreatic Adenocarcinoma
Interventions:   Drug: zolbetuximab;   Drug: nab-paclitaxel;   Drug: gemcitabine
Sponsor:   Astellas Pharma Global Development, Inc.
Recruiting

Fri, 25 Jan 2019 12:00:00 EST

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Condition:   Melanoma
Interventions:   Drug: Elesclomol (STA-4783);   Drug: Paclitaxel
Sponsor:   Synta Pharmaceuticals Corp.
Terminated

Thu, 30 Aug 2007 12:00:00 EDT

Clinical Study of Decitabine and Paclitaxel Combination Therapy

Condition:   Advanced Breast Cancer
Interventions:   Drug: Decitabine;   Drug: Paclitaxel
Sponsor:   Dong Wha Pharmaceutical Co. Ltd.
Unknown status

Thu, 14 Sep 2017 12:00:00 EDT

Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses

Condition:   Peripheral Arterial Disease (PAD)
Interventions:   Device: Zilver® Paclitaxel-Eluting Peripheral Stent;   Device: Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating;   Device: Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
Sponsor:   Cook Group Incorporated
Active, not recruiting

Tue, 18 Oct 2016 12:00:00 EDT

A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer

Condition:   Stage III Esophageal Squamous Cell Carcinoma
Interventions:   Drug: Paclitaxel and Cisplatin;   Drug: Paclitaxel and Fluorouracil;   Drug: Paclitaxel and Carboplatin;   Radiation: Radiotherapy
Sponsors:   Fudan University;   Huadong Hospital;   Wuxi No. 4 People's Hospital;   Jiangsu Cancer Institute & Hospital;   The First Affiliated Hospital of Xiamen University;   Jiangxi Provincial Cancer Hospital;   Shanxi Province Cancer Hospital;   Gansu Cancer Hospital
Active, not recruiting

Tue, 02 Jun 2015 12:00:00 EDT

Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

Condition:   Recurrent/Metastatic Gastric Cancer
Intervention:   Drug: Trastuzumab + Ramucirumab + Paclitaxel
Sponsor:   Yonsei University
Active, not recruiting

Mon, 17 May 2021 12:00:00 EDT

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

Condition:   HER2-positive Gastric Cancer
Intervention:   Drug: Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur
Sponsor:   Shengjing Hospital
Recruiting

Thu, 07 Oct 2021 12:00:00 EDT

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

Conditions:   Recurrent Malignant Solid Neoplasm;   Refractory Malignant Solid Neoplasm
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Sapanisertib
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Tue, 13 Feb 2018 12:00:00 EST

Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Radiation: Proton beam radiation therapy (PBT);   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Washington University School of Medicine
Completed

Tue, 24 Jun 2014 12:00:00 EDT

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group
Completed

Mon, 27 Jan 2003 12:00:00 EST

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Intervention:   Drug: carboplatin and paclitaxel
Sponsor:   Korean Gynecologic Oncology Group
Unknown status

Wed, 04 Apr 2012 12:00:00 EDT

Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery

Conditions:   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions:   Drug: vorinostat;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Terminated

Mon, 21 Apr 2008 12:00:00 EDT

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
Sponsor:   National Cancer Institute (NCI)
Completed

Tue, 30 Oct 2012 12:00:00 EDT

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

Conditions:   Breast Cancer;   HER2 Positive;   Combination Chemotherapy
Interventions:   Drug: Pyrotinib Maleate Tablets;   Drug: Albumin Paclitaxel;   Drug: Trastuzumab
Sponsors:   West China Hospital;   Jiangsu HengRui Medicine Co., Ltd.
Recruiting

Tue, 05 Nov 2019 12:00:00 EST

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

Conditions:   Breast Neoplasms;   Metastases, Neoplasm
Intervention:   Drug: ABI-007
Sponsor:   Celgene Corporation
Completed

Thu, 03 Oct 2002 12:00:00 EDT

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

Conditions:   Pancreatic Adenocarcinoma;   Unresectable Pancreatic Carcinoma;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Drug: Metformin Hydrochloride;   Dietary Supplement: Therapeutic Dietary Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Active, not recruiting

Mon, 12 Jan 2015 12:00:00 EST

Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   University of Alabama at Birmingham;   National Cancer Institute (NCI)
Completed

Tue, 09 Nov 2004 12:00:00 EST

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Condition:   Stage IV (Metastatic) Breast Cancer
Interventions:   Drug: ABI-007;   Drug: vinorelbine;   Drug: Trastuzumab;   Biological: G-CSF
Sponsor:   Celgene
Terminated

Thu, 01 Sep 2005 12:00:00 EDT

Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC

Condition:   Neoplasms, Breast
Intervention:   Drug: Lapatinib in combination with weekly paclitaxel
Sponsor:   GlaxoSmithKline
Completed

Mon, 07 Jun 2010 12:00:00 EDT

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Conditions:   Advanced Breast Carcinoma;   Metastatic Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Onalespib;   Drug: Paclitaxel;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Wed, 17 Jun 2015 12:00:00 EDT

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

Conditions:   Advanced Solid Tumors;   Ovarian Cancer;   Small Cell Lung Cancer
Interventions:   Drug: Alisertib;   Drug: Paclitaxel
Sponsor:   Millennium Pharmaceuticals, Inc.
Terminated

Fri, 20 Feb 2015 12:00:00 EST

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: Paclitaxel
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   NSABP Foundation Inc
Completed

Mon, 27 Jan 2003 12:00:00 EST

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Drug: Camrelizumab, Albumin Paclitaxel, Carboplatin
Sponsors:   Hunan Cancer Hospital;   Jiangsu HengRui Medicine Co., Ltd.
Recruiting

Tue, 23 Feb 2021 12:00:00 EST

Paclitaxel Eluting Balloon After Bare Metal Stent Implantation vs. Drug-Eluting Stent in St Elevation Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Device: Bare metal Stent plus Paclitaxel Balloon;   Device: Drug Eluting Stent
Sponsors:   Fundacion Investigacion Interhospitalaria Cardiovascular;   Effice Servicios Para la Investigacion S.L.
Terminated

Wed, 01 Aug 2018 12:00:00 EDT

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors;   Pancreatic Adenocarcinoma
Interventions:   Genetic: VCN-01;   Drug: Gemcitabine;   Drug: Abraxane®
Sponsor:   VCN Biosciences, S.L.
Completed

Mon, 27 Jan 2014 12:00:00 EST

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Condition:   Locally Advanced Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: nab-paclitaxel;   Device: RenovoCath
Sponsor:   RenovoRx
Recruiting

Tue, 22 Aug 2017 12:00:00 EDT

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma

Condition:   Melanoma
Interventions:   Drug: Temozolomide;   Drug: Abraxane;   Drug: Cisplatin;   Biological: Interleukin-2;   Biological: Interferon alpha 2b
Sponsor:   M.D. Anderson Cancer Center
Completed

Thu, 03 Sep 2009 12:00:00 EDT

A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients

Condition:   Human Epithelial Receptor (HER)-2 Positive Breast Cancer
Interventions:   Drug: Trastuzumab;   Drug: Paclitaxel
Sponsor:   Biocad
Completed

Wed, 09 Jan 2013 12:00:00 EST

Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer

Condition:   Recurrent/Metastatic Gastric Cancer
Intervention:   Drug: M7824+paclitaxel
Sponsor:   Yonsei University
Not yet recruiting

Thu, 08 Apr 2021 12:00:00 EDT

Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in Side Branches of de Novo Bifurcation Lesions (DEBSIDE)

Condition:   Coronary Disease
Intervention:   Device: Danubio paclitaxel-eluting balloon
Sponsors:   MINVASYS;   European Cardiovascular Research Center
Completed

Mon, 05 Dec 2011 12:00:00 EST

OCT- Versus Angiography-guided Paclitaxel Drug-Coated Balloon Angioplasty in De Novo Coronary Artery

Condition:   Coronary Artery Disease
Interventions:   Device: OCT-guided paclitaxel drug-coated balloon angioplasty;   Device: Angiography-guided paclitaxel drug-coated balloon angioplasty
Sponsor:   Beijing Anzhen Hospital
Recruiting

Wed, 19 Feb 2020 12:00:00 EST

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Conditions:   High Grade Serous Ovarian;   Fallopian Tube;   Primary Peritoneal Cancer
Interventions:   Drug: Carboplatin and Paclitaxel;   Drug: Nivolumab;   Procedure: Cytoreductive surgery;   Drug: Ipilimumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Bristol-Myers Squibb
Recruiting

Thu, 10 Aug 2017 12:00:00 EDT

Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients

Condition:   Breast Cancer Female
Interventions:   Drug: paclitaxel;   Drug: Iniparib (SAR2405550 -BSI-201)
Sponsors:   Sanofi;   SOLTI Breast Cancer Research Group
Completed

Fri, 17 Sep 2010 12:00:00 EDT

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Nab-paclitaxel;   Drug: MK-3475 (Phase I);   Drug: MK-3475 (Phase II)
Sponsors:   Nisha Mohindra, MD;   Hoosier Cancer Research Network;   Merck Sharp & Dohme Corp.;   Celgene Corporation
Active, not recruiting

Fri, 06 Mar 2015 12:00:00 EST

Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer

Condition:   Advanced Non-small Cell Lung Cancer
Interventions:   Drug: Endostar(Recombinant Human Endostatin Injection);   Drug: paclitaxel-carboplatin
Sponsor:   Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Completed

Wed, 02 Jul 2008 12:00:00 EDT

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions:   Drug: Nilotinib;   Drug: Nilotinib Hydrochloride Monohydrate;   Drug: Paclitaxel;   Other: Placebo;   Other: Questionnaire Administration
Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting

Fri, 20 Dec 2019 12:00:00 EST

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Condition:   Bladder Carcinoma in Situ (CIS)
Intervention:   Drug: ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Sponsor:   Fidia Farmaceutici s.p.a.
Not yet recruiting

Fri, 27 Aug 2021 12:00:00 EDT

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: thalidomide;   Radiation: radiation therapy
Sponsor:   National Cancer Institute (NCI)
Terminated

Mon, 27 Jan 2003 12:00:00 EST

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Conditions:   Pulmonary Sarcomatoid Carcinoma;   Non-small Cell Lung Cancer;   Lung Diseases;   Thoracic Neoplasms
Interventions:   Drug: Toripalimab;   Drug: Bevacizumab;   Drug: Nab-paclitaxel;   Drug: Carboplatin
Sponsor:   Sichuan Cancer Hospital and Research Institute
Recruiting

Tue, 26 Jan 2021 12:00:00 EST

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: BYL719;   Drug: Gemcitabine;   Drug: (nab)-paclitaxel
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Novartis
Completed

Wed, 04 Jun 2014 12:00:00 EDT

Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients

Conditions:   Coronary Stenosis;   Diabetes Mellitus
Interventions:   Device: Paclitaxel Eluting Balloon;   Device: paclitaxel eluting stent;   Device: bare metal stent
Sponsors:   Heart Centre Rotenburg;   B. Braun Medical SA
Completed

Thu, 19 Apr 2007 12:00:00 EDT

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

Condition:   Carcinoma, Squamous Cell
Interventions:   Drug: paclitaxel poliglumex;   Biological: cetuximab;   Radiation: radiation therapy (IMRT or 3D-CRT)
Sponsors:   State University of New York - Upstate Medical University;   CTI BioPharma
Unknown status

Thu, 17 Apr 2008 12:00:00 EDT

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

Condition:   Thyroid Gland Anaplastic Carcinoma
Interventions:   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Paclitaxel;   Drug: Pazopanib Hydrochloride;   Other: Placebo Administration
Sponsors:   National Cancer Institute (NCI);   NRG Oncology
Active, not recruiting

Sun, 07 Nov 2010 12:00:00 EDT

Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)

Condition:   Non-small Cell Lung Cancer, Stage III
Interventions:   Radiation: radiation therapy;   Drug: Paclitaxel Protein-Bound, and CARBOPLATIN
Sponsors:   University of Rochester;   Celgene Corporation
Withdrawn

Tue, 19 May 2009 12:00:00 EDT

Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent to Treat BTK Arteries

Condition:   Peripheral Arterial Disease
Intervention:   Device: Self-expandable drug eluting stent
Sponsor:   Flanders Medical Research Program
Completed

Thu, 28 Jun 2012 12:00:00 EDT

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: nab-paclitaxel;   Drug: Bevacizumab;   Drug: Trastuzumab
Sponsors:   SCRI Development Innovations, LLC;   Celgene Corporation;   Genentech, Inc.
Completed

Thu, 26 Oct 2006 12:00:00 EDT

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Conditions:   Advanced Malignant Solid Neoplasm;   Metastatic Malignant Solid Neoplasm;   Unresectable Malignant Solid Neoplasm
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Talazoparib
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Wed, 17 Dec 2014 12:00:00 EST

Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Wed, 26 May 2004 12:00:00 EDT

Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)

Condition:   Bladder Carcinoma in Situ (CIS)
Intervention:   Drug: ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)
Sponsor:   Fidia Farmaceutici s.p.a.
Completed

Mon, 15 Mar 2021 12:00:00 EDT

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

Condition:   Advanced Solid Tumor
Interventions:   Drug: paclitaxel;   Drug: TAK-228;   Drug: TAK-117
Sponsor:   Avera McKennan Hospital & University Health Center
Active, not recruiting

Tue, 16 May 2017 12:00:00 EDT

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Conditions:   Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Metastatic Head and Neck Squamous Cell Carcinoma;   Metastatic Hypopharyngeal Squamous Cell Carcinoma;   Metastatic Laryngeal Squamous Cell Carcinoma;   Metastatic Oral Cavity Squamous Cell Carcinoma;   Metastatic Oropharyngeal Squamous Cell Carcinoma;   Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Oral Cavity Squamous Cell Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Unknown Primary;   Stage IV Hypopharyngeal Carcinoma AJCC v8;   Stage IV Laryngeal Cancer AJCC v8;   Stage IV Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVB Hypopharyngeal Carcinoma AJCC v8;   Stage IVB Laryngeal Cancer AJCC v8;   Stage IVB Lip and Oral Cavity Cancer AJCC v8;   Stage IVC Hypopharyngeal Carcinoma AJCC v8;   Stage IVC Laryngeal Cancer AJCC v8;   Stage IVC Lip and Oral Cavity Cancer AJCC v8
Interventions:   Drug: Carboplatin;   Biological: Cemiplimab;   Drug: Paclitaxel
Sponsor:   Marcelo Bonomi
Not yet recruiting

Wed, 28 Apr 2021 12:00:00 EDT

Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Biological: interferon alpha;   Drug: 13-cis-retinoic acid;   Drug: paclitaxel
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Completed

Fri, 06 Jun 2003 12:00:00 EDT

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Condition:   Lung Cancer - Non Small Cell Squamous
Interventions:   Drug: Ipilimumab;   Drug: Placebo;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 28 Jan 2011 12:00:00 EST

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Conditions:   Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions:   Drug: paclitaxel;   Drug: carboplatin;   Drug: erlotinib
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 07 May 2003 12:00:00 EDT

Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: paclitaxel liposome injection
Sponsor:   Nanjing Luye Sike Pharmaceutical Co., Ltd.
Unknown status

Tue, 20 May 2014 12:00:00 EDT

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: RAD001
Sponsors:   M.D. Anderson Cancer Center;   Novartis;   National Cancer Institute (NCI)
Unknown status

Wed, 11 Jul 2007 12:00:00 EDT

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Conditions:   Gastric Neoplasms;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Biological: Pembrolizumab;   Drug: Paclitaxel
Sponsor:   Merck Sharp & Dohme Corp.
Terminated

Thu, 12 Jan 2017 12:00:00 EST

Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma

Condition:   Gastric Carcinoma
Intervention:   Drug: Liposomal paclitaxel and capecitabine
Sponsor:   Nanjing Sike Pharmaceutical Co., Ltd.
Unknown status

Thu, 20 Mar 2008 12:00:00 EDT

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Stand Up To Cancer;   Genentech, Inc.;   Celgene Corporation
Completed

Wed, 17 Mar 2010 12:00:00 EDT

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Conditions:   Carcinoma, Large Cell;   Neuroendocrine Tumors
Interventions:   Drug: RAD001;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Novartis Pharmaceuticals
Completed

Thu, 17 Mar 2011 12:00:00 EDT

Study of NAC of GA Therapy for Patients With BRPC

Condition:   Pancreatic Ductal Adenocarcinoma
Intervention:   Drug: Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
Sponsor:   Wakayama Medical University
Unknown status

Thu, 06 Oct 2016 12:00:00 EDT

Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: paclitaxel;   Drug: pazopanib
Sponsor:   National Cancer Institute, Naples
Completed

Thu, 19 Jul 2012 12:00:00 EDT

A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

Condition:   Non-hematologic Malignancy
Interventions:   Drug: Sapanisertib;   Drug: Paclitaxel
Sponsor:   Millennium Pharmaceuticals, Inc.
Completed

Thu, 09 Apr 2015 12:00:00 EDT

Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer

Condition:   ErbB2-Positive Stage I-III Breast Cancer
Intervention:   Drug: paclitaxel/carboplatin/lapatinib
Sponsors:   National University Hospital, Singapore;   National Cancer Centre, Singapore
Unknown status

Mon, 07 Mar 2011 12:00:00 EST

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Condition:   Triple-Negative Breast Cancer
Interventions:   Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Atezolizumab Placebo;   Drug: Paclitaxel
Sponsor:   Hoffmann-La Roche
Active, not recruiting

Mon, 24 Apr 2017 12:00:00 EDT

Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )

Condition:   Head and Neck Squamous Cell Cancer
Intervention:   Drug: Sintilimab and Nab-paclitaxel
Sponsor:   Shengyu Zhou
Unknown status

Wed, 05 Jun 2019 12:00:00 EDT

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Pazopanib Hydrochloride;   Other: Placebo
Sponsors:   National Cancer Institute (NCI);   NRG Oncology
Completed

Thu, 10 Nov 2011 12:00:00 EST

Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma (ARISE)

Condition:   Pulmonary Adenosquamous Carcinoma
Interventions:   Drug: Almonertinib;   Drug: Paclitaxel and carboplatin
Sponsors:   Fujian Cancer Hospital;   Jiangsu Hansoh Pharmaceutical Co., Ltd.
Not yet recruiting

Tue, 21 Apr 2020 12:00:00 EDT

MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC

Condition:   Stage IV Non-small Cell Lung Cancer
Intervention:   Drug: Belinostat, Carboplatin, Paclitaxel
Sponsors:   Acrotech Biopharma LLC;   Onxeo
Completed

Tue, 08 Mar 2011 12:00:00 EST

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: TH-302;   Drug: Nab-paclitaxel;   Drug: Gemcitabine
Sponsor:   Threshold Pharmaceuticals
Terminated

Tue, 28 Jan 2014 12:00:00 EST

Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: Zactima;   Procedure: neoadjuvant therapy
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Terminated

Wed, 11 Apr 2007 12:00:00 EDT

CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: CS-1008;   Drug: Placebo;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Daiichi Sankyo, Inc.
Completed

Thu, 08 Oct 2009 12:00:00 EDT

PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer

Condition:   Neoplasms Pancreatic
Interventions:   Drug: FOLFOX-A;   Drug: Gemcitabe and Abraxane;   Drug: G-CSF
Sponsors:   Judith Dixon-Hughes;   NHS Greater Glasgow and Clyde;   University of Glasgow
Recruiting

Tue, 05 Nov 2019 12:00:00 EST

First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)

Conditions:   Peripheral Artery Disease;   Femoropopliteal Artery Disease
Interventions:   Drug: Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland);   Device: Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)
Sponsors:   Balton Sp.zo.o.;   American Heart of Poland
Completed

Thu, 22 May 2014 12:00:00 EDT

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Condition:   Neoplasms, Breast
Interventions:   Drug: Pazopanib;   Drug: Lapatinib;   Drug: paclitaxel;   Drug: carboplatin
Sponsor:   GlaxoSmithKline
Completed

Fri, 13 Oct 2006 12:00:00 EDT

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Conditions:   Endometrial Cancer;   Ovarian Cancer
Interventions:   Drug: Ridaforolimus;   Drug: Paclitaxel;   Drug: carboplatin
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Merck Sharp & Dohme Corp.
Completed

Wed, 08 Dec 2010 12:00:00 EST

Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Cohort 1 neo-adjuvant;   Drug: Cohort 2 neo-adjuvant;   Drug: Cohort 1 adjuvant;   Drug: Cohort 2 adjuvant
Sponsors:   William Sikov MD;   Yale University
Completed

Mon, 18 Feb 2008 12:00:00 EST

Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Condition:   Advanced Gastric Cancer
Interventions:   Drug: Camrelizumab;   Drug: Apatinib Mesylate;   Drug: nab-paclitaxel;   Drug: S1
Sponsor:   Fujian Medical University
Recruiting

Thu, 12 Dec 2019 12:00:00 EST

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Procedure: cytoreductive surgery
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated

Wed, 31 May 2006 12:00:00 EDT

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Conditions:   Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma;   Stage II Oropharyngeal Squamous Cell Carcinoma;   Stage III Hypopharyngeal Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Laryngeal Squamous Cell Carcinoma;   Stage IV Oral Cavity Squamous Cell Carcinoma;   Stage IV Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Hypopharyngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Hypopharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Hypopharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Oral Cavity Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Nivolumab
Sponsors:   Sidney Kimmel Cancer Center at Thomas Jefferson University;   Bristol-Myers Squibb
Suspended

Fri, 17 Nov 2017 12:00:00 EST

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

Condition:   Endometrial Cancer
Interventions:   Drug: Carboplatin and Paclitaxel;   Radiation: Radiation Therapy
Sponsor:   Loyola University
Recruiting

Thu, 02 May 2019 12:00:00 EDT

Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients

Conditions:   Tubular Breast Cancer;   Mucinous Breast Cancer;   Invasive Ductal Breast Cancer;   Inflammatory Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Gonadotropin-releasing hormone agonist;   Drug: Letrozole
Sponsor:   RenJi Hospital
Active, not recruiting

Thu, 21 Aug 2014 12:00:00 EDT

Local Paclitaxel or Balloon Angioplasty Below the Knee

Conditions:   Stenosis;   Occlusion;   Restenosis
Interventions:   Device: SequentPlease OTW paclitaxel coated balloon catheter;   Device: conventional uncoated balloon for BTK endovascular therapy
Sponsors:   Prof. Dr. med. Gunnar Tepe;   InnoRa GmbH
Unknown status

Thu, 11 May 2017 12:00:00 EDT

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Gemcitabine;   Drug: Epirubicin;   Drug: Albumin-bound Paclitaxel
Sponsors:   SCRI Development Innovations, LLC;   Eli Lilly and Company;   Celgene Corporation
Completed

Mon, 19 Sep 2005 12:00:00 EDT

Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer

Conditions:   Esophagus Cancer;   Esophageal Cancer;   Cancer of the Esophagus
Interventions:   Radiation: Intensity Modulated Radiation Therapy;   Drug: Carboplatin;   Other: MD Anderson Symptom Inventory (MDASI)-Plus module;   Other: EuroQol (EQ-5D);   Other: SF-12;   Other: MOS Social Support Measure;   Other: CES-D;   Procedure: Blood for ctDNA (optional);   Procedure: Blood for SCCA;   Drug: Paclitaxel
Sponsor:   Washington University School of Medicine
Recruiting

Tue, 06 Aug 2019 12:00:00 EDT

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Condition:   Neoplasm, Unknown Primary
Interventions:   Drug: paclitaxel;   Drug: carboplatin;   Drug: bevacizumab;   Drug: erlotinib
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.
Completed

Fri, 04 Aug 2006 12:00:00 EDT

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Conditions:   Squamous Cell Carcinoma of the Head and Neck;   Carcinoma, Squamous Cell of the Head and Neck;   Cancer of Head and Neck;   Cancer of the Head and Neck;   Head and Neck Cancer;   Neoplasms, Head and Neck
Interventions:   Drug: nab-Paclitaxel;   Drug: Cisplatin;   Biological: Cetuximab;   Radiation: Intensity-Modulated Radiation Therapy
Sponsors:   Washington University School of Medicine;   Celgene Corporation
Active, not recruiting

Fri, 09 Oct 2015 12:00:00 EDT

Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma

Conditions:   Gastroesophageal Junction Adenocarcinoma;   Adenocarcinoma of the Stomach
Interventions:   Drug: Avelumab;   Drug: Ramucirumab;   Drug: Paclitaxel
Sponsor:   P. C. Thuss-Patience
Recruiting

Wed, 29 May 2019 12:00:00 EDT

Treatment of Drug-eluting Stent (DES) In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter

Condition:   In-Stent Restenosis
Interventions:   Device: SeQuent® Please;   Device: SeQuent® II
Sponsor:   Klinikum Coburg
Unknown status

Tue, 20 Oct 2009 12:00:00 EDT

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Condition:   Esophageal Cancer
Interventions:   Drug: cisplatin;   Drug: gefitinib;   Drug: paclitaxel;   Procedure: adjuvant therapy;   Radiation: radiation therapy
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI)
Terminated

Wed, 27 Jun 2007 12:00:00 EDT

Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

Condition:   NSCLC
Interventions:   Drug: Bevacizumab in Combination With Paclitaxel/Carboplatin;   Drug: IBI305 in Combination with Paclitaxel/Carboplatin
Sponsors:   Innovent Biologics (Suzhou) Co. Ltd.;   WuXi CDS Clinical Research (Shanghai) Co.Ltd.
Completed

Thu, 03 Nov 2016 12:00:00 EDT

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   Hellenic Oncology Research Group;   University Hospital of Crete
Completed

Thu, 05 Jun 2008 12:00:00 EDT

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Conditions:   Adult Solid Neoplasm;   Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions:   Drug: Cilengitide;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 13 Jan 2011 12:00:00 EST

ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Conditions:   Advanced Solid Tumor;   Metastatic Breast Cancer
Intervention:   Drug: Abraxane
Sponsor:   Orinove, Inc.
Recruiting

Wed, 15 May 2019 12:00:00 EDT

Sutent + Taxol for Advanced Esophageal Cancer

Condition:   Esophageal Cancer
Interventions:   Drug: Sunitinib malate;   Drug: Paclitaxel
Sponsors:   Hoosier Cancer Research Network;   Pfizer
Completed

Fri, 08 Aug 2008 12:00:00 EDT

Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer

Condition:   Cervical Cancer
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   Hoffmann-La Roche
Completed

Wed, 10 Jun 2015 12:00:00 EDT

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Conditions:   Stage IIIB Non-Small Cell Lung Cancer AJCC v7;   Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Selumetinib
Sponsors:   OHSU Knight Cancer Institute;   Oregon Health and Science University;   AstraZeneca
Completed

Tue, 21 Jul 2015 12:00:00 EDT

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Conditions:   Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IV Melanoma
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: bortezomib
Sponsor:   National Cancer Institute (NCI)
Completed

Tue, 07 Feb 2006 12:00:00 EST

Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)

Condition:   Ovarian Cancer
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab
Sponsors:   Massachusetts General Hospital;   Women and Infants Hospital of Rhode Island
Completed

Fri, 12 Aug 2005 12:00:00 EDT

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: tanespimycin;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 12 Jul 2004 12:00:00 EDT

Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors

Conditions:   Cervical;   Ovarian;   Lung;   Breast;   Renal
Interventions:   Drug: paclitaxel;   Drug: CBT-1(Registered Trademark);   Radiation: Tc 99m sestamibi
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 04 Sep 2009 12:00:00 EDT

Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer

Condition:   Urinary Bladder Neoplasms
Interventions:   Drug: Gemcitabine;   Drug: Paclitaxel;   Drug: Cisplatin
Sponsor:   The University of Texas Health Science Center, Houston
Terminated

Fri, 25 Sep 2015 12:00:00 EDT

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Conditions:   Stage III Intrahepatic Cholangiocarcinoma AJCC v7;   Stage IIIA Gallbladder Cancer AJCC v7;   Stage IIIB Gallbladder Cancer AJCC v7;   Stage IVA Gallbladder Cancer AJCC v7;   Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7;   Stage IVB Gallbladder Cancer AJCC v7;   Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma
Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Nab-paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Completed

Thu, 19 Mar 2015 12:00:00 EDT

A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer

Conditions:   Epithelial Ovarian Carcinoma;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Interventions:   Drug: weekly paclitaxel;   Drug: weekly cisplatin;   Device: oncothermia
Sponsor:   Seoul National University Hospital
Unknown status

Thu, 22 Jan 2015 12:00:00 EST

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Condition:   Metastatic Cancer Pancreas
Interventions:   Drug: PF-03084014;   Drug: Gemcitabine;   Drug: Nab-paclitaxel
Sponsors:   Pfizer;   Academic GI Cancer Consortium (AGICC)
Terminated

Wed, 09 Apr 2014 12:00:00 EDT

A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Paclitaxel + Carboplatin;   Drug: Paclitaxel only
Sponsor:   Tata Memorial Hospital
Active, not recruiting

Tue, 30 May 2017 12:00:00 EDT

Analysis of Linked Health Insurance Claims and Clinical Registries to Determine Device Surveillance With Paclitaxel-coated Medical Devices

Conditions:   Paclitaxel Adverse Reaction;   Outcome, Fatal
Intervention:   Device: Drug-coated device
Sponsors:   Universitätsklinikum Hamburg-Eppendorf;   GermanVasc;   BARMER;   MDEpiNet Verband Deutschland e.V.
Not yet recruiting

Thu, 24 Dec 2020 12:00:00 EST

Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

Conditions:   Metastatic Pancreatic Adenocarcinoma;   Locally Advanced Pancreatic Adenocarcinoma;   Inoperable Disease;   Localized Pancreatic Adenocarcinoma
Interventions:   Drug: SCO-101;   Drug: Gemcitabine;   Drug: Nab paclitaxel
Sponsors:   Scandion Oncology A/S;   Alcedis GmbH
Recruiting

Thu, 03 Dec 2020 12:00:00 EST

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Conditions:   Breast Cancer;   Carcinoma of the Breast
Interventions:   Drug: Paclitaxel;   Drug: Trastuzumab
Sponsors:   Eric P Winer, MD;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Massachusetts General Hospital;   Genentech, Inc.
Active, not recruiting

Thu, 11 Oct 2007 12:00:00 EDT

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Ipatasertib;   Drug: Paclitaxel;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Active, not recruiting

Thu, 09 Nov 2017 12:00:00 EST

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Conditions:   Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: carboplatin;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   Ritu Salani;   Genentech, Inc.
Completed

Wed, 13 Oct 2010 12:00:00 EDT

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Conditions:   Metastatic Esophageal Adenocarcinoma;   Metastatic Esophageal Squamous Cell Carcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Recurrent Esophageal Adenocarcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Esophageal Squamous Cell Carcinoma;   Recurrent Gastroesophageal Junction Adenocarcinoma;   Stage IV Esophageal Cancer AJCC v7
Interventions:   Biological: Cixutumumab;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Fri, 11 Jun 2010 12:00:00 EDT

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Conditions:   Ovarian Cancer;   Ovarian Neoplasms;   Ovarian Carcinosarcoma;   Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Fallopian Tube Cancer;   Fallopian Tube Neoplasms;   Primary Peritoneal Carcinoma;   Primary Peritoneal Serous Adenocarcinoma
Interventions:   Drug: Paclitaxel;   Drug: TAK228
Sponsors:   Imperial College London;   Takeda Pharmaceuticals International, Inc.;   North Eastern German Society of Gynaecological Oncology
Recruiting

Mon, 27 Aug 2018 12:00:00 EDT

Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting Stent

Condition:   Coronary Artery Disease
Interventions:   Device: CoroflexTM Please;   Device: Paclitaxel-eluting stent
Sponsor:   CardioVascular Research Foundation, Korea
Completed

Thu, 15 Oct 2009 12:00:00 EDT

Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: nab-paclitaxel followed by anthracycline and cyclophosphamide;   Drug: Docetaxel followed by anthracycline and cyclophosphamide
Sponsor:   Xijing Hospital
Recruiting

Mon, 02 Dec 2019 12:00:00 EST

Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis

Condition:   In-stent Stenosis of Infrapopliteal Arteries
Interventions:   Device: paclitaxel-coated balloon;   Device: non-coated balloon
Sponsors:   Herz-Zentrums Bad Krozingen;   University Heart Center Freiburg - Bad Krozingen
Withdrawn

Wed, 20 Jul 2011 12:00:00 EDT

Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Condition:   Melanoma (Skin)
Interventions:   Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Tue, 28 Nov 2006 12:00:00 EST

A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.

Condition:   Women With Primary Breast Cancer
Intervention:   Drug: FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel
Sponsor:   Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Completed

Tue, 26 Aug 2014 12:00:00 EDT

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

Conditions:   Gastric Cancer;   Gastroesophageal Junction Cancer
Interventions:   Drug: BBI608;   Drug: Paclitaxel;   Other: Placebo
Sponsor:   Sumitomo Dainippon Pharma Oncology, Inc
Completed

Tue, 01 Jul 2014 12:00:00 EDT

Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Conditions:   Malignant Pleural Effusion;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions:   Drug: imatinib mesylate;   Drug: paclitaxel
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Completed

Thu, 07 Dec 2006 12:00:00 EST

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: Enzalutamide;   Drug: Gemcitabine;   Drug: Nab-paclitaxel
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Astellas Pharma Inc
Completed

Wed, 14 May 2014 12:00:00 EDT

A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition:   Non-Small Cell Lung Cancer
Interventions:   Biological: Olaratumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Eli Lilly and Company
Completed

Thu, 11 Jun 2009 12:00:00 EDT

Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors

Condition:   Neoplasms
Intervention:   Drug: carboplatin + SU011248 (sunitinib) + paclitaxel
Sponsor:   Pfizer
Completed

Mon, 06 Aug 2007 12:00:00 EDT

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Adenocarcinoma
Interventions:   Drug: Ibrutinib;   Drug: Paclitaxel;   Drug: Gemcitabine
Sponsors:   Margaret Tempero;   Stand Up To Cancer;   Lustgarten Foundation
Completed

Tue, 29 Sep 2015 12:00:00 EDT

Real-world Data (RWD) of Ramucirumab Plus Paclitaxel

Conditions:   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Ramucirumab and paclitaxel;   Drug: Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy
Sponsor:   Hallym University Medical Center
Not yet recruiting

Mon, 07 Jun 2021 12:00:00 EDT

LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors

Condition:   Solid Tumors
Intervention:   Drug: LBH589, Paclitaxel, Carboplatin, Bevacizumab
Sponsors:   SCRI Development Innovations, LLC;   Novartis
Completed

Fri, 09 Nov 2007 12:00:00 EST

Paclitaxel/Carboplatin With or Without Cetuximab in CUP

Conditions:   Neoplasms, Unknown Primary;   Carcinoma
Interventions:   Drug: paclitaxel/carboplatin;   Drug: cetuximab
Sponsors:   Heidelberg University;   Merck KGaA, Darmstadt, Germany
Unknown status

Thu, 07 May 2009 12:00:00 EDT

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: carboplatin;   Drug: Nab-paclitaxel;   Drug: Bevacizumab
Sponsors:   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Celgene Corporation;   Genentech, Inc.
Completed

Tue, 25 Mar 2008 12:00:00 EDT

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

Conditions:   Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: Gemcitabine;   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   George Albert Fisher;   Genentech, Inc.;   Eli Lilly and Company
Completed

Thu, 23 Nov 2006 12:00:00 EST

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Conditions:   Gastroesophageal Junction Adenocarcinoma;   Gastric Adenocarcinoma
Interventions:   Drug: Ramucirumab;   Drug: Paclitaxel;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Completed

Tue, 13 Sep 2016 12:00:00 EDT

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Condition:   Squamous Non-Small Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Veliparib;   Drug: Paclitaxel;   Drug: Placebo to veliparib
Sponsor:   AbbVie
Completed

Tue, 08 Apr 2014 12:00:00 EDT

Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
Sponsor:   Hospital Universitario Madrid Sanchinarro
Unknown status

Thu, 24 Mar 2011 12:00:00 EDT

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

Conditions:   Metastatic Lung Non-Small Cell Squamous Carcinoma;   Metastatic Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Unresectable Lung Non-Small Cell Carcinoma;   Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pevonedistat
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Wed, 29 May 2019 12:00:00 EDT

Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: carboplatin+ paclitaxel;   Drug: paclitaxel
Sponsor:   Tao OUYANG
Completed

Fri, 12 Jun 2009 12:00:00 EDT

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Condition:   Advanced Gastric Adenocarcinoma
Interventions:   Drug: AZD1775;   Drug: paclitaxel
Sponsor:   Samsung Medical Center
Unknown status

Tue, 19 May 2015 12:00:00 EDT

Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients

Condition:   Non-small Cell Lung Cancer (NSCLC)
Intervention:   Biological: bevacizumab, carboplatin and paclitaxel
Sponsor:   Grupo de Investigación y Divulgación Oncológica
Unknown status

Mon, 11 Nov 2013 12:00:00 EST

Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Conditions:   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Squamous Cell
Interventions:   Drug: Paclitaxel for Injection(Albumin Bound);   Drug: carboplatin;   Radiation: thoracic radiation therapy
Sponsor:   First People's Hospital of Hangzhou
Unknown status

Mon, 19 Dec 2011 12:00:00 EST

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: olaparib;   Drug: paclitaxel;   Drug: carboplatin;   Drug: Drug: carboplatin
Sponsor:   AstraZeneca
Active, not recruiting

Fri, 05 Mar 2010 12:00:00 EST

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: HBI-8000;   Drug: Trastuzumab;   Drug: Paclitaxel
Sponsor:   HUYA Bioscience International
Withdrawn

Tue, 06 Oct 2015 12:00:00 EDT

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: PEGPH20;   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Enoxaparin
Sponsor:   Halozyme Therapeutics
Completed

Thu, 25 Apr 2013 12:00:00 EDT

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Condition:   Breast Cancer Metastatic
Interventions:   Drug: Abemaciclib;   Drug: Paclitaxel;   Drug: Letrozole;   Drug: Fulvestrant
Sponsors:   MedSIR;   Eli Lilly and Company
Recruiting

Mon, 26 Oct 2020 12:00:00 EDT

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: ABI-007
Sponsor:   Celgene Corporation
Completed

Fri, 05 Dec 2003 12:00:00 EST

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Drug: Anlotinib Hydrochloride, Paclitaxel, cisplatin
Sponsors:   Henan Cancer Hospital;   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Active, not recruiting

Wed, 21 Aug 2019 12:00:00 EDT

A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer

Condition:   Small Cell Lung Cancer
Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   Hoosier Cancer Research Network;   Genentech, Inc.;   Walther Cancer Institute
Completed

Mon, 24 Apr 2006 12:00:00 EDT

Evaluation of Votrient in Angiosarcoma

Condition:   Angiosarcoma
Intervention:   Drug: Pazopanib + Paclitaxel
Sponsors:   Heidelberg University;   Universitätsmedizin Mannheim;   Helios Klinikum Berlin-Buch;   University Hospital Dresden;   Universitätsklinikum Hamburg-Eppendorf;   University Hospital, Essen;   Hannover Medical School;   Klinikum der Universitaet Muenchen, Grosshadern;   Medical University of Vienna;   Medical University of Graz;   Medical University Innsbruck;   Novartis Pharmaceuticals
Terminated

Fri, 08 Aug 2014 12:00:00 EDT

PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis

Condition:   Peripheral Arterial Disease
Intervention:   Procedure: PacLitaxel Eluting Balloon Application
Sponsor:   Nantes University Hospital
Completed

Mon, 30 Apr 2012 12:00:00 EDT

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Vinorelbine;   Drug: Herceptin;   Drug: Filgrastim
Sponsors:   University of Washington;   Amgen;   Bristol-Myers Squibb;   GlaxoSmithKline
Terminated

Wed, 10 Jul 2002 12:00:00 EDT

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Condition:   Solid Tumors
Interventions:   Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin;   Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin;   Drug: BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1);   Drug: BKM120, Paclitaxel + Carboplatin
Sponsors:   Memorial Sloan Kettering Cancer Center;   Novartis Pharmaceuticals;   Sai Life Sciences
Completed

Wed, 16 Feb 2011 12:00:00 EST

Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer

Condition:   Breast Cancer
Interventions:   Other: Doxorubicin followed by Paclitaxel;   Other: Paclitaxel followed by Doxorubicin
Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
Completed

Tue, 09 Nov 2004 12:00:00 EST

Paclitaxel-bevacizumab in Advanced Lung Cancer

Condition:   Non-squamous Non-small Cell Lung Cancer
Interventions:   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsor:   Intergroupe Francophone de Cancerologie Thoracique
Completed

Wed, 09 Jan 2013 12:00:00 EST

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Apatinib;   Drug: Etoposide;   Drug: Paclitaxel
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Recruiting

Thu, 27 Jun 2019 12:00:00 EDT

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Condition:   Metastatic Pancreatic Adenocarcinoma
Interventions:   Drug: APX005M;   Drug: Nivolumab;   Drug: Nab-Paclitaxel;   Drug: Gemcitabine
Sponsors:   Parker Institute for Cancer Immunotherapy;   Bristol-Myers Squibb;   Apexigen, Inc.;   Cancer Research Institute, New York City
Active, not recruiting

Tue, 11 Jul 2017 12:00:00 EDT

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions:   Drug: AMG 386;   Drug: AMG 386 Placebo;   Drug: Paclitaxel
Sponsor:   Amgen
Completed

Fri, 17 Sep 2010 12:00:00 EDT

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: nab-paclitaxel;   Procedure: Surgery;   Drug: Adjuvant chemotherapy
Sponsors:   Ohio State University Comprehensive Cancer Center;   Celgene Corporation;   Genentech, Inc.
Completed

Fri, 09 May 2008 12:00:00 EDT

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: GDC-0941;   Drug: Placebo;   Drug: Paclitaxel
Sponsor:   Genentech, Inc.
Completed

Tue, 04 Dec 2012 12:00:00 EST

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Condition:   Anaplastic Thyroid Cancer
Interventions:   Drug: CS-7017;   Drug: Paclitaxel
Sponsor:   Daiichi Sankyo, Inc.
Terminated

Tue, 29 Jan 2008 12:00:00 EST

Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma
Interventions:   Drug: Cisplatin Combined With S-1;   Drug: Cisplatin Combined With Paclitaxel
Sponsor:   Fudan University
Unknown status

Tue, 09 Feb 2016 12:00:00 EST

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Condition:   Advanced/Metastatic Non-Small Cell Lung Cancer
Interventions:   Drug: Ixabepilone, 32 mg/m^2;   Drug: Paclitaxel, 200 mg/m^2;   Drug: Carboplatin (area under the concentration curve [AUC] 6)
Sponsor:   R-Pharm
Completed

Tue, 29 Jul 2008 12:00:00 EDT

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

Condition:   Recurrent Pancreatic Cancer
Interventions:   Drug: Tislelizumab;   Drug: Nab paclitaxel;   Drug: Gemcitabine
Sponsor:   Changhai Hospital
Recruiting

Wed, 26 May 2021 12:00:00 EDT

Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

Condition:   Carcinosarcoma, Ovarian
Interventions:   Drug: Galunisertib;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   University of Oklahoma;   Eli Lilly and Company
Active, not recruiting

Sun, 02 Jul 2017 12:00:00 EDT

Neoadjuvant Therapy for Ovarian Cancer

Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   Jason D. Wright;   Genentech, Inc.
Completed

Tue, 22 Jun 2010 12:00:00 EDT

Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations

Condition:   Breast Cancer
Interventions:   Drug: Vinorelbine plus Epirubicin;   Drug: Paclitaxel plus Epirubicin
Sponsor:   Fudan University
Completed

Fri, 11 Dec 2015 12:00:00 EST

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

Condition:   Non Small Cell Lung Cancer
Interventions:   Biological: Ramucirumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Eli Lilly and Company
Completed

Fri, 15 Aug 2008 12:00:00 EDT

Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries

Condition:   Coronary Artery Disease
Interventions:   Device: Genous stent implantation with paclitaxel-eluting balloon dilation;   Device: Genous stent implantation
Sponsors:   University of Ulm;   B. Braun Melsungen AG;   OrbusNeich
Completed

Tue, 12 Aug 2008 12:00:00 EDT

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: Carboplatin;   Drug: Abraxane
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed

Thu, 23 Aug 2007 12:00:00 EDT

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Conditions:   Borderline Resectable Pancreatic Cancer;   Locally Advanced Pancreatic Adenocarcinoma
Interventions:   Drug: Nab paclitaxel plus gemcitabine;   Drug: mFOLFIRINOX
Sponsor:   Fudan University
Recruiting

Thu, 05 Nov 2020 12:00:00 EST

Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

Condition:   Breast Cancer
Intervention:   Drug: Pembrolizumab 200mg +Paclitaxel 80mg/m2
Sponsor:   Yonsei University
Not yet recruiting

Wed, 30 Jun 2021 12:00:00 EDT

First Line TIP in Poor Prognosis TGCTs.

Condition:   Germ Cell Tumor
Interventions:   Drug: Paclitaxel;   Drug: Ifosfamide;   Drug: Cisplatin
Sponsor:   National Cancer Institute, Slovakia
Completed

Mon, 13 Apr 2015 12:00:00 EDT

Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

Conditions:   Carcinosarcoma;   Endometrial Neoplasms
Interventions:   Drug: Paclitaxel;   Drug: Cediranib;   Drug: Olaparib
Sponsors:   University of Manchester;   AstraZeneca;   Cardiff University
Unknown status

Wed, 27 Jun 2018 12:00:00 EDT

Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer

Condition:   HER-2 Positive Breast Cancer
Interventions:   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Carboplatin
Sponsors:   Zhimin Shao;   Roche Pharma AG
Unknown status

Mon, 05 Sep 2011 12:00:00 EDT

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Condition:   Metastatic Pancreatic Ductal Adenocarcinoma
Interventions:   Biological: NIS793;   Biological: Spartalizumab;   Drug: gemcitabine;   Drug: nab-paclitaxel
Sponsor:   Novartis Pharmaceuticals
Recruiting

Mon, 18 May 2020 12:00:00 EDT

Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Conditions:   Triple Negative Breast Cancer;   TNBC - Triple-Negative Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: CB-839
Sponsor:   Calithera Biosciences, Inc
Completed

Mon, 20 Feb 2017 12:00:00 EST

NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer

Condition:   HER2-positive Newly Diagnosed, Primary Breast Cancer
Interventions:   Drug: BKM120;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: BKM120 Placebo
Sponsors:   Novartis Pharmaceuticals;   Breast International Group;   German Breast Group;   SOLTI Breast Cancer Research Group
Completed

Fri, 22 Mar 2013 12:00:00 EDT

Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer

Condition:   Advanced Pancreatic Cancer
Interventions:   Drug: Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4;   Drug: Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4;   Drug: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4;   Drug: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
Sponsor:   PH Research, S.L.
Completed

Fri, 06 Mar 2015 12:00:00 EST

A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Paclitaxel Albumin Nanoparticle for Injectable Suspension
Sponsors:   Veeda Oncology;   Celgene Corporation
Completed

Thu, 10 Nov 2005 12:00:00 EST

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Sorafenib;   Drug: Cisplatin;   Drug: Paclitaxel
Sponsors:   Emory University;   Amgen;   Bayer
Terminated

Fri, 03 Sep 2010 12:00:00 EDT

Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

Condition:   Pancreatic Ductal Adenocarcinoma
Intervention:   Drug: nab-Paclitaxel + Cisplatin + Gemcitabine
Sponsors:   HonorHealth Research Institute;   Celgene
Active, not recruiting

Tue, 16 Apr 2019 12:00:00 EDT

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Condition:   Carcinoma, Non-Small Cell Lung
Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel;   Drug: Carboplatin plus Paclitaxel
Sponsor:   Bayer
Terminated

Fri, 10 Mar 2006 12:00:00 EST

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Conditions:   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Vorinostat;   Other: Placebo;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Terminated

Wed, 10 Aug 2011 12:00:00 EDT

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

Conditions:   Head and Neck Cancer;   Head and Neck Squamous Cell Carcinoma;   Cancer of the Head and Neck
Interventions:   Drug: nab-paclitaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Biological: Cetuximab
Sponsors:   Washington University School of Medicine;   Celgene Corporation
Active, not recruiting

Tue, 21 Oct 2014 12:00:00 EDT

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: Toripalimab, nab-paclitaxel, carboplatin;   Drug: Toripalimab;   Procedure: Surgical resection
Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting

Fri, 19 Mar 2021 12:00:00 EDT

Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation

Condition:   Uterine Carcinoma
Interventions:   Drug: Paclitaxel/Carboplatin;   Radiation: Pelvic radiation therapy
Sponsor:   Northwell Health
Not yet recruiting

Tue, 23 Jul 2019 12:00:00 EDT

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer

Conditions:   Endometrial Adenocarcinoma;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Radiation: Internal Radiation Therapy;   Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis
Sponsors:   Albert Einstein College of Medicine;   National Cancer Institute (NCI)
Terminated

Wed, 30 Dec 2009 12:00:00 EST

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

Conditions:   Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention:   Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine
Sponsor:   OncoMed Pharmaceuticals, Inc.
Completed

Thu, 30 Jan 2014 12:00:00 EST

Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: Abraxane ( Nab-paclitaxel);   Drug: Gemcitabine;   Drug: ODSH ( 2-O, 3-O Desulfated Heparin);   Drug: Abraxane ( nab-paclitaxel)
Sponsors:   Cantex Pharmaceuticals;   Translational Drug Development
Completed

Fri, 28 Oct 2011 12:00:00 EDT

The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Placebo;   Drug: Veliparib;   Drug: Carboplatin;   Drug: Temozolomide;   Drug: Paclitaxel
Sponsor:   AbbVie
Completed

Tue, 10 Jan 2012 12:00:00 EST

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Conditions:   Cancer Ovaries;   Cancer Peritoneal;   Cancer, Fallopian Tube
Interventions:   Drug: OMP-305B83;   Drug: Paclitaxel
Sponsor:   OncoMed Pharmaceuticals, Inc.
Completed

Wed, 25 Jan 2017 12:00:00 EST

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Conditions:   Locally Advanced Thymic Carcinoma;   Metastatic Thymic Carcinoma;   Recurrent Thymic Carcinoma;   Unresectable Thymic Carcinoma
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ramucirumab
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting

Wed, 03 Oct 2018 12:00:00 EDT

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;   Drug: Placebo in combination with cisplatin and docetaxel or paclitaxel
Sponsors:   BioNumerik Pharmaceuticals, Inc.;   Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.
Completed

Thu, 27 Aug 2009 12:00:00 EDT

A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma

Condition:   Urothelial Carcinoma
Intervention:   Drug: Toripalimab plus Nab-Paclitaxel +/- cisplatin
Sponsor:   Jun Guo
Not yet recruiting

Thu, 26 Dec 2019 12:00:00 EST

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: sildenafil;   Drug: placebo;   Drug: paclitaxel (taxol);   Drug: carboplatin (palaplatin)
Sponsor:   Hamamatsu University
Completed

Mon, 15 Sep 2008 12:00:00 EDT

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Onartuzumab;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Bevacizumab Placebo;   Drug: Onartuzumab Placebo
Sponsors:   Genentech, Inc.;   Hoffmann-La Roche
Completed

Mon, 23 Aug 2010 12:00:00 EDT

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Conditions:   Fallopian Tube Neoplasms;   Peritoneal Neoplasms;   Ovarian Neoplasms
Interventions:   Drug: ABI-007;   Drug: Carboplatin
Sponsor:   Celgene
Terminated

Tue, 05 Dec 2006 12:00:00 EST

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Condition:   Gastric Cancer With Positive Exfoliative Cancer Cells
Interventions:   Drug: apatinib;   Drug: paclitaxel;   Drug: S-1
Sponsor:   Hebei Medical University
Unknown status

Wed, 24 Oct 2018 12:00:00 EDT

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Skin Metastases;   Stage IV Breast Cancer
Interventions:   Drug: imiquimod;   Drug: Abraxane;   Other: laboratory biomarker analysis;   Genetic: RNA analysis;   Other: immunoenzyme technique
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Completed

Wed, 14 Jan 2009 12:00:00 EST

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Condition:   Prostate Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Jonsson Comprehensive Cancer Center;   Bristol-Myers Squibb
Completed

Mon, 27 Jan 2003 12:00:00 EST

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Conditions:   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions:   Drug: ganetespib;   Drug: paclitaxel;   Biological: trastuzumab;   Biological: pertuzumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI);   Synta Pharmaceuticals Corp.;   New York University Cancer Institute
Completed

Wed, 12 Feb 2014 12:00:00 EST

Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Conditions:   Cancer;   Non-Small Cell Lung Cancer;   Endometrial Carcinoma;   Ovarian Carcinoma
Interventions:   Drug: XL147 (SAR245408),;   Drug: paclitaxel;   Drug: carboplatin
Sponsor:   Sanofi
Completed

Mon, 22 Sep 2008 12:00:00 EDT